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Rheumatoid arthritis (RA) is a chronic inflammatory immune disease affecting the 
joints. CD4+CD25+ regulatory T cells (Tregs) are abundantly present in the inflamed 
joints of patients with RA, but inflammation still persists. The notion that Tregs are 
terminally differentiated suppressor cells has recently been disputed by studies 
showing that Tregs can display a significant degree of plasticity and even convert 
into IL-17-producing cells under inflammatory conditions. Therefore, the overall 
hypothesis of this thesis was that the pro-inflammatory environment impairs Treg 
function in RA by converting them into IL-17-producing cells. 
 
We show in this thesis that frequencies of CD25+CD127low Tregs with a CD45RO+ 
memory phenotype were increased at the site of inflammation in RA. These Tregs 
displayed a regulatory phenotype, with increased expression of the Th17 marker 
CD161. Furthermore, CD14+ monocytes with an activated phenotype were found in 
high numbers in the RA joint. Monocytes and Tregs could be found in close 
proximity in human tissue suggesting that they interact in vivo. 
We next studied the effects of in vitro-activated monocytes on Treg phenotype and 
function. Activated monocytes increased the percentages of IL-17+, IFNγ+, TNF-α+, 
and IL-10+ memory (CD45RA-) Tregs. Tregs from these co-cultures showed no loss in 
Treg markers or suppressive capacity, and were rather enhanced in their suppressor 
functions. 
Finally, Tregs from the peripheral blood of patients with RA showed a similar 
phenotype and cytokine expression profile compared to Tregs from healthy 
controls. RA Tregs were capable of suppressing autologous effector T cell 
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proliferation and cytokine secretion. However, Tregs from some patients showed a 
hampered ability to suppress monocyte-derived chemokines and cytokines.  
 
Together, these data suggest that Treg function is not globally impaired in patients 
with RA and that Tregs exposed to a pro-inflammatory environment, such as occurs 
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Chapter 1: Introduction 
1.1 Immune tolerance 
The concept of immune tolerance was first predicted by Sir Frank Macfarlane 
Burnet in 1949 and was proven experimentally in the early 1950ies by Sir Peter 
Brian Medawar studying graft reactions in mouse embryos [1]. They both received 
the Nobel Prize in 1960 for the “discovery of acquired immunological tolerance”. 
Today, we distinguish two types of immune tolerance namely central tolerance and 
peripheral tolerance. 
 
Central tolerance occurs during B lymphocyte and T lymphocyte development in the 
primary lymphoid organs - bone marrow and thymus, respectively. For T cells, the 
first checkpoint of self-tolerance involves the deletion of auto-reactive T cells, which 
are T lymphocytes that interact too strongly with self-antigen bound to self MHC 
molecules. Auto-reactive T cells are deleted via apoptosis induction during negative 
selection; a process that is mediated by the autoimmune regulator (Aire) [2, 3]. 
CD4+CD8+ double-positive thymocytes that receive TCR (T cell receptor) signals just 
below the threshold undergo positive selection. This results in the transduction of 
pro-survival signals and the maturation into CD4+ or CD8+ single-positive cells, 
depending on whether thymocytes express TCRs that bind self-peptide-MHC-class-II 
complexes or TCRs that bind self-peptide-MHC-class-I complexes, respectively. 
Single positive cells then exit the thymus as mature naïve CD4+ or CD8+ T cells. 
Central tolerance mechanisms in the thymus are very efficient. However, not all 
potentially self-reactive T cells are eliminated, which is in part because not all self-
antigens will be expressed in the thymus. 
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Peripheral tolerance complements central tolerance and is acquired when matured 
lymphocytes have entered the periphery. T cells that have exited the thymus and 
are self-reactive can be silenced by anergy (hypo-responsiveness) due to absence of 
co-stimulatory signals, by deletion or get suppressed by regulatory cells to prevent 
autoimmunity. 
 
1.2 Regulatory cells 
Immune regulation is essential for the maintenance of peripheral tolerance, the 
prevention of autoimmune diseases and the limitation of chronic inflammation. 
Almost every type of lymphocyte can display regulatory properties in some 
circumstances, which is briefly discussed in the following sections. 
 
1.2.1 CD4+ regulatory T cells 
CD4+ regulatory T cells (Tregs) are the best described regulatory cell population. 
They are essential in maintaining self-tolerance and homeostasis (reviewed in [4]) 
through their ability to modulate the activation, proliferation and effector functions 
of a wide range of immune cells including B cells, CD4+ and CD8+ T cells, NK cells and 
antigen-presenting cells (APCs) [5-15], which will be further described in detail in 1.4. 
As a double-edged sword they can also suppress anti-tumour immune responses 
thereby favouring tumour progression. 
 
CD4+ Tregs are broadly divided into two classes namely, naturally-occurring Tregs 
(nTregs) and inducible Tregs (iTregs), also known as adaptive Tregs. 
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NTregs are generated in the thymus, predominantly the thymic medulla, by high-
affinity binding to MHC molecules containing self-peptides, which are presented by 
thymic APCs, and sufficiently high per cell avidity [16, 17]. They are characterised as 
CD4+CD25+ T cells and will be described in more detail in 1.3. 
 
ITregs, as the name implies, are induced in the periphery from naïve CD4+ T cells, 
and comprise a heterogeneous population including Tr1 cells and Th3 cells. Tr1 cells 
are characterised by high production of IL-10 in the absence of IL-4 [18] and their 
ability to kill APCs via granzyme B and perforin [19]. They express low levels of FoxP3 
and are positive for PD-1, CTLA-4 [20], ICOS [21], and CD226 [19], but none of these 
markers are selective to these cells. Recently, the combination of LAG-3 and CD49b 
has been described to allow for identification of Tr1 cells [22]. TGF-β-producing Th3 
cells were first identified in oral tolerance studies [23]. Th3 cells can also produce IL-
4, which distinguishes them from Tr1 cells [24]. 
ITregs have been shown to be involved in Th2-mediated immunity i.e. allergic 
inflammation and asthma and controlling the microbiota in the gut, whereas nTregs 
seem to play a more important role in autoimmunity [25]. 
 
A lot has changed in Treg cell biology in the last decade, which will be discussed 
later on, making the original terminology inaccurate. In 2012, a workshop on Treg 
nomenclature was held at a conference on Tregs and T helper cells, where a group 
of well-known scientists studying Treg biology came up with recommendations for 
new nomenclature criteria [26]. They suggested referring to the formerly known 
‘natural Tregs’ as thymus-derived Tregs (tTreg) and to peripherally-derived Tregs 
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(pTregs) instead of ‘inducible Tregs’ to clearly demonstrate their anatomical origin 
of differentiation. Furthermore, it should be clearly indicated when Tregs have been 
generated in vitro, by referring to these cells as in vitro-induced Tregs (iTregs) [26]. 
 
1.2.2 CD8+ regulatory T cells 
CD8+ cytotoxic T cells (CTLs) are capable of recognising virally-infected cells and 
induce cell death by secreting cytotoxic enzymes. Although the existence of CD8+ T 
cells with suppressor capacities has been described almost 40 year ago [27, 28] they 
remained relatively understudied. In 2003, Cosmi et al. described the existence of 
CD8+CD25+ Tregs, which shared features with CD4+ Tregs [29]. It has further been 
shown that CD8+ Tregs exert their suppressor functions via direct killing of target 
cells [30, 31] or secretion of soluble factors such as immunoregulatory IL-10 [32]. They 
preferentially target activated T cells [33] and Th1 cells in particular, whereas they do 
not seem to be able to suppress Th2 cells [34]. Surface markers for human CD8+ Tregs 
still need to be clearly defined, but similarly to CD4+ Tregs they can also express 
CD25 and FoxP3 [29, 35]. Finally, it was also shown that CD8+CD28-FoxP3+ Tregs play 
an important role in the induction of CD4+CD25+ Tregs as well as in promoting their 
function [36]. 
 
1.2.3 TCRαβ CD4-CD8- T cells 
CD4-CD8- (DN) T cells with suppressive properties have been described by Strober et 
al. in 1989 [37]. They are a rare subset of regulatory cells, which can inhibit CD4+ and 
CD8+ T cell responses [38-40] and do not express FoxP3 [39]. It has recently been shown 
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that DN Tregs are further able to downregulate CD80/CD86 on DCs via CTLA4 and 
kill target cells via Fas-FasL interactions [41]. 
 
1.2.4 Regulatory B cells 
B cells are generally considered as positive regulators of immune responses through 
their ability to produce antibodies against foreign antigens and as efficient APCs. 
The existence of B cells with regulatory functions, a term that was first introduced 
by Mizoguchi et al. in the late 1990ies [42], has been well documented over the years 
[43, 44]. These cells are commonly referred to as Bregs or B10 cells due to their ability 
to produce the anti-inflammatory cytokine IL-10 [45] and are important in the 
regulation of autoimmune responses by suppressing CD4+ T cell responses [46, 47]. It 
has further been described that they are able to support the maintenance of Treg 
numbers [48, 49]. Despite the evidence of their existence in humans a lot of questions 
still remain regarding their origin, the expression of specific surface markers for 
their identification and isolation as well as the identification of a lineage-specific 
transcription factor although it has been reported that Bregs can also express the 
Treg-specific transcription factor FoxP3 [50]. 
 
The main focus of this PhD thesis was to study the phenotype and function of CD4+ 
regulatory T cells. I will therefore focus on this particular regulatory population in 
the following sections. 
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1.3 Brief history of CD4+CD25+ Tregs 
The existence of thymic-derived cells with regulatory properties, which play a role in 
autoimmunity, has been postulated based on a classic day 3 neonatal thymectomy 
experiment by Nishizuka and Sakakura in 1969 [51]. In the early 1970ies, when 
studying the process of “high-zone” tolerance, Gershon and Kondo showed that the 
suppression of antibody responses was mediated by thymus-derived cells, which 
they later on referred to as “suppressor T cells” [52, 53]. The lack of surface markers 
for the identification of these cells at the time made it impossible to isolate T cells 
with suppressor potential for further investigation. 
In 1985, Sakaguchi continued to study suppressor T cells in mice and the 
transmembrane glycoprotein CD5 (Lyt-1) was found to be expressed on the surface 
of these cells [54, 55]. Ten years later, he was finally able to identify these cells as 
CD4+CD25+ T cells [56]. He showed that the transfer of CD4+ T cells depleted of CD25+ 
cells with an anti-CD25 mAb into BALB/c athymic nude mice led to the spontaneous 
development of organ-specific autoimmune diseases such as thyroiditis, gastritis 
and insulitis. Conversely, reconstitution with these cells shortly after thymectomy 
prevented disease [57]. Suri-Payer et al. provided further evidence that regulatory T 
cells represent a unique lineage of cells, since the mere induction of CD25 
expression on T cells did not lead to suppression of post-thymectomy autoimmunity 
[58]. Subsequent studies in humans followed, which could also identify suppressor 
cells as CD4+ T cells expressing the high-affinity IL-2R α-chain (CD25) on their surface 
[6, 7, 59-61]. The suppressive potential was further ascribed to the CD4+CD25hi T cell 
compartment in particular, which comprises about 1-3% of the total percentage 
CD4+CD25+ T cells [62]. 
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The forkhead box protein P3 (FoxP3), which is a member of the forkhead/winged-
helix family of transcriptional regulators, was shortly thereafter identified as the 
lineage-specific transcription factor for murine [16, 63, 64] and human Tregs [65]. FoxP3 
is the master regulator of the phenotype, differentiation and function of regulatory 
T cells [66, 67]. The importance of the transcription factor FoxP3 in immune tolerance 
is underlined by the existence of severe systemic autoimmune diseases in scurfy 
mice, which have a spontaneous loss-of-function mutation in the FoxP3 gene [68]. In 
humans, a similar genetic anomaly exists, which is called IPEX (immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome, resulting in 
dysfunctional Tregs and subsequent autoimmunity [69-71]. Finally, patients with a 
deficiency in CD25 show IPEX-like syndromes [72, 73] and CD25-deficient mice develop 
autoimmune disorders similar to the scurfy mouse [74], highlighting the importance 
of CD4+CD25+FoxP3+ Tregs in maintaining self-tolerance. Furthermore, the target 
genes of FoxP3 include key modulators of T cell function, which get suppressed 
upon FoxP3 binding [75]. 
 
 









FoxP3 = transcription factor
(mice)
Fontenot, Khattri, Hori
CD4+CD25+ T cells (human)
Taams, Levings, Dieckmann, Ng, Jonuleit
CD4+CD25hi T cells
Baecher-Allan





Chapter 1: Introduction 
24 
1.4 Mechanisms of action of Tregs 
Multiple mechanisms of Treg-mediated suppression have been postulated since the 
discovery of these cells. These mechanisms can basically be divided into two types 
of suppression: contact-dependent or soluble factor-mediated, which are 
summarised below (see also Figure 1.2).  
 
CTLA-4 (CD152) deficiency leads to fatal lymphoproliferation and the development 
of autoimmune diseases [76]. CTLA-4 (cytotoxic T lymphocyte antigen-4) is 
constitutively expressed by Tregs [76-79] and competes with the closely related CD28 
molecule for binding to the co-stimulatory molecules CD80 (B7.1) and CD86 (B7.2) 
expressed on APCs [15] (reviewed in [80]). Tregs can inhibit effector T cell activation by 
interfering with the contact formation between T cells and DCs via CD28 and 
CD80/CD86 [81]. Tregs can further downregulate the expression of CD80/CD86 on 
mature DCs or inhibit the upregulation of these molecules on immature DCs via 
CTLA-4 [13, 15, 76], which suppresses the ability of DCs to stimulate T cells via CD28. 
This downregulation of CD80/CD86 can also be mediated by capture of these 
surface molecules by CTLA-4, a process known as trans-endocytosis [82]. Ligation of 
CD80/CD86 can further inhibit the production of IL-6 and TNF-α by nuclear 
translocation of Foxo3, which limits T cell survival [83]. It has also been shown that 
Tregs can downregulate CD80 and CD86 expressed on T cells, which directly 
transmits a negative signal to effector T cells [84]. Furthermore, Tregs might mediate 
suppression via CTLA-4 as ligation of CD80/CD86 can increase indoleamine 2,3-
dioxygenase (IDO) secretion by DCs [85, 86]. IDO is an enzyme that catalyses the 
essential amino acid tryptophan into kynurenine and other metabolites, which leads 
Chapter 1: Introduction 
25 
to starvation of T cells or induction of cell cycle arrest [87]. IDO can further feedback 
on Tregs by enhancing their activity or inducing them from CD4+CD25- T cells [88-92]. 
 
Tregs are not able to produce IL-2 by themselves but need IL-2 for their survival and 
effector functions [93-97]. It has been shown in mice that Tregs deprive CD4+CD25- T 
cells of IL-2 by consumption, which induces apoptosis [98], a finding that could not be 
reproduced in humans [99]. Furthermore, the beneficial effects of IL-2 on Treg 
function have been debated [100], and it has therefore been suggested that Tregs 
rather suppress the production of IL-2 by effector T cells upon cell contact, which 
limits the activation and survival of effector T cells [100, 101]. 
The ecto-5’-nucleotidase CD39 catalyses ATP to ADP/AMP, and the ecto-NTPDase-1 
CD73 further degrades AMP to the nucleoside adenosine [102]. Adenosine activates 
P1 purinergic G protein-coupled receptors (GPCR) expressed on immune cells, one 
of which is A2A expressed on effector T cells. The activation of A2A leads to an 
increase of cAMP in Teff, which inhibits their proliferation [103]. It has been 
described that Tregs can also directly transfer cAMP into Teff via membrane gap 
junctions [104]. The two ecto-enzymes CD39 and CD73 are highly expressed on Tregs 
[105, 106] and have been suggested to play a role in Treg-mediated suppression [107, 108] 
by suppressing Teff proliferation, CTL effector functions and to impact the secretion 
of pro-inflammatory cytokines by DCs (reviewed in [109]). 
 
LAG3 (lymphocyte-activation gene 3, CD223) is a CD4 homolog that shows high 
binding affinity with MHC class II molecules. When bound to MHC class II expressed 
on DCs, LAG3 induces inhibitory signals on DCs and suppresses their 
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immunostimulatory capacity [110, 111]. MHC class II is expressed on B cells, 
monocytes, macrophages and activated T cells, which suggests that Tregs can 
possibly suppress these cells via LAG3, but experimental evidence still needs to be 
provided. 
 
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is also expressed at high 
levels on Tregs and induces immunoregulatory IL-10 and TGF-β production by DCs 
following interaction, which in turn inhibits T cells [112]. Tregs can upregulate CD95L 
(Fas ligand) following activation and induce apoptosis via Fas in CD8+ T cells, an 
ability that is enhanced in cancer patients [113]. 
Furthermore, Galectin-1 is selectively upregulated in Tregs and involved in their 
ability to suppress T cells [114]. Galectin-1, a member of the family of beta-
galactoside binding proteins, is known to induce cell cycle arrest and apoptosis in 
activated T cells [115], which suggests that this is an additional mechanism how Tregs 
can suppress Teff, but experimental evidence still needs to be provided. 
 
Another form by which Tregs can exert their regulatory activity is by the release of 
granzyme A (human) and granzyme B (mice) and perforin, which leads to lysis of 
target cells including T cells, B cells, NK cells, monocytes and CTLs [116-119]. The 
release of inhibitory cytokines by Tregs such as IL-10 and TGF-β can induce Tr1 cells 
[120] and Th3 cells [121, 122], respectively. Human and mouse Tregs express membrane-
bound TGF-β [123, 124], which could mediate cell-contact-mediated suppression. Tregs 
have been shown to inhibit NKG2D-mediated NK cell cytotoxicity via TGF-β [10, 124]. 
Furthermore, in the absence of CTLA-4, Tregs were able to suppress T cell 
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proliferation via TGF-β [125]. Tregs can induce IL-10 production by DCs [11] and 
CD4+CD25- T cells in a contact-dependent manner [14], which can render these cells 
immunosuppressive [126]. Only recently, a new inhibitory cytokine was described 
named IL-35, which is a member of the IL-12 heterodimeric cytokine family and has 
been suggested to play an important role in Treg-mediated suppression [127, 128].  
 
 
Figure 1.2 Mechanisms of Treg-mediated suppression of effector cells. 
 
 
1.5 The discovery of new markers for CD4+CD25+ Tregs 
The expression of CD25 is transiently upregulated on T cells following activation [129-
131], making it difficult to use this marker for isolation of pure Tregs. FoxP3 is a 
reliable marker for functionally suppressive Tregs in mice; in humans, recently-
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activated human effector T cells (Teff) can transiently up-regulate the Treg-specific 
transcription factor FoxP3 [65, 132-135]. Furthermore, the intracellular detection of 
FoxP3 makes it difficult to isolate these cells for functional studies, which led to an 
intensive search for new surface markers in the last decade. Since then, various 
surface markers have been proposed as possible candidates to better identify and 
characterise a regulatory T cell, which will be described in the following section. 
As described above, positive expression of the ectoenzymes CD73 and CD39 [105, 106, 
136, 137] and a high expression of CTLA-4 [76-79] have been described as Treg-specific 
markers. Furthermore, the expression of L-selectin (CD62L) is not restricted to Tregs 
but can help to discriminate between recently activated T cells (CD62Llow) and Tregs 
(CD62L+) [138]. Tregs have been shown to express the tumour necrosis factor 
receptor (TNFR) superfamily members CD27 [139, 140], OX-40 (CD134) [141, 142] and 
GITR (glucocorticoid-induced TNFR family related gene) [143, 144]. Furthermore, 
positivity for LAG3 [110], HLA-DR [145] and ICOS (CD278) [146] have been shown to be 
characteristic for Tregs. To be able to discriminate between tTregs and pTregs, CD31 
was suggested as a marker to identify recent thymic emigrants [147, 148]. The positive 
expression of the Ikaros family of zinc-finger protein member Helios (IKZF2) was 
ascribed to tTregs [149-152], although the specificity of this transcription factor has 
been questioned [153, 154]. Finally, neuropilin-1 is found to be expressed by Tregs, 
preferentially by tTregs [155-158], which is true at least for mice [159]. 
 
Although all these markers are highly expressed by Tregs, they can also be 
expressed by other cells and it is only the combination of markers that can help to 
identify Tregs. One of the best characterised and well-accepted combinations is a 
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high expression of CD25 with concomitant low expression of the IL-7 receptor α-
chain CD127, which has been proven effective in identifying Tregs with suppressive 
capacity expressing high amounts of FoxP3 [160, 161]. Nevertheless, effector T cells can 
downregulate CD127 expression following activation [162] and it has been further 
suggested that CD4+CD25+CD127low Tregs and CD4+CD25+FoxP3+ Tregs do not 
represent the same population [163]. 
A landmark study by Miyara et al. in 2009 revealed that human CD4+FoxP3+ Tregs 
are heterogeneous comprising at least three phenotypically and functionally distinct 
populations based on FoxP3 and CD45RA/RO cell surface marker expression. These 
three distinct subsets were called population I, II and III and showed differences in 
the degree of FoxP3 DNA methylation, their cytokine secreting capacity as well as 
their in vitro suppressive activity [164]. Population I being CD45RA+FoxP3low was 
referred to as “resting” Tregs, whereas population II was characterized as CD45RA-
FoxP3high cells and was termed activated Tregs. Both populations were potent 
suppressors in vitro, whereas population III characterized by CD45RA-FoxP3low 
expression, was non-suppressive and capable of producing the pro-inflammatory 
cytokine IL-17 [164, 165]. 
 
1.6 Stability of Tregs in vivo 
The stability of Tregs in vivo has been studied using adoptive transfer of FoxP3+ 
Tregs into lymphopenic hosts [166, 167] as well as reporter mice to track Treg fate [168, 
169]. Komatsu et al. revealed that the great majority of Tregs retained their FoxP3 
expression upon adoptive transfer and that only a small subpopulation of Tregs lost 
FoxP3 expression, which could be reacquired following activation [166]. Rubtsov et al. 
Chapter 1: Introduction 
30 
further showed by tracking Treg cell fate in vivo that the large majority of FoxP3+ 
Tregs is stable under physiological and inflammatory conditions [169]. However, 
another study argued that a substantial percentage of Tregs was unstable (‘ex-
Tregs’) and produced inflammatory cytokines, and that the adoptive transfer of 
these autoreactive cells resulted in rapid onset of diabetes [168]. Furthermore, 
Duarte et al. showed that 50% of FoxP3-GFP+ Tregs lost FoxP3 expression following 
adoptive transfer into lymphocyte-deficient mice, which resulted in loss of 
suppressive function [167]. The frequency of unstable ‘ex-Tregs’ in physiological 
conditions remains controversial, but it has been suggested that these ‘ex-Tregs’ 
rather mark a population of T cells that transiently expresses FoxP3 but has never 
been earmarked to become a bona fide Treg, which is defined by demethylation of 
the FoxP3 locus rather than stable FoxP3 expression [170]. 
 
1.7 FoxP3 epigenetics 
It has become increasingly clear over the past years that FoxP3 expression per se is 
not sufficient for the induction of the Treg transcriptional landscape [171]. Recently-
activated effector T cells can transiently up-regulate FoxP3 expression without 
acquiring regulatory functions [65, 132-135] and furthermore, a pro-inflammatory 
cytokine-producing FoxP3+ Treg population (population III) has been identified in 
humans that was suggested to be non-suppressive [164]. Epigenetic modifications 
such as DNA methylation, nucleosome positioning and the modifications of histones 
play an essential role in determination and maintenance of stable T cell lineages as 
these modifications get passed on when a cell divides (reviewed in [172, 173]). As such, 
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Treg-specific epigenetic changes are crucial in maintaining their phenotypic and 
functional stability (reviewed in [174]). 
 
The human FoxP3 locus has four non-coding regions (introns), which are subject to 
epigenetic regulation (reviewed in [174]). A CpG-rich enhancer region within the 
FoxP3 locus, called the TSDR (Treg-specific demethylation region), has recently been 
identified to determine long-term stability of FoxP3 expression when 
hypomethylated [175-177]. The TSDR is highly conserved in mouse and human cells 
and is often referred to as CNS2 or intron 1. Full demethylation of methylcytosines 
in the TSDR, which occurs during early stages of Treg development in the thymus 
[178], confers stable FoxP3 expression and is found in Tregs, but not in conventional T 
cells [175, 176, 179]. However, repetitive in vitro stimulation was shown to lead to 
methylation in the TSDR and concomitant loss of FoxP3 expression in human 
CD45RA- Tregs [180]. Furthermore, the pro-inflammatory cytokine-producing Treg 
population III in humans was shown to be partially methylated at the TSDR [164]. 
 
Various studies have recently addressed the complexity of the transcriptional 
network of FoxP3 and regulatory T cells. Hypomethylation of Treg signature genes 
termed ‘nTreg-Me’ consisted of Tnfrsf18 (GITR) at exon 5, Ctla4 at exon 2 and Eos 
(Ikzf4) at intron 1 and FoxP3 and were shown to be crucial for Treg identity [177]. 
Furthermore, it was shown that FoxP3 does not establish a new enhancer landscape 
but binds within enhancer elements, which have been established by predecessors 
and are occupied by FoxP3 co-factors e.g. the nuclear factors ETS and RUNX [181]. 
Furthermore, structurally related transcription factors such as Foxo1 preferentially 
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acted as ‘placeholders’ for FoxP3 at sites subject to FoxP3-mediated 
downregulation of target genes [181]. The expression of any of the ‘quintet’ 
transcription factors, namely IRF4, Eos (IKZF4), GATA-1, Lef1 or Satb1, were shown 
to act in synergy with FoxP3 to induce a Treg-like gene signature in CD4+ T cells, 
which further enhanced the transcriptional activity of FoxP3 [182]. A study by the 
Rudensky group using a proteomic approach further showed that FoxP3 forms large 
heterogeneous protein complexes with multiple feedback loops containing 
transcription factors such as GATA-3, Runx1 and chromatin regulators [183]. These 
important findings confirmed previous studies highlighting the importance of GATA-
3 in Treg function [184, 185]. Stable expression of FoxP3 and functional activity was 
stabilised by the cooperative binding of the Runx/Cbf-β complex with Foxp3 to the 
demethylated CNS2 element [186, 187]. 
 
1.8 IL-17+ Tregs 
Mosmann et al. characterised two lineages of T helper cells in 1986, called Th1 and 
Th2 cells based on their distinct cytokine profile, expression of lineage specific-
transcription factors and their differences in mediating immune responses [188]. Th1 
cells help in fighting intracellular bacteria and protozoa. They are induced by IL-12 
and IFNγ and express the lineage-specific T-box transcription factor T-bet and STAT4 
[189, 190]. They are characterised by the production of IFNγ, lymphotoxin and IL-2 [191]. 
Th2 cells on the other hand help in fighting helminthic parasites [192], and are 
involved in the pathogenesis of asthma and allergy. Th2 cells need IL-4 for their 
differentiation and secrete the effector cytokines IL-4, IL-5 and IL-13. The lineage-
specific transcription factor is GATA-3, which is induced by STAT-6 together with 
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TCR signalling [193]. Once activated, GATA-3 induces the expression of c-maf, which 
initiates the transcription of Th2-associated cytokines [194]. However, it has been 
shown in recent years that the Th1/Th2 paradigm is not the end of the story and 
that T helper cell diversity is far greater. 
 
In 2005, a third effector arm of T helper cells was described, which is characterised 
by the production of IL-17, hence called Th17 cells [195, 196]. Th17 cells are important 
in the defence against extracellular bacteria and fungi, particularly at mucosal 
surfaces. However, this subset of T helper cells is also an important contributor to 
the pathology in autoimmune diseases [197]. Th17 cells express the lineage-specific 
transcription factor RORγt (Retinoid acid-related orphan receptor), which is STAT3-
dependent [198] and RORα also acting via STAT3 [199]. They further require the 
transcription factor IRF4 for their differentiation [200]. In addition to IL-17 (IL-17A), 
they can secrete the pro-inflammatory cytokines IL-17F, IL-21 and IL-22. Although 
studies have indicated a key role for IL-23 in Th17 cell induction [201, 202], IL-23 was 
shown to be dispensable for in vitro Th17 differentiation in mice [203]. It is now 
commonly believed that IL-23 is important for the survival, expansion and 
pathogenicity of committed Th17 cells, which seems to be dependent on another 
cytokine, IL-21 [204, 205]. IL-21 upregulates the expression of the IL-23R and 
additionally induces its own expression in an autocrine manner. Furthermore, the 
combination of IL-6 and TGF-β was found sufficient for the induction of IL-17 
expression in TCR-activated naïve CD4+ T cells in vitro [206, 207]. Further work 
demonstrated that IL-6 can be replaced by IL-21 for the induction of IL-17-producing 
CD4+ T cells [204, 205], which has been debated by other papers [208, 209]. 
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Although there are many similarities between mouse and human Th17 cells, there 
seem to be certain phenotypical and functional differences. TGF-β was described to 
be essential for human Th17 differentiation [210-212] and has further been shown to 
be critical for the upregulation of RORC [210], which is the human homolog of RORγt. 
However, the importance of TGF-β for human Th17 differentiation has been 
debated [213] and the cytokines critical for human Th17 differentiation seem to be 
exchangeable and involve either IL-1β and IL-23 [214], a combination of IL-23, IL-1β 
and IL-6 [212] or just IL-21 [210]. Previous work from our lab has further demonstrated 
that optimal Th17 induction in human memory CD4+ T cells is achieved by contact-
dependent stimulation by TLR-activated monocytes [215]. Human Th17 cells express 
the chemokine receptor CCR6 [216, 217], which suggests that these cells home to sites 
with excess CCL20, the ligand for CCR6. Indeed, this has been recapitulated in an 
animal model of arthritis where CCR6+ arthritogenic Th17 cells were recruited to 
inflamed joints via CCL20 [218]. In humans, the expression of the C-type lectin-like 
receptor CD161, which was initially described as an NK cell marker [219], was further 
described as a Th17 marker, which allows identifying T cells that become IL-17+ [220-
222]. 
 
It has been shown recently that human Th17 cells are plastic and can be induced to 
co-produce IFNγ [216]. Furthermore, Staphylococcus aureus was able to induce co-
production of IL-10 in Th17 cells, whereas Candida albicans induced IFNγ in Th17 
cells, which was dictated by monocyte-derived IL-1β [223]. The concept of plasticity 
of Th17 cells in different inflammatory conditions was further confirmed in mice 
using fate mapping analysis in IL-17 reporter mice [224]. 
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Although Tregs and Th17 cells display very distinct phenotypes and effector 
functions as described above, they share a reciprocal developmental pathway [225]. 
The differentiation of both Th17 cells and Tregs from naïve CD4+ T cells requires 
TGF-β, but the combination with pro-inflammatory cytokines such as IL-6 dictates 
whether a cell becomes a Treg or Th17 cell [203, 206, 226]. It was further demonstrated 
that Foxp3 antagonizes the activity of the Th17-specific transcription factors RORγt 
and RORα inhibiting Th17 differentiation [227], an effect that was overcome by IL-6 
and is mediated by STAT3 [228]. Furthermore, the vitamin A metabolite retinoic acid 
was described to regulate the TGF-β-dependent reciprocal development of Tregs 
and Th17 cells by favouring Tregs due to the ability to inhibit IL-6 [229]. Very recently, 
IL-27, a member of the IL-12 cytokine family, was suggested to be able to regulate 
the mutual relationship of Tregs and Th17 [230]. It was further shown that hypoxia-
inducible factor 1 (HIF-1) can regulate the balance between Treg and Th17 cell 
differentiation by targeting FoxP3 for degradation and enhancing Rorγt trancription 
[231]. This is in striking contrast to a study by Clambey et al. however, where hypoxia 
stimulated HIF-1α-dependent FoxP3 transcription and HIF-1α was crucial for Tregs 
to suppress inflammation [232]. Finally, Tregs can even promote Th17 responses in 
mice through consumption of IL-2 [233-236]. 
 
The differentiation of Tregs and Th17 cells is tightly linked and it has become 
increasingly evident over the past years that Tregs exert more plasticity than we 
initially thought. Recently, various studies revealed the existence of IL-17+ Tregs in 
vitro and in vivo [228, 237-247] e.g. in the peripheral blood (PB) of healthy controls [238, 
241], and at increased frequencies in PB from patients with inflammatory bowel 
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disease [246]. IL-17+ Tregs were further found at sites of inflammation such as human 
tonsils [241], periodontitis lesions [248], psoriatic skin [249], and the lamina propria of 
patients with Crohn’s disease [247]. It was shown that the combination of the pro-
inflammatory cytokine IL-1β and rhIL-2 in particular led to the conversion of Tregs 
into pro-inflammatory IL-17-producing cells in vitro [237, 239, 242, 244, 245]. Tregs from 
patients with psoriasis showed an enhanced propensity to differentiate into IL-17+ 
cells, which was accompanied by decreased FoxP3 expression and increased 
expression of retinoic acid receptor-related orphan receptor C2 (Rorc2) [249]. Two 
studies further showed that IL-17 expression by Tregs led to a down-regulation of 
Foxp3 with a concomitant upregulation of Rorc2 expression [237, 244]. These findings 
overall suggest that Tregs in an inflammatory environment may convert into IL-17–
producing cells and the obvious question that arises is whether these Tregs retain 
their suppressive function. 
 
1.9 Treg function in a pro-inflammatory environment 
Former work by our lab has shown that co-stimulation through the addition of anti-
CD28 mAb to co-cultures, as well as the addition of the pro-inflammatory cytokines 
IL-7 and TNF-α had an impact on Treg anergy and suppressive function [250]. It was 
further demonstrated by other groups that IL-7 abolished the ability of human Tregs 
to suppress the proliferation of Teff [139, 251]. The negative effects of IL-7 on Treg 
function were suggested to be due to a downregulation of CD39 expression by 
memory Tregs [252]. Evidence for negative effects of the pro-inflammatory cytokine 
TNF-α on Treg function was further provided by Valencia et al. in 2006. The addition 
of TNF-α inhibited the suppressive function of Tregs, which was accompanied by a 
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down-regulation of FoxP3 [253]. TNF-α preferentially activated the canonical NF-κB 
pathway in human Tregs, which led to the transcription of NF-κB target genes and 
the upregulation of surface marker expression such as OX-40 and 4-1BB, overall 
impairing Treg function [254]. Stimulation through the TNFR superfamily members 
GITR and OX-40 were previously shown to break Treg function [143, 255]. In line with 
the findings described above, work by Ehrenstein and other groups showed that 
Tregs in patients with rheumatoid arthritis were defective [253, 256-258], and that anti-
TNF-α therapy restored immune tolerance by the induction of a de novo Treg 
population [256]. 
 
However, beneficial effects of TNF-α on Treg function have also been reported [259]. 
Th17 cells were shown to promote the expansion of Tregs and stabilise Foxp3 
expression, which was due to high TNF-α and IL-2 secretion by T cells [260]. 
Furthermore, TNF-α together with IL-2 upregulated the expression of TNFR2, 4-1BB 
and OX40 on Tregs, which resulted in activation and optimal suppressor function 
[261]. TNF-α was further shown to be important for tTreg, which express high levels 
of TNFR2, but not pTreg functions [262]. In a mouse model for diabetes, effector T 
cells were able to boost Treg function for optimal protection, which was partially 
dependent on TNF-α [263]. 
 
A role for DC-derived IL-6 in impairing Treg function has been shown by a landmark 
study in mice by Pasare et al. [264]. This was recapitulated in a study investigating 
human psoriatic skin lesions, where IL-6 secreted by in vitro-derived DCs led to 
impaired CD4+CD25high Treg function [265]. However, in IL-6-transgenic mice with 
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constantly elevated serum levels of IL-6, Tregs were found to be increased in 
numbers and were able to suppress the proliferation of T cells [266]. 
In a human model of systemic inflammatory response induced by cardiac surgery 
Treg numbers were found to be increased [267]. These Tregs sustained a Treg 
phenotype expressing FoxP3, CTLA-4 and GITR, but showed a decreased ability to 
suppress Teff proliferation, an effect that could further be mimicked by adding 
serum obtained after cardiac surgery to cultures suggesting a role for soluble 
factors, although a role for IL-6 was excluded [267]. Although the data are not 
conclusive, it might indicate that a pro-inflammatory environment impairs Treg 
function. 
 
One of the key questions that still needs to be answered is whether Tregs that are 
induced to express pro-inflammatory cytokines such as IL-17 can still exert 
suppressive capacities. 
Miyara et al. suggested that the so-called population III (CD45RA-FoxP3low) is able to 
convert into IL-17-producing cells, and is non-suppressive [164]. This has been 
debated however, in a recent paper, where it was confirmed that the ‘Th17 
potential’ was indeed restricted to population III, particularly to CD161-positive 
cells, but these cells were as suppressive as the other Treg subpopulations [245]. In 
other studies, IL-17+ Tregs were induced in vitro from naïve Tregs in the presence of 
IL-1β and rhIL-2, and were shown to be impaired in their suppressive function [239, 
244]. It was further suggested that Tregs can be separated into Helios- Tregs 
(Aiolos+IL-1RI+) and Helios+ Tregs (Eos+IL-1RI-), which were both suppressive, but 
Helios- Tregs downmodulated suppressive function in response to IL-1β [268]. 
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However, beneficial effects of IL-1β in combination with TGF-β1 and IL-2 on the 
maintenance of FoxP3 expression by Tregs have been demonstrated, which led to 
an enhanced capacity of Tregs to suppress in vitro and in vivo [269]. In mice, in vitro-
induced IL-17+ Tregs displayed increased Runx1 expression, which stabilised the 
expression of FoxP3 and Rorc2 and these IL-17+ Tregs showed increased suppressive 
capacity compared to IL-17- Tregs [270]. Single-cell cloning further suggested that 
Tregs can transiently lose their suppressive function when actively secreting IL-17 
[242], whereas in other studies IL-17+ Treg clones were shown to be persistently 
suppressive [238, 241, 242]. 
 
In Crohn’s disease, IL-17+ Tregs from the inflamed intestinal mucosa of patients 
were shown to be suppressive [247]. Furthermore, CD4+CD25high Tregs isolated from 
ulcerative colitis or colon carcinoma tissues expressed higher transcript levels of IL-
17 than their blood counterparts and secreted significant amounts of IL-17 
following in vitro culture, but showed similar suppressive potential compared to IL-
17-FoxP3+ T cells [271]. FoxP3+IL-17+ T cells from the peripheral blood of patients with 
colon or colorectal cancer were able to suppress T cell proliferation [272, 273]. 
IFNγ+ and IL-17+ FoxP3+ Tregs were further shown to accumulate in the CNS of mice 
with experimental autoimmune encephalomyelitis (EAE), which showed reduced 
FoxP3 levels [274]. It has been suggested however, in another study that FoxP3+ Tregs 
in the inflamed CNS of mice with EAE are not converted into IL-17-producing cells 
due to their reduced responsiveness to IL-6 [275]. Additionally, Tregs from patients 
with type 1 diabetes contained increased percentages of IFNγ+ cells, but these cells 
showed high levels of FoxP3 expression and possessed suppressive activity [276]. 
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Koenecke et al. suggested that IFNγ production by Tregs was essential for the 
prevention of graft-versus-host disease [277]. 
 
Together these data indicate that pro-inflammatory cytokine expression by Tregs 
does not necessarily lead to impaired suppression and might be beneficial for 
optimal suppressor functions, a hypothesis that is supported by elegant studies in 
mice. Zheng et al. recently showed that IRF4 can form complexes with FoxP3, which 
regulates the expression of a set of genes that enable Tregs to suppress Th2 
responses [278]. Similarly, it was shown in another study that the expression of T-bet 
enables Tregs to migrate and accumulate at the site of Th1 responses due to the 
upregulation of CXCR3 [279]. Furthermore, ablation of STAT3 in Tregs led to the 
inability of Tregs to control Th17 responses [280]. Finally, Tregs that expressed Bcl6 
were able to regulate germinal centre responses [281, 282]. It was also shown that 
Tregs are able to acquire tissue-specific features, e.g. same chemokine receptor 
expression as effector T cells, which suggests that they home to the same sites 
(reviewed in [283]). Furthermore, Tregs isolated from adipose tissue exhibit a distinct 
gene signature compared with those from lymphoid tissue e.g. spleen and lymph 
nodes [284] and the unique properties of these fat-resident Tregs are orchestrated by 
the expression of the nuclear receptor PPARγ (peroxisome proliferator-activated 
receptors γ) [285]. 
 
Together these data suggest that regulatory T cells are able to sense environmental 
cues and adapt to the environment they are exposed to, to exert optimal 
suppressor function (reviewed in [286]). 
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1.10 Rheumatoid Arthritis (RA) 
Here in this thesis we used the systemic, chronic inflammatory disease rheumatoid 
arthritis (RA) as a model to understand how Treg function is influenced by a pro-
inflammatory environment. RA is characterised by inflammation of the joints and 
the surrounding tissue, which can be disabling and painful. A first detailed 
description of the disease was provided back in 1800 in a doctoral thesis by Landre´-
Beauvais. The term ‘rheumatoid arthritis’ was firstly used in 1859 by Sir Alfred 
Garrod (reviewed in [287]). 
 
1.10.1 Characteristics of the disease 
Approximately 0.5-1% of the world population suffer from this severe disease with 
more than 400,000 cases in the UK and women having a 3 times higher prevalence 
than men [288]. The disease can start at any age, but the prevalence rises with 
increasing age and typically occurs between 40-60 years of age. Patients with RA 
show an increased risk of cardiovascular disease (CVD), which is most likely the 
cause of the high mortality rate [289]. 
 
The 1987 American College of Rheumatology (ACR) criteria for classification of RA 
are well accepted [290]. Patients need to display 4 of the 7 disease features to be 
diagnosed with RA, namely morning stiffness, arthritis of 3 or more joint areas, 
arthritis of hand joints, symmetric arthritis, rheumatoid nodules, serum rheumatoid 
factor, or radiographic changes [290]. The major criticism for the 1987 ACR criteria 
was that they did not allow identification of earlier stages of the disease. Therefore, 
the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria 
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were designed to “redefine(s) the current paradigm of RA” [291]. A study by 
Humphreys et al. compared both criteria and supported the hypothesis of increased 
sensitivity for the 2010 criteria [292]. 
 
RA is a heterogeneous disease, but patients can be sub-classified based on the 
erosive status of the disease as measured by radiographs or based on the serology 
measuring positivity or negativity for anti-cyclic citrullinated protein antibodies 
(ACPA) and rheumatoid factor (RF), termed seropositive or seronegative RA, 
respectively. Due to the presence of autoantibodies, which precede the disease by 
many years [293-295], it is considered as an autoimmune disease. However, 
autoantibodies can be absent in some patients with RA and present in healthy 
individuals [296], which suggests that a more complex mechanism is involved in the 
disease. The acute phase response is indicative for a wide range of acute and 
chronic inflammatory conditions and is commonly increased in RA leading to a rise 
in both C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). 
However, the existence of patients with normal ESR and active synovitis has been 
described [297]. 
 
One early inflammatory event in RA is angiogenesis, which leads to the formation of 
new blood vessels and the invasion of synovial tissue. The hallmark of RA is a 
chronic inflammation of the lining of the synovial joint - the synovium, which 
provides nutrients for cartilage. The synovium consists of the outer layer 
(subintima) and the inner layer (intima), which under normal conditions is about 1-3 
cells thick, but hypertrophic in RA (8-10 cells). Inflammation of the synovium, also 
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known as synovitis, leads to joint pain, tenderness, swelling and stiffness. If 
inflammation persists the inflamed synovium invades causing deformity and 
damage of cartilage and bone leading to severe disability. This overall leads to 
destruction of the adjacent articular cartilage and the bone. 
 
Bone erosions in the context of RA were first described over a century ago by Baker 
(1855) and Weichselbaum (1878). Bone erosions can be detected by radiography 
and are associated with disease severity [298]. Synovitis, RANKL expression as well as 
local pro-inflammatory cytokine and autoantibody production stimulate osteoclast 
differentiation and inhibit osteoblast differentiation leading to an imbalance in 
bone resorption and bone repair (reviewed in [299]). Destruction of joints occurs 
when inflamed synovial tissue erodes and starts degrading adjacent cartilage and 
bone through the action of locally produced cytokines and metalloproteinases [300]. 
 
The exact cause of disease is as yet unknown, but risk factors include age, gender, 
genetic components and hormones as well as environmental factors e.g. smoking, 
and Porphyromonas gingivalis infection. Smoking is the best characterised 
environmental risk factor, which was first described in 1987 [301] and leads to a two 
times higher risk for male smokers and a 1.3 times higher risk for female smokers to 
develop RA [302]. There is a 15% concordance rate among monozygotic twins [303], 
which suggests genetic predisposition. Genome-wide association studies (GWAS) 
have helped to identify 46 risk loci among individuals with RA, which include HLA-
DRB1, PTPN22 and CTLA-4 [304, 305]. MHC association (HLA-DR4) with RA was already 
found in the late 1970ies [306] and HLA-DR positivity for certain alleles was suggested 
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to be associated with more severe disease [307]. The HLA-DRB1 locus is estimated to 
make up 30-50% of the genetic components to susceptibility, which is dependent 
on ethnicity [308]. A recent publication by Raychaudhuri et al. has demonstrated that 
the increased risk of developing RA can be attributed to five amino acid locations in 
not only HLA-DR, but also HLA-DP and HLA-B [309]. The authors further claimed that 
these locations explain almost completely the MHC association in seropositive 
disease. Another susceptibility locus is PTPN22, which encodes the protein tyrosine 
phosphatase Lyp. The R620W SNP (single nucleotide polymorphism) in the PTPN22 
gene results in an arginine to tryptophan substitution that is associated with RA 
with an odds ratio of 1.7 [310-313]. Another non-HLA SNP associated with RA is CTLA-4, 
but various studies in cohorts with different genetic backgrounds led to conflicting 
results about the association of the 49A/G and CT60 polymorphism in CTLA-4 and 
RA [313-316]. 
 
1.10.2 Treatment of RA 
During the last 10-15 years, there have been significant advancements in the 
treatment of RA due to the development of a wide range of drugs targeting specific 
aspects of the immune response (reviewed in [317]). The disease can be relatively 
well controlled in most patients although it is still not possible to cure rheumatoid 
arthritis at the moment.  
 
The first line of treatment in RA is the administration of non-steroidal anti-
inflammatory drugs (NSAIDs), which as the name implies reduce inflammation to 
relieve patients from symptoms such as pain and stiffness. NSAIDs include drugs like 
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aspirin and ibuprofen, which target the enzyme COX (cyclooxygenase) preventing 
the generation and release of prostaglandins from damaged tissue. However, 
NSAIDs fulfil a symptomatic treatment approach and do not interfere with the 
underlying immunopathology. 
To ‘modify’ the disease by reducing pain, swelling and joint destruction, disease-
modifying anti-rheumatic drugs (DMARD) are administered. The antifolate drug 
methotrexate (MTX) is the most commonly used DMARD, known for its efficacy but 
can also cause substantial side effects such as vomiting and nausea, which can be 
reduced by supplementing folic acid [318]. MTX is thought to act by suppressing 
enzymes involved in purine and pyrimidine metabolism, which leads to the 
inhibition of DNA replication and finally the accumulation of immunoregulatory 
adenosine. Other DMARDs commonly used to treat patients with RA include 
sulfasalazine and the pyrimidine synthesis inhibitor leflunomide. 
However, not all patients will respond to DMARD therapy. In the UK, when patients 
with RA fail to respond to at least two different DMARDs they qualify for TNF 
inhibitor (TNFi) therapy according to the NICE (National Institute for Health and 
Clinical Excellence) guidelines [319]. TNFi drugs are the most commonly used biologic, 
which has been the major breakthrough in the last decade. The pleiotropic cytokine 
TNF-α plays a crucial role in the pathogenesis of RA [320]. First experimental evidence 
for the effectiveness of blocking TNF-α in RA was provided using rheumatoid 
synovial cell cultures in the late 1980ies [321], which led to the first clinical trials with 
the antibody cA2 [322, 323], which is now known as infliximab. There are currently 5 
different TNFi drugs available that are approved for use in clinical care, the three 
first-generation agents etanercept, infliximab, and adalimumab as well as the two 
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second-generation agents certolizumab and golimumab. Infliximab, adalimumab 
and golimumab are monoclonal antibodies against TNF-α. Etanercept is a fusion 
protein of TNFRII attached to an IgG1 tail whereas Certolizumab is a recombinant 
humanized F(ab)2’ fragment [324]. On the downside, administration of TNFi drugs 
increases the risk of serious infections [325], especially tuberculosis [326, 327]. Other 
biological drugs include tocilizumab, a humanized IL-6R mAb, which inhibits IL-6 by 
binding to its soluble or membrane-bound receptor [328] and anakinra, a 
recombinant human IL-1R antagonist (IL-1Ra), which works by blocking the 
biological activity of IL-1 [329]. Rituximab is a chimeric anti-CD20 mAb, which targets 
B cells expressing CD20, interferes with the activation of these cells and depletes 
them [330]. In 2012, the tyrosine kinase inhibitor tofacitinib was approved by the FDA 
due to data on the efficacy and safety of the drug obtained from a large phase III 
clinical trial [331]. Tofacitinib interferes with the JAK-STAT pathway by targeting 
JAK1/JAK3. 
 
1.10.3 Cellular involvement 
A large number of cells have been described to contribute to the pathogenesis of 
RA including T cells, monocytes, macrophages, neutrophils, B cells, osteoclasts and 
synoviocytes. 
 
1.10.3.1 Monocytes in RA 
Human monocytes are a heterogeneous cell population of circulating white blood 
cells, which are known to play an important role in tissue repair as well as clearance 
of invading pathogens and cell debris. They can be subdivided into three distinct 
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populations based on their surface expression of CD14 and CD16 [332, 333]. The 
biggest population are the CD14+CD16- monocytes, which comprise about 80-90% 
of all peripheral blood monocytes and can be characterised by high expression of 
CCR2 and low expression of CX3CR1 
[334]. They are the main producers of IL-10 in 
response to LPS compared to the other monocyte populations, but can also produce 
significant amounts of IL-6, IL-8, CCL2 and CCL3 [333]. The population of 
CD14dimCD16+ monocytes have poor phagocytic capacity and do not express the Fc 
receptors CD32 (FcγRII) and CD64 (FcγRI). In 2010, they were referred to as so-
called “patrolling” monocytes [333] in analogy to the previously described mouse 
subset of Gr1lowCX3CR1
high monocytes [335]. CD14dimCD16+ monocytes do not induce 
ROS, IL-1β and TNF-α secretion following LPS stimulation, but they have the 
capacity to produce IL-1β, TNF-α and CCL3 in response to TLR7 and TLR8 stimulation 
[333]. CD14+CD16+ monocytes comprise the smallest population of human monocytes 
and are characterised by expression of the Fc receptors CD64 and CD32. They are 
highly phagocytic and major producers of TNF-α and IL-1β in response to LPS [336-
338]. An increase of CD14+CD16+ monocyte frequencies was reported in different 
chronic inflammatory conditions such as sepsis [339], asthma [340], solid tumors [341] as 
well as rheumatoid arthritis [342, 343] and atherosclerosis [344]. The spontaneous 
release of IL-1β by monocytes was reported in early arthritic patients [345, 346] 
suggesting that they are activated [347].  
 
It was long believed that monocytes infiltrate inflamed tissue through recruitment 
via chemokine receptor signalling pathways and differentiate into macrophages or 
dendritic cells depending on the signals they receive. However, it has been 
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described recently that there are tissue-resident macrophages that derive from 
haematopoietic progenitors in the yolk sac independent of monocytes [348]. Fate 
mapping studies by Ginhoux et al. further demonstrated that microglia, the CNS-
resident macrophages, are an ontogenically distinct mononuclear phagocyte 
population [349]. Furthermore, macrophages from different tissues were shown to 
harbour specific gene signatures and there was only a small group of transcripts 
that built a ‘core’ macrophage signature [350]. 
 
The importance of monocytes and macrophages in RA is supported by their 
abundant presence in the inflamed synovium of patients with RA [351]. They show 
clear signs of activation such as high expression of MHC class II as well as production 
of pro-inflammatory cytokines and chemokines [352]. Recruitment of monocytes into 
the RA joint is mediated by the presence of chemokines such as MIP-1α or MCP-1. 
Macrophage infiltration is correlated with inflammation and joint damage [353, 354]. It 
has been shown by labelling monocytes with technetium-99m that monocytes 
infiltrate into the synovium when re-infused into the same patient [355]. TNF-α is 
pre-dominantly produced by macrophages in RA [352] and treatment with TNF-
inhibitor drugs is effective in the majority of patients [356], which further suggest an 
important role of these cells in the pathogenesis of RA. It was further suggested 
that monocytes are able to differentiate into osteoclasts, which is mediated by M-
CSF [357] and RANKL [358], leading to bone resorption [359]. This was further 
potentiated in the presence of IL-1β and TNF-α [360]. 
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1.10.3.2 T cells in RA 
Earlier work showed that T cells are the main infiltrate in the synovium in RA [361] 
and that these cells are predominantly of a CD45RO+ memory phenotype [362]. T 
cells in the synovium express activation markers such as CD69, and CD69 expression 
correlates with disease activity [363]. The involvement of T cells in the pathogenesis 
of RA is well documented and the MHC class II association of the disease [306] further 
suggests an involvement of CD4+ T cells, in particular. It was further shown in 
experimental mouse models of arthritis that autoreactive T cells could transfer the 
disease [364]. Furthermore, CD4 deficiency in mice resulted in reduced susceptibility 
to collagen-induced arthritis, whereas CD8 absence had no impact on disease [365]. 
The efficacy of anti-CD4 mAb in animal models provided further evidence that CD4+ 
T cells are critical in the pathogenesis of RA [366, 367]. These findings could however 
not be recapitulated in clinical trials with patients with RA using an anti-CD4 mAb 
[368-370]. Nevertheless, abatacept, which is a CTLA-4 Ig fusion protein and prevents T 
cell activation, has proven to be clinically effective [371, 372]. 
 
RA has been typically viewed as a Th1-mediated disease [373, 374], but there is 
emerging evidence in the last decade that Th17 cells play an important role [375-379]. 
The pathogenicity of IL-17 in patients with RA has been described in the late 
1990ies before Th17 cells were even discovered [380, 381]. In animal models, 
overexpression of IL-17 was shown to exacerbate synovial inflammation in CIA [382] 
and conversely blocking of IL-17 in adjuvant arthritis led to a reduction in joint 
inflammation [383]. Patients with RA display increased levels of IL-17 in serum and 
synovial fluid [384-387], which seem to be correlated with disease activity [386]. 
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Furthermore, increased percentages of IL-17+ T cells are found ex vivo in patients 
with RA, especially at the site of inflammation and the percentage of those cells 
correlated with PDUS-defined synovitis [388]. The expression of IL-17 mRNA in 
synovial tissue was further shown to predict joint damage progression [389]. More 
recently, two monoclonal antibodies against IL-17, namely ixekizumab and 
secukinumab, have been tested in phase II clinical trials in patients with RA, and 
proven to be safe [390-392]. However, results of the on-going phase III trials for 
secukinumab are awaited to validate IL-17 blockers as effective therapeutic drugs in 
RA. IL-17 is thought to induce the production of matrix metalloproteinases (MMPs) 
[393] from stromal cells, and in combination with TNF-α leads to irreversible cartilage 
damage in RA [394]. IL-17 has further been shown to increase the expression of 
RANKL on osteoblasts, which promotes osteoclast differentiation and leads to bone 
destruction [395, 396]. Furthermore, IL-17 was shown to upregulate IL-1β and TNF-α by 
human macrophages [397].  
 
1.10.3.3 Tregs in RA 
Evidence for the involvement of Tregs in chronic inflammatory autoimmune 
diseases was provided by experimental arthritis models in mice. Morgan and co-
workers could show that the depletion of CD25+ cells in DBA/1 mice using a CD25-
specific mAb prior to a single immunization with type II collagen resulted in severe 
arthritis compared to control mice [398]. They further showed that the adoptive 
transfer of CD4+CD25+ T cells during the early phase of chronic arthritis resulted in a 
reduction of disease severity and Tregs could be detected in the inflamed synovium 
soon after transfer, indicating that regulation mediated by CD4+CD25+ T cells may 
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occur in the joint [399]. As depletion of CD25+ cells with an anti-CD25 mAb can 
possibly eliminate other cell types expressing CD25, such as effector T cells, NK cells 
and B cells [400], the scurfy mouse was used in other studies to investigate whether 
the absence of Tregs had an effect on the onset and severity of arthritis. Scurfy mice 
bear a mutation in the foxp3 gene and as a consequence are totally devoid of Tregs, 
which results in severe multi-organ inflammation [63, 68]. Similar to the results 
obtained with CD25-depleting antibodies, the absence of Tregs resulted in an earlier 
onset of disease as well as a more aggressive progression [401, 402]. 
 
Tregs and their role in rheumatoid arthritis have been studied extensively during 
the last years. However, determination of their frequencies in peripheral blood of 
RA patients led to conflicting results. Some studies reported increased [403-407] or 
similar frequencies [257, 408-412], whereas others showed that Treg frequencies were 
decreased in PB of patients with RA [413, 414] when compared to healthy controls. 
Data on the suppressive capability of Tregs from peripheral blood of patients with 
RA are also contradictory. Various studies showed a normal ability of CD4+CD25+ 
Tregs to suppress T cell proliferation [403-405, 413] as well as to suppress cytokine 
production by effector cells [403, 405, 411]. Ehrenstein et al. however showed that Tregs 
from patients with active RA are impaired in inhibiting pro-inflammatory cytokine 
production by T cells (IFNγ, TNF-α) and monocytes (TNF-α) [257]. The inability of 
Tregs from patients with RA to suppress IFNγ production by autologous Teff was 
further demonstrated by other groups [253, 415]. TNF-α was suggested to be critical in 
impairing Treg function [253, 258]. This finding was supported by the fact that anti-
TNF-α therapy restored immune regulation in RA by the induction of a de novo Treg 
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population [256, 257]. It was further shown in a study that membrane-bound TNF-α+ 
Tregs were less suppressive and that treatment of patients with RA with TNFi led to 
a reduction of membrane-bound TNF-α+ Tregs [416]. Reasons for these discrepant 
results are not well understood and cannot merely be explained by differences in 
surface markers used for isolation of Tregs or different patient cohorts [417]. 
 
The analysis of Treg frequencies in the synovial fluid of patients with RA is much less 
conflicting and papers show a consistent increase [403, 405, 408-414]. Only one recently 
published paper showed that Treg frequencies were similar in SF and PB [258] and 
the reasons for that discrepancy are not understood. Interestingly, synovial fluid-
derived Tregs were shown to display full capacity to suppress proliferation and 
cytokine production ex vivo [403, 405, 408-411]. They seemed to be even more 
suppressive than their blood-derived counterparts, which may be due to their highly 
activated phenotype e.g. increased CD69, MHC class II, GITR, OX-40 and CTLA-4 
expression [403, 408]. Similar results were obtained in juvenile idiopathic arthritis (JIA) 
[418]. Furthmore, recent work suggests that Tregs are intact in JIA but synovial 
effector T cells might be refractory to Treg-mediated suppression [419, 420]. 
Hyperactivation of PKB/c-Akt in Teff was shown to be associated with Teff 
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1.10.3.4 Treg-APC crosstalk 
Effective priming of naïve CD4+ T cells requires cell-to-cell contact with dendritic 
cells (DCs), which involves the interaction of CD28 expressed on T cells with the co-
stimulatory molecules CD80/CD86 expressed on APCs [422]. Antigen-specific T cells 
get activated and mature into effector cells, which re-enter the circulation and exert 
their effector function. The crosstalk between DCs and T cells is therefore key in 
bridging the innate and adaptive immune response. DCs also play an important role 
in establishing tolerance in the steady state as immature DCs can silence self-
reactive T cells or expand regulatory T cells [423]. It has recently been shown using 
intravital microscopy that Tregs form long-lasting interactions with DCs [81, 424], 
which can prevent contacts between DCs and T cells [81]. The interaction of mature 
DCs with Tregs can lead to abrogation of Treg function [264, 425-428], but conversely, 
Tregs are also able to suppress DCs by down-regulation of CD80/CD86 [13, 14], and 
suppression of pro-inflammatory cytokine production [429]. Furthermore, DCs are 
able to induce Tregs and increase their suppressive function [430, 431]. It has been 
shown in patients with RA with low disease activity that plasmacytoid DCs (pDCs) 
were able to induce the conversion of CD4+CD25- T cells into Tr1 cells via IDO [432]. 
These induced Tr1 cells were effective in suppressing proliferation of naïve CD4+ T 
cells [432]. 
 
As described above it is widely believed that DCs, but not macrophages, prime naïve 
T cells in vivo. However, it was shown that blood monocytes can be recruited into 
lymph nodes to T cell areas by microbial stimuli [433] and it has become increasingly 
clear over the years that monocytes are not just precursors of macrophages or DCs 
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but may also play distinct roles in polarising and expanding T cells (reviewed in [434]). 
In a mouse model of collagen-induced arthritis, cells expressing CD68, a 
glycoprotein highly expressed by monocytes and macrophages, initiated arthritis by 
the activation of autoreactive T cells [435]. Furthermore, autoreactive Th1 responses 
were shown to activate inflammatory monocytes in experimental inflammatory 
arthritis, which caused their mobilization to lymph nodes and supported Th17 cell 
responses [436]. The presence of macrophages with increased expression of co-
stimulatory molecules at the site of inflammation has been well reported in patients 
with RA [250, 437-440] suggesting that synovial macrophages can influence T cell 
reactivity. The interaction of activated T cells with monocytes leads to the 
production of the pro-inflammatory cytokines IL-1β and TNF-α [441-443] as well as 
MMPs [444], which are important contributors to the pathogenesis of RA [352]. It has 
further been shown that the interaction of T cells with monocytes play an important 
role in cartilage destruction [445]. Furthermore, the ability of monocytes to 
differentiate into osteoclasts is induced by IFNγ+ T cells [446]. Our group previously 
showed that in vivo activated CD14+ monocytes from the inflamed synovium 
specifically promote Th17 responses in co-cultures with CD4+ T cells in a cell-contact 
dependent manner [447]. Furthermore, Rossol et al. showed that patients with RA 
have increased frequencies of “pro-inflammatory” CD14brightCD16+ monocytes in the 
peripheral blood, which could potently induce Th17 cells in vitro [448]. These data 
overall suggest that the interaction of monocytes and T cells might contribute to the 
pathogenesis of RA, which thus far has not been well studied.  
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1.11 Hypothesis and summary of thesis aims 
Rheumatoid arthritis is a chronic inflammatory disease, which is characterised by 
the infiltration of various types of immune cells including CD4+ T cells and 
macrophages into the inflamed joint. Despite the presence of T cells with a 
regulatory phenotype, immune regulation appears disturbed. In recent years, 
studies have challenged the notion that CD4+CD25+FoxP3+ Tregs are terminally 
differentiated suppressor cells by showing that Tregs exhibit plasticity during 
development and in the periphery (reviewed in [449, 450]). The pro-inflammatory 
cytokine IL-1β, in particular, was shown to mediate the conversion of human Tregs 
into IL-17-producing cells in vitro [237, 239, 242, 244, 245]. Monocytes are important 
mediators of inflammation, are potent producers of pro-inflammatory cytokines 
such as IL-1β, and have been shown to be present at the site of inflammation in RA. 
We therefore hypothesised that activated monocytes impair Treg function in RA by 
converting them into IL-17-producing cells. 
 
The first aim of this thesis was to determine the presence and phenotype of CD14+ 
monocytes and CD4+CD25+CD127low regulatory T cells in the peripheral blood and 
the synovial fluid of patients with RA. We further wished to investigate whether 
there is evidence for the interaction of Tregs and monocytes in vivo (Chapter 3). The 
second aim was to investigate whether activated monocytes could induce IL-17-
expressing Tregs and whether this impaired Treg function (Chapter 4). The final aim 
was to investigate whether Tregs in the peripheral blood of patients with RA are 
intrinsically defective (Chapter 5). 
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Chapter 2: Materials and Methods 
2.1 Healthy volunteers and patients 
Peripheral blood (PB) was drawn from healthy adult volunteers by an experienced 
phlebotomist using venepuncture and a 21 G needle (BD Biosciences, Oxford, UK). 
Blood was collected in vacuum tubes containing the anticoagulant heparin (BD 
Biosciences) to prevent clotting of the blood and samples were processed within 
the following 2 hrs. Healthy controls (HC, n=42) were recruited from university or 
hospital staff and students, and blood was taken with written informed consent. PB 
was also obtained from patients with rheumatoid arthritis (RA, n=48) or psoriatic 
arthritis (PsA, n=19) and where available synovial fluid (SF) was collected by knee 
aspiration from patients (RA, n=15 and PsA, n=11). Ethics approval for this study 
was given by the Bromley Research Ethics Committee (06/Q0705/20). Patients were 
classified based on the 2010 ACR/EULAR criteria for RA [291, 451, 452] or the CASPAR 
classification criteria for PsA [453]. Blood parameters such as C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR), rheumatoid factor (RF) positivity and patient 
characteristics (age, sex and disease duration) were documented on the day of 
sample collection. The disease activity score 28 (DAS28), which scores the severity 
of the disease by assessing 28 joints, was calculated by a rheumatologist (Dr Bina 
Menon) based on the following formula [454]: 
 
               √             √              (   )            
(TEN28: tender joint count; SW28: swollen joint count; SA: subjective assessment of disease activity on a scale 
of 0-100) 
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A DAS28 greater than 5.1 is indicative of a high disease activity, whereas a DAS28 
between 3.2 and 5.1 is classified as moderate disease activity. A DAS28 < 3.2 is 
defined as low disease activity and patients with a DAS28 < 2.6 are considered as 
being in remission. 
 
A summary listing the demographic and clinical parameters for PB and SF samples 
obtained from patients with RA and details on HC PB samples are shown in Table 
2.1. The patient characteristics for the individual donors are shown Table 2.2. 
 
 
Table 2.1 Summary of patient characteristics for PB and SF samples and HC PB samples. 
Summary of demographic and clinical parameters for patients with RA and HC. 
DAS28: disease activity score; DMARD: disease-modifying anti-rheumatic drug; N/A: not available; 
NSAID: non-steroidal anti-inflammatory drug; TNFi: TNF inhibitor drug. 
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Table 2.2 Patient characteristics for each individual donor. 
Clinical and demographic details relating to the individual patient samples (n=48) indicating the 
sample type, age, gender as well as the clinical parameters where available. 
DAS28: disease activity score; DMARD: disease-modifying anti-rheumatic drug; N/A: not available; 
NSAID: non-steroidal anti-inflammatory drug; TNFi: TNF inhibitor drug. 
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2.2 Cell isolation 
2.2.1 Isolation of mononuclear cells from peripheral blood and synovial fluid 
The hydrophilic polysaccharide Ficoll™, which has a molecular weight of 400,000 Da, 
can be used to separate peripheral blood or synovial fluid into its components 
through a density gradient [455, 456]. 
 
Peripheral blood (PB) or synovial fluid (SF) was diluted 1:1 with phosphate-buffered 
saline (1x PBS, PAA, Pasching, Austria), carefully layered on 15 ml of Ficoll™ density 
gradient (LSM 1077, PAA) in 50 ml falcon tubes and subsequently spun at 1600 rpm 
for 20 min in a centrifuge (Eppendorf 5810R, Hamburg, Germany) at room 
temperature (RT) without break. During the centrifugation step, blood gets 
separated into four different layers as shown in Figure 2.1. The erythrocytes, which 
have the highest density, concentrate at the bottom of the tube, whereas the cells 
of interest - the peripheral blood mononuclear cells (PBMC) - separate between the 
blood plasma and the Ficoll™ layer due to the intermediate density of the cells. 
 
 
Figure 2.1 Human peripheral blood after Ficoll™ density gradient centrifugation. 
Peripheral blood is diluted with 1x PBS and layered on Ficoll™ in 50 ml falcon tubes. Tubes are 
centrifuged for 20 min without break. Pictures shows different layers obtained after density gradient 
centrifugation of human blood. 
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Following centrifugation, the interphase consisting of PBMC or SFMC was collected 
into 50 ml falcon tubes with a Pasteur pipette and cells washed twice with 1x PBS by 
centrifugation at 1200 rpm for 10 min at RT. Supernatants were removed and cell 
pellets resuspended in complete medium (RPMI 1640 (Gibco®, Paisley, UK) 
supplemented with 1% Pen-Strep (Gibco®), 10 mM Glutamine (Gibco®) and 10% 
foetal bovine serum (FBS, batch#: F9665, lot#: 030M3399, Sigma, St. Louis MO, 
USA)). Cells were counted using trypan blue (see 2.2.2) and brought up to a cell 
concentration of 10x106 cells per ml complete medium for ex vivo stains (see 2.7.1). 
 
When PBMC/SFMC were used for further isolation of CD14+ monocytes (see 2.2.3), 
cells were resuspended in ice-cold MACS buffer (1x PBS/ 0.5% BSA (PAA)/ 2 mM 
EDTA (Life Technologies, Paisley, UK)) at a concentration of 80 μl per 107 cells. 
 
2.2.2 Live cell counting using trypan blue 
To determine the total number of live cells in a cell solution with known volume, a 
haemocytometer and trypan blue staining was used. The haemocytometer consists 
of a robust glass microscopic slide, which has a rectangular indentation in its centre 
building two counting chambers. On top of the indentation an engraving of various 
square fields with definite sizes can be found. The grid in each chamber consists of 9 
big squares, which are built out of 16 small squares. An adequate volume of the cell 
solution was diluted with the diazo dye trypan blue (Sigma), which can be used for 
dead cell counts as the dye is only able to enter cells with a disrupted cell 
membrane [457], and a total volume of 10 µl of the diluted cell solution was loaded 
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into the haemocytometer. After the number of live cells has been counted in four 
big squares, the total cell count was calculated based on the following formula: 
 
(cell count of four big squares / 4) x dilution factor x 104 x total volume = total # of cells 
 
2.2.3 CD14+ monocyte isolation 
For the isolation and purification of CD14+ monocytes from PBMC or SFMC, a 
system based on magnetism was used, which is called magnetic-activated cell 
sorting (MACS). PBMC or SFMC were counted, 10 µl superparamagnetic anti-CD14 
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) per 107 cells added for 
positive selection and samples incubated for 15 min at +4°C in the fridge. Following 
incubation, cells were washed with ice-cold MACS buffer, supernatants discarded 
and cell pellets resuspended in 1 ml of MACS buffer. The cell suspension was then 
applied to an LS column (Miltenyi Biotec), which was placed into a magnetic field. 
The column was washed 3 times with 3 ml of MACS buffer and the negative fraction 
collected in 15 ml falcon tubes, whereas the positively-labelled CD14-expressing 
monocytes were retained inside the column. After removing the column from the 
magnetic field, CD14+ cells were eluted using a plunger and counted with trypan 
blue. Purity was confirmed by staining for the appropriate surface markers followed 
by flow cytometry using a BD FACSCantoII (BD Biosciences, Oxford, UK) and was 
consistently found to be >97% for PBM (see Figure 4.1, Chapter 4) with an average 
purity of 98±0.1% (mean±SEM) for HC (n=58) and 98±0.2% for patients with RA 
(n=13). However, isolation of synovial fluid monocytes (SFM) led to less pure cells 
(<90%) due to high percentages of neutrophils in the synovial fluid and its sticky 
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nature. Therefore, MACS-isolated monocytes were further sorted using a BD FACS 
Aria™ (BD Biosciences) when paired PB and SF samples were used, to increase the 
purity of the samples (see 2.2.6). 
 
2.2.4 CD4+ T cell isolation 
To isolate PB CD4+ T cells, the CD14- cell fraction, which was collected during the 
CD14+ monocyte isolation procedure, was used. A cocktail of primary biotin-
conjugated monoclonal antibodies (mAb) directed against CD8, CD14, CD16, CD19, 
CD36, CD56, CD123, T cell receptor γ/δ, and glycophorin A (Miltenyi Biotec) was 
added at a concentration of 5 μl per 107 cells for 5 min to label cells for negative 
selection. Anti-biotin coated magnetic particles (Miltenyi Biotec), which bind to the 
antibody-coated cells, were then added at 10 μl per 107 and cells incubated for 
another 10 min. Cells were subsequently applied to an LS column retained in a 
magnetic field, leading to unbound CD4+ T cells to be eluted during the washing 
step (3 x 3 ml MACS buffer). Purity staining was not routinely performed as the 
enriched CD4+ T cell fraction was used for cell sorting into Tregs and Teff (see 2.2.7). 
 
2.2.5 Memory CD4+ T cell isolation 
Memory CD4+ T cells were isolated by negative selection using magnetic cell 
separation (Miltenyi Biotec) similar to the procedure described for CD4+ T cells (see 
2.2.4). Briefly, cells were incubated with a cocktail of biotin-conjugated mAb against 
CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCRγ/δ, glycophorin and CD45RA (10 
µl per 107 cells) for 10 min at +4°C. Cells were further incubated with anti-biotin 
MicroBeads (20 µl per 107 cells) for 15 min and washed with MACS buffer followed 
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by application to a magnetic LS separation column. In this step, bead-bound cells 
were retained in the magnetic field whereas the unlabelled memory CD4+ T cells 
(CD4+CD45RA- T cells) were eluted. Purity of isolated memory CD4+ T cells was 
confirmed by flow cytometry and was always greater than 95% with an average 
purity of 97±0.2% (mean±SEM, n=29). MACS-isolated memory CD4+ T cells were 
then further used for flow sorting to obtain highly pure Tregs and Teff as described 
in 2.2.7. 
 
2.2.6 Sorting of CD14+ monocytes 
To increase the purity of MACS-isolated CD14+ monocytes from SF, paired PB and SF 
CD14+ monocyte samples from patients with RA were stained with 0.5 μl CD14-
APC/Cy7 (BioLegend, San Diego CA, USA) per 1x106 cells for 15 min at +4°C. Cells 
were washed once with MACS buffer by centrifugation at 1200 rpm for 10 min 
(+4°C) and resuspended in MACS buffer (2x107 per ml) before cells were sorted into 
12x75 mm polystyrene FACS tubes (BD Biosciences) with a BD FACS Aria™ machine 
based on positive CD14 expression leading to purities greater than 99% as 
determined by the cell sorter. 
 
Where indicated, MACS-isolated CD14+ monocytes from HC were stained with 
CD16-AlexaFluor488 (BioLegend) (1 μl per 106 cells) for 15 min after blocking with 
20 μl of FcR Blocking Reagent (Miltenyi Biotec) per 10⁷ cells (10 min, +4°C). Cells 
were washed with MACS buffer and sorted into highly pure CD16+ and CD16- cells 
using a BD FACS Aria™. A representative example is shown in Figure 4.9 (chapter 4). 
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2.2.7 Sorting of Tregs and effector T cells 
Freshly isolated, enriched memory CD4+ T cells were stained with CD25-PE (Miltenyi 
Biotec) and CD127-FITC (BioLegend) antibodies for 20 min at +4°C in 1x PBS 2% FBS 
followed by a washing step with 1x PBS 2% FBS. Labelled cells, resuspended at 1-
2x107 cells per ml, were sorted into Tregs (CD25+CD127low), CD25intCD127+ and 
CD25-CD127+ effector T cells (Teff) or CD25low/-CD127+ Teff using a BD FACS Aria™ 
leading to purities greater than 98% (Figure 4.4, Chapter 4). After sorting, cells were 
transferred into 15 ml falcon tubes, washed with complete medium, re-counted 
using trypan blue and resuspended at the desired cell concentration. 
 
For the experiments described in chapter 5, Tregs and Teff were sorted using a 
slightly different protocol to also obtain the CD45RA+ cell fraction. Bulk CD4+ T cells 
were freshly isolated and cells stained with CD4-PerCP/Cy5.5 (BioLegend), CD25-PE 
(Miltenyi Biotec), CD45RA-APC/Cy7, CD45RO-PacificBlue and CD127-FITC (all 
BioLegend) for 20 min in MACS buffer (+4°C). Following a washing step with MACS 
buffer, cells were sorted into CD4+CD45RA+CD45RO-CD25+CD127low Tregs (CD45RA+ 
Tregs), CD4+CD45RA-CD45RO+ CD25+CD127low Tregs (CD45RO+ Tregs), CD4+CD45RA-
CD45RO+CD25intCD127+ (CD25int Teff) and CD4+CD45RA-CD45RO+CD25-CD127+ Teff 
(CD25- Teff) using a BD FACS Aria™ as described in the sorting strategy in chapter 5 
(Figure 5.1). Samples were transferred into 15 ml falcon tubes, washed with 
complete medium and resuspended at the desired concentration based on the cell 
counts determined by the sorting machine. 
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2.3 In vitro activation of monocytes 
To activate CD14+ monocytes in vitro, cells were either stimulated with the TLR4 
ligand LPS (E. coli strain 0111:B4, Sigma) or cytokines, which are commonly 
associated with SF. Freshly isolated monocytes (10x106/ml) were either incubated 
with 100 ng/ml LPS, a cytokine cocktail consisting of human recombinant (hr) IL-1β, 
IL-6, IL-10, IL-17, TNF-α, OPN and IFNγ (R&D Systems, Minneapolis MN, USA) (see 
Table 2.3) or with complete medium (as the control) for 30 min at 37°C in 
eppendorf tubes with a hole in the top of the lid. Following incubation, cells were 
washed twice with medium, re-counted with a haemocytometer and plated for co-
culture assays, phenotypic staining or cytokine analysis. 
 
Name Company Concentration 
IL-1β R&D Systems 10 ng/ml 
IL-6 R&D Systems 10 ng/ml 
IL-10 R&D Systems 10 ng/ml 
IL-17 R&D Systems 10 ng/ml 
IFNγ R&D Systems 10 U/ml 
OPN R&D Systems 10 ng/ml 
TNF-α R&D Systems 10 ng/ml 
 
Table 2.3 List of recombinant cytokines and their final concentrations used in in vitro assays. 
 
2.4 Co-culture of Tregs or Teff with monocytes 
In vitro-activated or control-treated monocytes (1x105) were co-cultured with either 
Tregs or Teff for 3 days at a 1:1 ratio in the presence of 100 ng/ml soluble α-CD3 
mAb (Okt-3, Janssen-Cilag, Buckinghamshire, UK) in 96-well U-bottom culture plates 
in an incubator (Sanyo) at 37°C with 5% CO2. Soluble α-CD3 was used to polyclonally 
activate T cells by crosslinking of the CD3/TCR complex [458], whereas co-stimulation 
of CD28 was provided by the presence of monocytes in the culture plate. 
 
Chapter 2: Materials and Methods 
66 
Where indicated, blocking antibodies for IL-1β, IL-6 and TNF-α or CD58 (R&D 
Systems) (see Table 2.4) were added to co-cultures of LPS-mono with Tregs. In other 
experiments, hrIL-1β, IL-6 and TNF-α (all at 10 ng/ml) were added to co-cultures of 
mono-med with Tregs. Where supernatants of activated monocytes were 
transferred, these were collected from autologous or allogeneic LPS-pre-activated 
monocytes after 40 hrs and added 1:1 (v/v) to co-cultures of Tregs and mono-med. 
In some experiments sorted PBM and SFM from patients with RA were co-cultured 
with allogeneic Tregs or Teff from HC at a 1:1 ratio in the presence of soluble α-CD3 
mAb; in one experiment autologous PB Tregs from a patient with RA were used. 
 
Name Clone Isotype Company Concentration 
anti-human IL-1β 8516 mIgG1 R&D Systems 1 μg/ml 
anti-human IL-6 1936 mIgG2b R&D Systems 10 μg/ml 
anti-human TNF-α 1825 mIgG1 R&D Systems 1 μg/ml 
anti-human CD58 polyclonal goat IgG R&D Systems 10 μg/ml 
mouse IgG1 control 11711 - R&D Systems 2 μg/ml 
mouse IgG2b control 20116 - R&D Systems 10 μg/ml 
goat IgG control polyclonal - R&D Systems 10 μg/ml 
 




2.5 CFSE suppression assay 
To measure the proliferation of cells, carboxyfluorescein succinimidyl ester (CFSE) 
was used [459]. CFSE is a fluorescent dye that passively diffuses into cells across the 
plasma membrane. Inside the cell, intracellular esterases cleave the acetate groups 
of the molecule leading to its conversion into fluorescent esters and its retention 
inside the cell. Proliferation can then be monitored due to the fact that the 
fluorescence of CFSE halves following each cell division [460]. 
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Freshly sorted CD4+CD45RA-CD25-CD127+ Teff (2-5x106/ml) were labelled with 2 µM 
CFSE (Molecular Probes™, Eugene OR, USA) in 1x PBS for 15 min at 37°C in 
eppendorf tubes. Following incubation, cells were transferred into 15 ml falcon 
tubes and 2 ml pre-warmed complete medium was added to quench the probe. 
Cells were centrifuged for 10 min at 1200 rpm at RT, the supernatant discarded and 
cells resuspended in 1 ml complete medium. Complete modification of the probe 
was allowed in a further incubation step of 30 min at 37°C. Thereafter, cells were 
washed twice with complete medium, recounted and 1x106 cells plated in a 24-well 
plate in a total volume of 1000 µl. At the same time, unlabelled sorted CD4+CD45RA-
CD25+CD127low Tregs at various concentrations (1x104-5x104) were cultured in 
separate wells in a 96-well U-bottom plate with 5x104 monocytes either pre-treated 
with LPS (cytokines) or medium in the presence of soluble α-CD3 mAb in a total 
volume of 100 µl. The next day, CFSE-labelled Teff were taken off the plate, washed 
and recounted and 5x104 cells added to the Treg-monocyte co-cultures in the 
presence of α-CD3 mAb. Cell culture volumes were made up to a total volume of 
250 μl and proliferation assessed 48 hrs later. 
In chapter 5, this protocol was slightly adapted, in the sense that CFSE-labelled 
CD4+CD45RO+CD45RA-CD25-CD127+ or CD4+CD45RO+CD45RA-CD25intCD127+ Teff 
were added to the monocyte and Treg co-cultures from day 0. 
To determine the percentage proliferation of cells, fluorescence (FL-1) was assessed 
at day 3 using a BD FACSCantoII. Analysis was performed by gating on live CFSE+ 
cells and determining the % of divided cells. The percentage suppression of cell 
proliferation was calculated based on the following formula: 
 
[ 100 – (% proliferation (condition w/ Treg) / % proliferation (condition w/o Treg) * 100) ] 
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2.6 Flow Cytometry 
Flow cytometry or fluorescence-activated cell sorting (FACS) allows characterisation 
of single cells by size, granularity, and internal complexity as well as their 
fluorescence intensity. When cells are acquired on a FACS machine they are pressed 
into the injector, where a precise stream of fluid is created. A beam of light of a 
single wavelength is directed onto the stream. Each suspended particle passing 
through the beam scatters light in several ways. Cells can be labelled with specific 
antibodies that are coupled to fluorescence dyes (e.g. FITC, PE). These dye 
molecules are activated to fluoresce and the emitted and scattered light is 
measured by specific detectors. The scattered light provides information about the 
size (FSC) and the granularity of the cell (SSC), whereas the fluorescence provides 
information whether the antibody has bound its specific target molecule either 




Figure 2.2 Representative example for dotplots obtained by flow cytometry. 
(A) SSC (y-axis) vs. FSC (x-axis) analysis of PBMC, which provides information about the granularity 
and the size of the cell, respectively. (B) Representative example for positive CD3 staining within 
PBMC, shown as dotplot (left) and histogram (right). 
 
The BD FACS CantoII is equipped with three lasers (405 nm - violet laser, 488 nm - 
blue laser and 633 nm - red laser) allowing the use of up to 8 fluorochromes for 
multi-colour flow analysis. 
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2.6.1 Compensation Beads 
When performing multi-colour flow analysis, compensation is crucial to prevent 
overlapping of the emission spectra, which would lead to false positive results. 
Compensation is ideally performed with the cells that were stained in the 
experiment to account for auto-fluorescence. However, cell numbers are often a 
limiting factor, which is why compensation beads are commonly used. Anti-mouse 
(or anti-rat) CompBeads (BD Biosciences) are polystyrene microparticles that are 
coupled to an antibody specific for the κ light chain of mouse (rat) immunoglobulin 
(Ig), hence positively binding all murine (rat) Ig antibodies. The kit also contains 
negative beads, which do not show any binding specificity and serve as the negative 
control. Spectral overlap values are then measured for the different fluorochromes 
in every detector using single-stained controls for all the fluorchromes used. The BD 
FACS CantoII machine has an automated compensation programme, which 
calculates the spectral overlap values automatically and applies it to the acquired 
samples of interest. 
 
2.6.2 Phenotypic staining 
To phenotype PBMC and SFMC, cells were stained with different surface antibodies 
listed in Table 2.5. Cells (0.5-1x106 cells) were usually stained in a total volume of 
100 μl FACS buffer (1x PBS/ 1% BSA / 0.1% NaN3) in eppendorf tubes for 30 min at 
+4°C. Thereafter, cells were washed with FACS buffer and centrifuged at 8000 rpm 
for 5 min in an eppendorf centrifuge. Cells were fixed with 2 % PFA for 10 min (see 
2.6.3.), and then acquired on a BD FACS CantoII machine. 
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For sample analysis the FlowJo 7.6.1 software (Tree Star Inc., Ashland OR, USA) was 
used and live cells gated based on forward (FSC) and side scatter (SSC). Duplets 
were excluded by FSC-W vs. FSC-A analysis and FMO (fluorescence minus one), 
isotype controls or unstained cells were used to account for background staining. 
Results were expressed as either a percentage of positive cells or as the geometric 
mean fluorescence intensity (MFI) of the population. 
 
Antigen Fluorochrome Clone Company μl per stain 
CD2 PacificBlue TS18 BioLegend 0.1 μl 
CD3 APC/Cy7 HIT3a BioLegend 1.25 μl 
CD3 PE/Cy7 UCHT1 BioLegend 1 μl 
CD4 PerCP/Cy5.5 SK3 BioLegend 0.1 μl 
CD4 PacificBlue SK3 BioLegend 1 μl 
CD14 APC/Cy7 HCD14 BioLegend 1 μl 
CD14 APC UCHM-1 AbD Serotec 1 μl 
CD16 AlexaFluor488 3G8 BioLegend 1 μl 
CD19 PE HIB19 BioLegend 1 μl 
CD25 PE 4E3 Miltenyi Biotec 2 μl 
CD39 PE/Cy7 A1 BioLegend 2 μl 
CD40 PE LOB7/6 AbD Serotec 2 μl 
CD45RA APC/Cy7 HI100 BioLegend 2 μl 
CD45RO PacificBlue UCHL1 BioLegend 1 μl 
CD54 AlexaFluor647 HCD54 BioLegend 1 μl 
CD58 PE 248310 R&D Sytems 5 μl 
CD69 FITC FN50 AbD Serotec  2 μl 
CD86 PacificBlue IT2.2 BioLegend 2 μl 
CD127 AlexaFluor488 HCD127 BioLegend 5 μl 
CD127 FITC A019D5 BioLegend 1 μl 
CD161 AlexaFluor647 HP-3G10 BioLegend 2 μl 
CD161 PE/Cy7 HP-3G10 BioLegend 5 μl 
HLA-DR PerCP/Cy5.5 G46-6 BD Biosciences 2 μl 
 
Table 2.5 List of flow cytometric surface antibodies. 
 
2.6.3 Fixation with PFA 
Paraformaldehyde (PFA) is a crosslinking reagent, which preserves the cell structure 
but can obstruct antibody binding. The aldehyde group of PFA can combine with 
nitrogen and other atoms of proteins, forming a cross-link. Overfixation (longer 
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than 10-15 minutes) can modify the amino acids of an epitope the antibody is 
directed to and therefore prevent antibody binding. 
Cells were fixed with a 2% PFA solution (diluted in 1x PBS) for 10 min before cells 
were acquired on a flow cytometer or permeabilised for cytokine analysis (see 
2.7.1). 
 
2.7 Cytokine analysis 
2.7.1 Intracellular Cytokine Staining (ICCS) 
Phorbol 12-myristate 13-acetate (PMA, Sigma), also known as TPA (12-O-
tetradecanoylphorbol-13-acetate), activates protein kinase C (PKC) due to its 
similarity to the second messenger diacylglycerol (DAG) [461]. The calcium ionophore 
ionomycin (Sigma) is produced by the bacterium Streptomyces conglobatus and acts 
by increasing intracellular Ca2+ concentrations; it synergises with PMA and enhances 
the activation of PKC [462]. GolgiStop (BD Biosciences) contains monensin, which 
interferes with the protein transport from the endoplasmatic reticulum (ER) to the 
Golgi leading to the accumulation of cytokines inside the cells [463]. 
 
For ex vivo staining, isolated PBMC or SFMC (2x106 cells per ml) were stimulated 
with 50 ng/ml PMA and 750 ng/ml ionomycin for three hours in the presence of 
GolgiStop (0.67 μl per 1 ml) in a 24-well plate. Following incubation, cells were 
taken off the plate, transferred to eppendorf tubes and washed with FACS buffer. 
Cells were then stained for CD3, CD14 and CD45RO on the surface for 30 min at 
+4°C, which was followed by a washing step and fixation with 2% PFA for 10 min. As 
the expression of CD4 on T cells gets downregulated following PMA stimulation [464] 
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staining for CD4 was performed intracellularly together with IL-10, IL-17, IFNγ, TNF-
α or FoxP3 for 30 min at RT using 1x FoxP3 perm buffer (BioLegend), which was 
preceded by a 15 min incubation step with 1x FoxP3 perm buffer alone. Cells were 
acquired on a BD FACS CantoII within the next 24 hrs and analysis performed using 
the FlowJo software and the gating strategy as described in Figure 2.3. 
 
For intracellular cytokine staining (ICCS) after in vitro co-culture (3 days), 
supernatants (110 μl) were first collected and cells then stimulated with PMA and 
ionomycin for 3 hrs. GolgiStop was added for another 3 hrs and thereafter cells 
were surface stained for CD2 and CD14, followed by fixation with 2% PFA. Cells 
were stained intracellularly for IL-10, IL-17, IFNγ and TNF-α using Saponin buffer (1x 
PBS/ 0.5% Saponin) for 30 min at +4°C. Saponin is a mild membrane solubilizer, 
which forms large enough pores for antibodies to go through without dissolving the 
plasma membrane [465]. When FoxP3 or Ki-67 staining was combined with ICCS, 1x 
FoxP3 perm buffer was used as described for the ex vivo stains. Samples were 
acquired on a BD FACS CantoII and analysis performed using the FlowJo software as 
described in the gating strategy (Figure 2.4). See Table 2.6 for a list of antibodies 
used for ICCS. 
 
Antigen Fluorochrome Clone Company μl per stain 
IL-10 AlexaFluor488 JES3-9D7 BioLegend 5 μl 
IL-17 PE BL168 BioLegend 5 μl 
IFNγ PerCP/Cy5.5 4S.B3 BioLegend 0.5 μl 
TNF-α APC Mab11 BioLegend 5 μl 
TNF-α FITC Mab11 BioLegend 15 μl 
FoxP3 AlexaFluor647 259D BioLegend 5 μl 
Ki-67 AlexaFluor488 Ki-67 BioLegend 5 μl 
Isotype AlexaFluor647 MOPC-21 BioLegend 5 μl 
 
Table 2.6 List of intracellular and intranuclear antibodies for flow cytometry. 
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Figure 2.3 Gating strategy for ex vivo stains. 
Mononuclear cells (MC) were isolated from peripheral blood (PB) or synovial fluid (SF) using Ficoll 
density gradient centrifugation. Cells (2x10
6
 cells per ml) were stimulated with 50 ng/ml PMA and 
750 ng/ml ionomycin for 3 hrs in the presence of GolgiStop. Cells were taken off the plate and 
stained for CD14, CD3 and CD45RO on the surface. After fixation with 2% PFA, cells were stained for 
intracellular molecules (e.g. cytokines, FoxP3) using FoxP3 perm buffer. (A) Live cells were gated 
based on size and granularity (FSC vs. SSC) and CD14
+




 cells were gated and 
duplets excluded based on FSC-W vs. FSC-A analysis. If relevant, cells were further gated based on 







 T cells. Gates were based on the control stains (surface only), which were 
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Figure 2.4 Gating strategy for ICCS of co-cultures on day 3. 
For intracellular cytokine analysis of co-cultures of Tregs or Teff with autologous monocytes (day 3), 
cells were re-stimulated with PMA and ionomycin in the presence of GolgiStop. (A) Live mononuclear 
cells were gated based on size and granularity, and T cells gated based on positive CD2 expression 
and CD14-negativity. Duplets were excluded using FSC-W vs. FSC-A analysis and autofluorescent 
monocytes further excluded by negative AmCyan gating. (B) Cytokine gates for determination of the 
% of cells expressing the indicated cytokines were based on appropriate control staining (surface 
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2.7.2 Enzyme-linked immunosorbent assay (ELISA) 
The enzyme-linked immunosorbent assay (ELISA) is a detection method for proteins 
in solution such as cell culture supernatants. This method can therefore be used to 
quantify the levels of cytokine or chemokine secretion by cells. 
 
A typical sandwich ELISA is performed in a 96-well plate. A capture antibody, which 
is directed against a specific epitope of the protein to be detected, is coated on the 
wells of the plate one day before the assay. The following day, excess capture 
antibody is washed away with washing buffer (1x PBS/ 0.05% Tween20). Wells are 
further blocked for 1 hr to prevent nonspecific binding using 1x PBS containing 1% 
of the protein bovine serum albumin (BSA), which saturates the unoccupied binding 
sites thereby reducing the background. Next, the standards for the protein to be 
detected as well as the samples with unknown concentrations are added. The 
standard is provided with the individual ELISA kit and has a known concentration. A 
dilution series of the standard is performed, which is used for determination of the 
protein concentration later on based on a standard curve. After incubation of the 
samples and standards for 2 hours at RT, plates are washed and a biotinylated 
detection antibody, which binds to another epitope of the bound protein, is added 
for 1-2 hrs, depending on the ELISA kit. Finally, a streptavidin-HRP antibody that 
binds to the Fc portion of the detection antibody is added after another washing 
step, making the sandwich complete. A substrate solution is added, which is 
disintegrated by the streptavidin-conjugated enzyme horseradish peroxidase, 
resulting in a colour reaction. Depending on the experimental setup the colour 
reaction may need to be stopped to achieve a colour change that can be measured 
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with an ELISA reader (Wallac). The intensity of colour directly correlates with the 
amount of antigen present in the original sample taking into account possible 
dilution factors. 
 
The concentration of the antigen in each sample (pg/ml) was calculated with the 
equation of the linear trendline of the standard curve graph, which plots the mean 




Figure 2.5 Representative example for a typical standard curve of an IL-6 ELISA. 
 
For detection of cytokines following monocyte pre-stimulation with either medium 
or LPS, cell culture supernatants were obtained after 40 hrs. For cytokine detection 
after monocyte-T cell co-cultures, supernatants were taken after 3 days, before and 
after a 3 hr PMA and ionomycin re-stimulation. Supernatants were centrifuged to 
remove cell debris and stored at -80°C until further used. IL-1β (R&D Systems), IL-6, 
IL-10, IL-17, IFNγ (all BioLegend), TNF-α (R&D Systems and BioLegend), Ready-SET-
Go!® IL-23, IL-27 and TGF-β1 (eBioscience, San Diego CA, USA) ELISA kits were used 
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2.7.3 Human 25-plex Cytokine Array 
Some of the cell culture supernatants were analysed by a human 25-multiplex bead 
cytokine array (Life Technologies), which allows the simultaneous detection of 25 
cytokines and chemokines on the Luminex platform (Luminex, Austin TX, USA). 
This assay uses the so-called xMAP technology, which makes use of polystyrene 
beads (microspheres) that are coupled to capture antibodies specific for the 
different analytes. The different microspheres are spectrally encoded internally with 
red and infrared fluorophores of different intensities thereby defining a certain 
bead region. The technology combines flow cytometry with ELISA and assays are 
carried out in 96-well filter plates. The red laser of the Luminex machine excites the 
beads that pass through the detection chamber to allow classification of the beads 
based on their specific bead region, whereas the green laser excites any 
fluorescence that is caused by successful binding of Streptavidin-RPE to the 
sandwich complex consisting of the beads, the bound analytes in the sample and 
the detection antibody. 
The assay was carried out according to manufacturer’s instructions, but all reagents 
were halved in volume. Plates were acquired on a Luminex FlexMap 3D machine 
using the Xponent 4.0 software (Luminex). Analysis of the data was performed by 
the software provided on the Luminex machine. 
 
2.8 Immunohistochemistry (IHC) 
Immunohistochemistry (IHC), which was first developed by Nakane and Pierce for 
single staining in 1967 [466], is used to detect the presence and/or localisation of 
antigens in tissue sections. The principle relies on antibody binding to the protein of 
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interest, which is then visualised by secondary antibody-enzyme-substrate reactions 
(e.g. horseradish peroxidase or alkaline phosphatase), which convert colourless 
chromogen into colour and permanently stain the specimen. 
 
Tissue sections from paraffin-embedded tonsil blocks that were chilled on a cold 
plate were cut as a ribbon with a manual microtome (Leica, Milton Keynes, UK) at a 
thickness of 5 μm and were floated on a water bath set at 45°C to stretch the 
individual sections. Sections were transferred on Superfrost Ultra Plus slides 
(Thermo Scientific, Runcorn, Cheshire, UK) and allowed to dry. To remove the 
excess paraffin around the tissue, slides were left on a heating block at +60°C until 
the excess paraffin had melted and the tissue was completely deparaffinised. Next, 
the tissue sections were rehydrated to allow optimal staining as most dyes are 
water soluble. To achieve this, slides were incubated in a container filled with 
Xylene for 2 x 10 min, followed by incubation in IMS (denatured alcohol) for 2 x 10 
min. Slides were left in a container filled with ddH2O until further processed. 
As methylene bridges can form during the fixation process of the tissue of interest, 
which leads to cross-linking of proteins, antigen retrieval is usually performed to 
break these methylene bridges. A plastic container was filled with target retrieval 
solution (DAKO, Ely, Cambridgeshire, UK) and pre-warmed in a water bath set at 
+95°C; the solution turns milky-cloudy once it has reached its optimal temperature. 
Slides were incubated in the pre-warmed retrieval solution for 40 min and 
afterwards cooled down at RT for approx. 20 min in ddH2O. Slides were washed 
once with ddH2O and then twice with 1x TBST wash buffer (50 mM Tris-Cl, 0.1% 
Tween20, pH 7.6). 
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Next, slides were marked with a waterproof pen drawing lines around the tissue. To 
prevent unspecific binding due to endogenous peroxidase activity, sections were 
blocked for 5-10 min at RT with dual endogenous enzyme block solution provided 
with the EnVision®+ Dual Link System-HRP (DAB+) kit (Dako). Thereafter, slides were 
washed with wash buffer, excess buffer tapped off and slides incubated overnight 
at +4°C with a CD68 antibody (clone: PG-M1, DAKO) or the appropriate isotype 
control (mIgG3) (Table 2.8) at a 1:100 dilution in a humidified chamber to prevent 
drying of the tissue. 
 
The following day, slides were washed twice with wash buffer and excess buffer 
tapped off. Next, slides were incubated for 30 min at RT in the dark with polymer-
HRP, which is coupled to antibodies (Abs) against rabbit or mouse IgG therefore 
binding to the primary antibody (mIgG3). Following incubation, slides were washed 
twice with wash buffer, excess buffer removed and sections incubated with 3,3’ 
diaminobenzidine (DAB) substrate chromogen (1 drop per 1 ml substrate buffer) for 
about 5 min at RT until the brown colour had developed. Thereafter, sections were 
washed thoroughly with wash buffer. 
 
Next, staining for FoxP3 was performed using the EnVision™ G|2 System/AP, 
Rabbit/Mouse (Permanent Red) kit (Dako). The FoxP3 Ab (clone: 236A/E7, AbCam, 
Cambridge, UK) was used at a concentration of 1:100 and slides incubated for 1 hr 
at RT in the dark. Slides were washed 2x with wash buffer, excess buffer removed 
and sections covered with rabbit/mouse (LINK), which is a dextran polymer coupled 
with Abs to rabbit or mouse IgG. Following incubation for 30 min, slides were 
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washed twice, excess wash buffer tapped off and sections incubated with alkaline 
phosphatase (AP) enzyme (enhancer), which is an AP-labelled amplification 
polymer. Incubation was performed for 30 min at RT in the dark and slides washed 
with wash buffer twice thereafter. Next, Permanent Red chromogen was diluted 
1:100 in substrate buffer and sections incubated with the solution for 5-20 min at 
RT protected from light. Once the pink colour had properly developed, slides were 
washed thoroughly with ddH2O. 
 
Haematoxylin counterstain was routinely performed on tissue sections by briefly 
soaking slides in Haemalum (VWR International Ltd., Lutterworth, Leicestershire, 
UK), which is a dye staining nucleic acids in the cell nucleus. Slides were washed 
thoroughly with tap water and the tissue de-hydrated by incubation in IMS 
(denatured alcohol) for 2 x 10 min, followed by incubation in Xylene for 2 x 10 min. 
Finally, the slides were mounted by distributing mounting medium (VWR) on a 
coverslip, which was then placed on the stained section. 
 
For analysis of the staining, the total number of CD68+ and FoxP3+ cells was counted 
in 2 high powered fields (HPF = 40x magnification) and the percentage of 
CD14+/CD68+ cells co-localising with FoxP3, or the percentage of FoxP3+ cells co-
localising with CD14/CD68 calculated. 
 
Antigen Isotype Clone Company concentration 
used 
CD68 mIgG3 PG-M1 DAKO 1:100 
FoxP3 mIgG1 236A/E7 AbCam 1:100 
isotype mIgG1 - DAKO 1:100 
 
Table 2.7 List of antibodies used for IHC. 
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2.9 Statistical Analysis 
Significance testing was performed using Prism 5 software (GraphPad, San Diego 
CA, USA). Data were tested for normality with the D’Agostino and Pearson omnibus 
normality test, followed by the appropriate parametric or non-parametric test, as 
indicated in the figure legends. 
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Chapter 3: The presence and phenotype of monocytes and Tregs in the 
peripheral blood and synovial fluid of patients with RA 
3.1 Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease mainly affecting the 
small joints of the hand and feet, which is characterised by inflammation and 
swelling of the synovial membrane. The synovial membrane (SM) is a small tissue 
lining the joints, which secretes synovial fluid to lubricate the joint and prevent 
friction. In disease conditions such as RA, chronic inflammation causes the 
formation of new blood vessels and increased synovial permeability, which 
facilitates the infiltration of various immune cells including fibroblast-like 
synoviocytes (FLS), macrophages, T cells and neutrophils transforming the synovium 
(reviewed in [467]). The excessive production of pro-inflammatory cytokines leads to 
further recruitment of cells into the tissue, enhanced proliferation of synovial cells 
and synovial hyperplasia [468]. Synovial fluid starts to accumulate in the joint space, 
which is commonly aspirated to reduce swelling and pain. 
 
A pivotal role for macrophages in the pathogenesis of RA has been suggested 
(reviewed in [354]) due to the finding that increased percentages of macrophages 
accumulate in the inflamed synovial joints [351, 355, 469]. They are further known to be 
an important source for pro-inflammatory cytokines in the rheumatic joints [470]. The 
degree of macrophage infiltration is correlated with joint destruction as measured 
by radiography [471] and it has been suggested that a change in the number of 
synovial sublining macrophages can be used to discriminate between effective and 
ineffective treatment [472, 473], which highlights the importance of macrophages in 
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the pathogenesis of RA. Furthermore, peripheral blood monocytes from patients 
with RA were shown to express increased transcript levels of pro-inflammatory 
cytokines [474] and to spontaneously secrete pro-inflammatory cytokines such as IL-
1β [345, 346, 475] indicative of an activated phenotype. 
 
The genetic association of HLA-DR1 and HLA-DR4 [306] with RA suggests that the 
disease is at least partially driven by CD4+ T cells [476] and it had already been 
described in the 1980ies that activated T cells can be found in the synovial 
membrane in RA [477-481].  
 
The interaction of T cells with macrophages and dendritic cells (DCs) is crucial for 
the initiation and amplification of T-cell-dependent immune responses, and has 
been suggested to play a role in chronic inflammatory processes in the synovium 
([482]; reviewed in [483]). The pro-inflammatory cytokine TNF-α is known to play a 
fundamental role in the pathogenesis of RA [322] and it has been well characterised 
that T cells can stimulate contact-mediated TNF-α and IL-1β production by 
monocytes (reviewed in [445, 484]). Furthermore, cytokine-activated T cells, which 
show similarities to synovial T cells [485], were able to stimulate TNF-α production by 
monocytes [443]. In recent years, it has become increasingly clear that monocytes are 
not merely “naïve” precursors of macrophages as it was previously believed but 
may play a distinct role in the polarisation and expansion of T lymphocytes 
(reviewed in [434]).  
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Regulatory T cells (Tregs) are a subpopulation of T cells, which play an essential role 
in immune regulation via their ability to suppress the activation of effector cells. 
CD4+CD25+ Tregs and their role in rheumatoid arthritis have been studied 
extensively over the years. However, determination of their frequencies in the 
peripheral blood of patients with RA led to contrary results (reviewed in [417]). Some 
studies reported increased [403-407], or similar [257, 258, 408-412, 486-490] percentages when 
compared to PB of healthy controls, whereas others showed that the percentages 
were decreased in the circulation [413, 414, 491-497] (Table 3.1). These discrepancies 
cannot simply be explained by differences in gating strategies as more recent 
studies including CD127 in the staining panel also led to contrary results [258, 405, 488, 
489, 494, 496]. Low expression of CD127 has been described to be superior to identify 
Tregs when used in combination with CD25 [160, 161]. The data on Treg frequencies in 
the synovial fluid of patients with RA (see Table 3.2) however, are much more 
consistent. Almost all studies agree on an increase in their frequencies compared to 
their PB counterparts [403, 405, 408-414, 489], except for one recent paper [258] and reasons 
for the discrepancies in the last paper are not understood. 
 
 














RA PB: 17±1% 
HC PB: 11±0.4% 
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RA PB: 23.0±1.3% 
HC PB: 14.4±1.6% 
p<0.001  
(mean±SEM) 
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most active RA 
RA PB: 0.7% (0.1-1.8%) 
HC PB: 1.1% (0.9-2.3%) 
(median (range)) 








RA PB: 0.7% (0.04-2.9%) 
HC PB: 1.2% (0.3-2.4%) 
(median (range)) 
















RA PB: 5.5±4.1% 
HC PB: 6.7±5.0%  
(mean±SD) 








n=60 RA PB: 10.52±5.87% 
HC PB: 11.11±4.58%  
(mean±SD) 














n=75 RA PB: 6.8% 
HC PB: 6.7% 












RA PB: 4.8% (1.8-13.0) 
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RA PB: 1.7±0.88% 
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 n= 43 
early active RA 
RA PB: 4.25% 
HC PB: 5.30% 
p=0.001  
(mean) 










RA PB: 3.1±1.5% 
HC PB: 5.5±1.2% 
p<0.05 
(mean±SD) 
Jiao Z (2007) 
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 n=20 RA PB: 2.1±0.2% 












RA PB: 5.36±1.55% 
























RA PB: 3.8±1.0% 
HC PB: 5.0±1.3% 
p<0.001 
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RA PB: 1.34% (0.41-2.21) 
HC PB: 3.76% (2.11-9.80) 
(active RA, p<0.0001; 
remission group: % similar 
















RA PB: 1.8±1.2% 
HC PB: 2.6±1.8% 
(p=0.023; DAS<3.2 


















most active RA 
 
RA SF: 7.1% (1.8-20%) 
RA PB: 0.7% (0.1-1.8%) 
HC PB: 1.1% (0.9-2.3%) 
p<0.005  
(median (range)) 







n=135 RA SF: 2.3% (0.2-19.9%) 
RA PB: 0.7% (0.04-2.9%) 
HC PB: 1.2% (0.3-2.4%) 
p<0.0001  
(median (range)) 









RA SF: 24±2.0% 
RA PB: 17±1.0% 
HC PB: 11±0.4% 
P<0.0001 
(mean±SEM) 












RA SF: 12±4.8% 
RA PB: 5.5±4.1% 
HC PB: 6.7±5.0% 
p=0.034 
(mean±SD) 
Mottonen M (2005) 
 












n=20 RA SF: 17.77±7.92% 
RA PB: 10.52±5.87% 
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RA PB: 3.1±1.5% 
HC PB: 5.5±1.2% 
p<0.05 
(mean±SD) 
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 n=10 (paired) RA SF: 13.5% 
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RA PB: 1.7±0.88% 





As CD14+ monocytes and Tregs can both be found in abundance at the site of 
inflammation in RA [353], one of the main aims of this thesis was to study the effects 
of the interaction of monocytes and regulatory T cells in the context of 
inflammation. 
 
To address this aim, we first performed a detailed characterisation of the 
phenotype and frequencies of CD14+ monocytes and CD25+CD127low Tregs in the 
peripheral blood and synovial fluid of patients with RA and investigated whether 
there was evidence for the interaction of monocytes and Tregs in vivo.
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3.2 Results 
3.2.1 CD14+ monocyte frequencies in the peripheral blood of patients with RA 
First, it was investigated whether there are differences in the frequencies of CD14+ 
monocytes in peripheral blood of patients with RA and healthy controls (HC). 
Mononuclear cells (MC) from peripheral blood (PB) of patients with RA (n=43) and 
from PB of HC (n=42) were isolated using Ficoll density gradient centrifugation. Cells 
were immediately stained for CD14 and CD19 on the surface and samples acquired 
on a BD FACS CantoII after fixation with 2% PFA. Frequencies of peripheral blood 
monocytes (PBM) were determined as the percentage of CD14+ cells negative for 
CD19 within PBMC using the FlowJo software and the gating strategy shown in 
Figure 3.1A. 
 
No significant differences in the percentages of CD14+ monocytes in the peripheral 
blood of patients with RA and HC were observed (p=0.2136), but patients with RA 
showed a high variation in their PBM frequencies ranging from 6.0% to up to 46% 
(Figure 3.1B). Furthermore, the overall frequencies were higher compared to HC 
(median: 15.2% vs. 12.7%). 
 
Our patient cohort consisted predominantly of female donors (n=38 female (88%) 
vs. n=5 male (11%)) as RA is more prevalent in women than in men [288]. Our healthy 
control donor pool however, consisted of 64% female (n=27) and 36% male donors 
(n=15). We assessed whether gender had an effect on PBM frequencies, which 
would impact the cumulative data.  
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Figure 3.1 Determination of CD14
+
 monocyte frequencies in peripheral blood of patients with RA 
and healthy controls. 
(A, B) PBMC were isolated from the peripheral blood (PB) of healthy controls (HC, n=42) and patients 
with rheumatoid arthritis (RA, n=43) using Ficoll density gradient centrifugation. Frequencies of cells 
were determined based on positive CD14 expression and CD19-negativity as shown in the gating 
strategy in (A) and are plotted as the median (B). Mann Whitney test as determined by D’Agostino & 
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Interestingly, we observed a significant difference in CD14+ monocyte frequencies 
within PBMC of healthy female vs. male controls (11.6±1.1% vs. 15.3±1.1, 
p=0.0389), but not in patients with RA (Figure 3.2A). It needs to be noted however, 
that due to the higher prevalence of RA in females we only obtained peripheral 
blood samples from 5 male patients. When we sex-matched HC and patients with 
RA and compared CD14+ monocyte frequencies between female donors only, a 
significant increase in the percentage of monocytes was observed in patients with 
RA (n=38) compared to HC (n=27) (median: 15.5% vs. 11.4%, p=0.0385) (Figure 
3.2B). 
 
It has been well described in the literature that aged individuals show a decreased 
ability to respond to infections. This may partially be explained by the lower 
production of reactive oxygen species (ROS) by aged macrophages (reviewed in 
[498]), which is one of their main mechanisms to exert antimicrobial activity, and the 
decreased rate at which monocytes migrate to sites of injury [499].  
 
As our cohort of patients was significantly older than our healthy control donor 
pool, which consisted mostly of students and staff recruited from the lab or the 
hospital (RA 55±2.1 vs. HC 37±2.2 years, p<0.0001) (Figure 3.2C), we assessed 
whether age would have an impact on monocyte frequencies in the peripheral 
blood. We observed no positive correlation in either healthy controls or patients 
with RA when we plotted the frequencies of CD14+ monocytes vs. the age of donors 
(Figure 3.2D). Furthermore, in n=17 age-matched female patients and healthy 
controls (HC: 49±3.0 and RA 49±2.8), we still observed higher percentages of CD14+ 
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Figure 3.2 Age- and gender-mediated effects on CD14
+
 monocyte frequencies. 
(A) Frequencies of CD14
+
 monocytes were determined as described in Figure 3.1 in PBMC isolated 
from healthy controls (HC, n=42) and patients with rheumatoid arthritis (RA, n=43) and grouped into 
female vs. male donors. (B) Frequencies of CD14
+
 monocytes from female donors only were 
compared between HC (n=27) and patients with RA (n=38). (C) Age of healthy controls and patients 
with RA. (D) Age of HC (n=42) and patients with RA (n=42) was correlated with percentages of CD14
+
 
monocytes. (E) Comparison of CD14
+
 monocyte frequencies in n=17 age-matched female donors. 
Mann Whitney test or unpaired t test were used for statistical analysis as determined by D’Agostino 
& Pearson omnibus normality test: * p<0.05, *** p<0.001. 
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monocytes in PB of patients with RA compared to healthy controls (median: 16.3% 
vs. 11.2%, p=0.0516) (Figure 3.2E). This indicates that CD14+ monocyte frequencies 
appear increased in the peripheral blood of female patients with RA compared to 
healthy controls. 
 
3.2.2 The effect of treatment on CD14+ monocyte frequencies 
We next wanted to determine whether different treatment strategies could impact 
monocyte frequencies. We compared the percentages of CD14+ monocytes in the 
different treatment groups, comprising n=4 patients on non-steroidal anti-
inflammatory drugs (NSAID) and n=7 on TNF inhibitor (TNFi) therapy; the majority 
of patients were on disease-modifying anti-rheumatic drug (DMARD) therapy (n=36) 
as this was one of our selection criteria. 
 
We did not find significant differences in the percentages of CD14+ monocytes in 
the different treatment groups (Figure 3.3A). The patient DMARD group was the 
one with the highest variation, but at the same time it was also the biggest group of 
donors. One patient had a TB infection (indicated in red) and had unusually high 
percentages of monocytes within PBMC, which may be due to the infection [500]; this 
data point was therefore taken out in Figure 3.3B. 
 





 monocyte frequencies in different treatment groups. 
(A, B) Comparison of CD14
+
 monocyte frequencies in PB from HC (n=42) and patients with RA on 
NSAID (n=4), DMARD (n=35/36) or TNFi therapy (n=6/7). Data are plotted as the median in scatter 





percentiles). Kruskal-Wallis test with Dunn’s Multiple Comparison test was used for statistical 
analysis. Red dots indicate the one patient that had a TB infection, which was excluded in (B). 
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3.2.3 CD14+ monocytes are present in high numbers at the site of inflammation 
As we had observed slightly increased percentages of CD14+ monocytes in the 
peripheral blood of patients with RA compared to HC, we next determined the 
frequencies of CD14+ monocytes at the site of inflammation. Throughout the course 
of our study we had access to 14 synovial fluid (SF) samples, which were obtained 
by knee aspiration from patients with RA.  
 
PBMC and SFMC were isolated from the peripheral blood (n=43) and synovial fluid 
(n=11) from patients with RA. CD14+ monocyte frequencies were determined as 
described in Figure 3.1. Percentages of CD14+ monocytes were higher in SF 
compared to PB (28.6% vs. 15.2%, p=0.0850) (Figure 3.4A). Furthermore, high 
percentages of CD14+ monocytes were also found in the one synovial tissue sample 
we had access to (20.1%, data not shown). However, when we analysed paired PB 
and SF samples (n=10) we did not observe a consistent increase in SF (Figure 3.4B). 
 
Psoriatic arthritis (PsA) is a type of inflammatory arthritis with unknown aetiology, 
which affects more males than females, and shows clinical, genetic, serological, and 
radiological differences to RA [501-503]. About 20-30% of patients suffering from the 
chronic inflammatory skin disease psoriasis develop the arthropathy PsA [504]. It 
mostly presents as an asymmetrical oligoarthritis, which is different to patients with 
RA showing a more symmetrical joint involvement with polyarthritis. Further 
differences are that patients with PsA are negative for rheumatoid factor (RF) and 
anti-cyclic citrullinated protein antibodies (ACPA), whereas the majority of patients 





 monocyte frequencies in PB and SF from patients with inflammatory arthritis. 
(A, B) PBMC and SFMC were isolated from PB (n=43) and SF (n=11) from patients with RA and 
frequencies of CD14
+
 monocytes determined based on the gating strategy described in Figure 3.1. (B) 
shows the percentage of CD14
+
 cells in paired samples (n=10) from patients with RA and n=8 from 
patients with PsA. Mann Whitney test (A) or paired t test (B) were used for statistical analysis. (C) 
CD14
+
 monocyte frequencies were compared within PBMC (n=43) and SFMC (n=11) from patients 
with RA and PBMC (n=16) and SFMC (n=9) from patients with psoriatic arthritis (PsA). Data were 
analysed using Kruskal-Wallis test with Dunn’s Multiple Comparison test. 
 
Chapter 3: The presence and phenotype of monocytes and Tregs in RA 
96 
with RA show positive serology [505]. Finally, RA is MHC class II-associated [306], but 
PsA on the other hand is an MHC class I-associated disease [506-509]. 
 
As rheumatoid arthritis and the seronegative disease psoriatic arthritis present 
different clinical, serologic, radiographic and genetic features, it suggests that there 
are also differences in the immunopathology. We therefore included patients with 
PsA in our analysis to assess whether the observed abundance of CD14+ monocytes 
at the site of inflammation was specific to rheumatoid arthritis.  
 
We isolated PBMC from patients with PsA (n=16) and where available SFMC from 
patients with PsA (n=9). The frequencies of CD14+ monocytes were determined 
using the gating strategy from Figure 3.1. No significant differences were observed 
in the percentages of CD14+ monocytes in PsA vs. RA as determined by Kruskal-
Wallis test but the overall percentages were slightly higher in PsA compared to RA, 
especially in SF (32±6.1% vs. 25±4.3%) (Figure 3.4C). Furthermore, analysis of paired 
PB and SF samples from patients with PsA showed that the percentages of CD14+ 
monocytes at the site of inflammation were similar or increased relative to PB 
(p=0.0864), whereas in some of the patients with RA lower percentages were 
observed in SF compared to PB (Figure 3.4).  
Overall these data indicate that CD14+ monocytes are present at the site of 
inflammation in inflammatory arthritis and in some patients in increased 
percentages. 
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3.2.4 Monocytes from patients show an activated phenotype 
Peripheral blood monocytes (PBM) from patients with RA were shown to 
spontaneously secrete pro-inflammatory cytokines such as IL-1β [345, 346, 475], which is 
indicative for an activated phenotype. We therefore assessed the phenotype of 
PBM from patients with RA and healthy controls by flow cytometry. 
 
PBMC isolated from peripheral blood of patients with RA (n=30) and HC (n=27) were 
stained for CD14, CD16, CD40, CD54, CD86 and HLA-DR on the surface and analysed 
by flow cytometry after fixation with 2% PFA. To determine the phenotype of HC 
and RA PBM, PBMC were gated on CD14+ cells and the mean fluorescence intensity 
(MFI) of the indicated surface markers compared. PBM from patients with RA 
showed a significantly higher expression of CD16, CD40 and CD54 and a trend 
towards increased HLA-DR expression compared to HC PBM (Figure 3.5A), overall 
suggesting an activated phenotype for RA PBM. 
 
We phenotyped CD14+ monocytes within paired PBMC and SFMC samples (n=12) to 
investigate the activation status of these cells at the site of inflammation. Synovial 
fluid monocytes (SFM) from patients with RA were found to have a highly activated 
phenotype when compared to their peripheral blood counterparts, as determined 
by a significantly increased expression of CD16, CD40, CD54, CD86 and HLA-DR, 
which is represented in Figure 3.5 as the cumulative and individual data of the 
sample pairs (Figure 3.5B, D) as well as a representative example (histograms) for 
the expression of the indicated surface markers (Figure 3.5C). 
 





 monocytes from patients with RA show an activated phenotype. 
(A-D) Surface expression of the indicated markers was determined in PB CD14
+
 monocytes (PBM) 
from patients with RA (n=30) and HC (n=27) (A) and paired PBM and SF CD14
+
 monocytes (SFM) from 
patients with RA (n=12) (B). (C) Representative histograms (overlay) for surface expression of the 
indicated markers on paired RA PBM (black line) and RA SFM (filled, grey) and the isotype (dashed 
line) are shown. The individual data are shown in (D). Analysis was performed using unpaired t test 
or Mann Whitney test (A) and paired test or Wilcoxon matched-pairs signed rank test (B, D): * 
p<0.05, ** p<0.01 and *** p<0.001. 
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Monocyte frequencies were increased in patients with RA and showed an activated 
phenotype. We next sought to investigate whether there was a link between the 
disease activity, as determined by DAS28 [290], and the percentage of CD14+ 
monocytes in PB and SF. We did not find a positive correlation between PBM 
frequencies and DAS28 (Figure 3.6A). However, the percentages of synovial fluid 
monocytes positively correlated with DAS28 (Figure 3.6B) as determined by 
Spearman correlation for non-parametric testing (r=0.7112, p=0.0268). 
 
These data overall suggest that CD14+ monocytes with an activated phenotype are 
present in increased frequencies in patients with RA and that the frequencies of 
CD14+ cells found at the site of inflammation correlate with disease activity.  





 monocytes vs. DAS28. 
(A, B) Spearman correlations between disease activity scores (DAS28) of patients with RA and CD14
+
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3.2.5 Treg frequencies in PB of HC and patients with RA are similar 
There is controversy in the field regarding Treg numbers in the blood of patients 
with RA and the reasons for these discrepancies are not well understood (reviewed 
in [417]). To determine the percentages of Tregs we used the combination of the 
surface markers CD25 and CD127, which has recently been suggested to be superior 
in identifying Tregs compared with staining for the Treg marker CD25 alone [160, 161] 
as T cells can upregulate CD25 expression following activation [129-131].  
 
We analysed the percentages of CD25+CD127low Tregs within CD3+CD4+ T cells in PB 
from HC (n=42) and patients with RA (n=42) by flow cytometry using the gating 
strategy shown in Figure 3.7. We found no significant differences in the percentages 
of CD3+CD4+ T cells between HC and patients with RA in the peripheral blood (Figure 
3.7A). Similar percentages were also observed for the frequencies of CD25+CD127low 
Tregs within CD4+ T cells (Figure 3.7B). We also determined the percentage of 
CD45RO+ and CD45RO- cells within CD3+CD4+ T cells as the cells found at the site of 
inflammation in RA are predominantly of a CD45RO+ memory phenotype [362] and 
CD4+CD25high Tregs reside predominantly in the memory compartment [62]. We 
found no differences in the percentage of CD45RO+ (Figure 3.7C) and CD45RO- T 
cells (Figure 3.7E) and the frequencies of CD25+CD127low Tregs within those T cell 
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Figure 3.7 Determination of Treg frequencies within peripheral blood of patients with RA and 
healthy controls. 
(A-F) PBMC were isolated from PB of HC (n=42) and patients with RA (n=42) using Ficoll density 
gradient centrifugation. Frequencies of cells were determined based on the gating strategy shown in 
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As some CD4+ T cells can co-express the two CD45 isoforms CD45RA (naïve) and 
CD45RO (memory) during transition from a naïve to a memory cell [510-513], we 
further included CD45RA in our staining panels. We compared CD25+CD127low Treg 
frequencies within CD45RA-CD45RO+ (memory) and CD45RA+CD45RO- (naïve) T cells 
in the peripheral blood of HC (n=11) and patients with RA (n=12) using the gating 
strategy shown in Figure 3.8A. We did not observe significant differences in Treg 
frequencies within memory or naïve T cells (Figure 3.8B) confirming the results 
obtained with CD45RO staining only (Figure 3.7).  
These data show that Treg frequencies are similar in the peripheral blood of 
patients with RA and healthy controls. 
 
3.2.6 Increased age of patients with RA does not affect Treg frequencies 
It has been reported in the literature that Treg frequencies increase with age [514-516] 
and that aged Tregs might be reduced in their ability to suppress IL-17 production 
by effector T cells (Teff) due to reduced STAT3 activation although effectively 
suppressing proliferation of Teff and IFNγ production [517]. 
 
As described earlier in this chapter, our cohort of patients was significantly older 
than our healthy control donor pool (Figure 3.2C). Nevertheless, CD4+CD45RO+ and 
CD4+CD45RO- T cell frequencies were similar between our healthy control group 
and patient cohort (Figure 3.8C, E). In line with that, we found no correlation 
between CD4+CD45RO+ T cell frequencies and age in both healthy controls and 
patients with RA (Figure 3.9A). Furthermore, CD45RO+ Treg frequencies did not 
correlate with age in either HC or patients with RA (Figure 3.9B). 
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 Treg frequencies. 

















 T cells from HC (n=11) and patients with RA (n=12) using the gating described 
in (A). Cumulative data are shown as mean±SEM in (B) and unpaired t test was used for statistical 
analysis as determined by D’Agostino & Pearson omnibus normality test. 
 
Chapter 3: The presence and phenotype of monocytes and Tregs in RA 
105 
 
Figure 3.9 Increased age of patients does not affect CD45RO
+
 Treg frequencies. 




 T cells (A) and CD45RO
+
 Tregs (B) were correlated with age of 
healthy controls (n=42) and patients with RA (n=42) using Spearman for non-parametric testing. (C) 
Comparison of CD45RO
+
 Tregs frequencies in n=20 age-matched HC and patients with RA (median). 
Data were analysed using Mann Whitney test. 
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To ensure that the increased age of patients did not affect the comparison of Treg 
frequencies between HC and patients with RA, we age-matched n=20 HC and 
patients (HC: 49±2.5 and RA: 49±2.4). The frequencies of age-matched HC and RA 
CD45RO+ Tregs were very similar (9.8±0.7% vs. 9.8±0.8%) (Figure 3.9C) and 
CD45RO+ Treg frequencies did also not correlate with age in both patients with RA 
and HC (Figure 3.9B). Furthermore, we did not observe gender-specific differences 
in regulatory T cell frequencies in either patients or in HC (data not shown), overall 
supporting the finding that Treg frequencies are not different in the peripheral 
blood of patients with RA relative to HC.  
 
3.2.7 The effect of treatment on Treg frequencies 
It has been suggested in the literature that treatment of patients with RA with TNF-
inhibitor (TNFi) drugs induces CD4+CD25+ Treg frequencies [256, 257]. We therefore 
sought to investigate whether Treg frequencies were affected by different 
treatment strategies in our cohort of patients with RA.  
 
In the 46 patients from whom we isolated PBMC for Treg frequency analysis, n=5 
were on non-steroidal anti-inflammatory drugs (NSAID), n=7 were on TNFi, and the 
majority of patients were on disease-modifying anti-rheumatic drug (DMARD) 
therapy (n=34). No significant changes were seen in CD25+CD127low Treg 
frequencies within CD3+CD4+ T cells, CD45RO+ T cells or CD45RO- T cells in the 
different treatment groups analysed by Kruskal-Wallis test (Figure 3.10A), although 
there was a trend towards an increase in CD3+CD4+ Treg frequencies in TNFi-treated 
vs. DMARD-treated patients (p=0.0802, when tested non-parametrically).
Chapter 3: The presence and phenotype of monocytes and Tregs in RA 
107 
 
Figure 3.10 Treg frequencies in different treatment groups. 

















 T cells in PB from HC (n=42) and patients with RA on NSAID (n=5), DMARD (n=34) or 
TNFi therapy (n=7). Data are plotted as the median using box-and-whisker plots showing the min to 




 percentiles). Kruskal-Wallis test with Dunn’s Multiple 
Comparison test was performed for statistical analysis. (B) Treg frequencies in patients with RA (n=3) 
pre- and post-TNFi treatment were compared. Red dots indicate the one patient that had a TB 
infection. 
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However, overall n numbers for the TNFi group were relatively small (n=7) and 
patients treated with NSAID also showed higher percentages than DMARD-treated 
patients in CD3+CD4+ and CD45RO- Tregs (Figure 3.10A). 
 
For three patients, we had access to peripheral blood samples that were taken pre- 
and post-TNFi therapy (after 2-3 months). The percentages of peripheral blood 
Tregs did not consistently increase following TNFi therapy but rather decreased in 
CD3+CD4+ T cells and CD45RO+ T cells (Figure 3.10B). A larger cohort of patients 
would be needed to be able to draw conclusions. Furthermore, one of the patients 
indicated in red was previously diagnosed with a tuberculosis (TB) infection, which 
could have had an effect on Treg frequencies [518, 519] and should therefore probably 
be excluded from the analysis. 
 
3.2.8 Tregs from patients with RA show a similar phenotype to HC Tregs 
It has recently been suggested that a subpopulation of Tregs, the so-called 
population III (CD45RA-FoxP3low), is able to convert into IL-17-producing cells, and 
shows no suppressive properties [164]. We next investigated whether Tregs from 
patients with RA showed a decrease in Treg-associated markers and an increase in 
pro-inflammatory markers such as the Th17 marker CD161, which could indicate 
decreased suppressive function by RA Tregs, as it has been suggested by several 
groups [253, 256-258, 415].  
We surface-stained isolated PBMC from HC (n=40) and patients with RA (n=36) with 
CD3, CD4, CD45RO, CD25, CD127, CD39 and CD161 and analysed the phenotype of 
Tregs by flow cytometry. Tregs were gated based on positive CD25 expression and 
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low expression of CD127 in either the CD3+CD4+CD45RO+ T cell (CD45RO+ Tregs) or 
CD3+CD4+CD45RO- T cell (CD45RO- Tregs) compartment of RA and HC PBMC and the 
MFI levels for CD4, CD25, CD127, CD39 and CD161 were quantified. 
 
CD45RO+ and CD45RO- Tregs from patients with RA showed a similar expression of 
CD4, CD25 and CD127 (Figure 3.11 A, B). Furthermore, there was no significant 
difference in the expression of the ectoenzyme CD39 on RA and HC Tregs. CD39 
converts extracellular ATP to ADP/AMP and has recently been described to be a 
Treg-specific surface marker [105, 106]. The expression of the Th17 marker CD161 [220, 
221], which has been described to identify a subpopulation of Tregs with the 
potential to express the pro-inflammatory cytokine IL-17 [245, 520], was also similar 
between HC and RA Tregs, which may suggest that Tregs from the peripheral blood 
of patients with RA do not show an increased potential to produce IL-17.  
 
3.2.9 Tregs from some patients with RA show increased expression of FoxP3 
We next determined the expression of the Treg-specific transcription factor FoxP3 
in CD25+CD127low Tregs within the CD3+CD4+CD45RO+ T cell (CD45RO+ Tregs) or 
CD3+CD4+CD45RO- T cell (CD45RO- Tregs) compartment. PBMC were isolated from 
patients with RA (n=30) and HC (n=23) and stained for CD3, CD4, CD25 and CD127 
on the surface. Thereafter, cells were fixed with 2% PFA, permeabilised and 
intranuclearly stained for FoxP3. A representative histogram for FoxP3 expression in 
CD45RO+ Tregs from patients with RA (black) and HC (grey) is shown in Figure 
3.12A.  
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 T cells (B) of PBMC 
isolated from HC (n=40) and patients with RA (n=36). Expression of the indicated markers within the 
Treg gates is shown as mean±SEM (MFI). Analysis was performed using unpaired t test or Mann 
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 T cells (B) of PBMC 
from HC PB (n=23) and patients with RA (n=30). Representative histograms for the expression of 
FoxP3 (MFI) within the Treg gates is shown in (A) and the cumulative data (mean±SEM) in (B). 
Analysis was performed using unpaired t test as determined by D’Agostino & Pearson omnibus 





with DAS28 in patients with RA (n=29). 
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Taken the data together, we observed a significant increase in FoxP3 expression 
(MFI) in both CD45RO+ and CD45RO- Tregs from patients with RA compared to HC, 
which was more pronounced in the CD45RO- Treg subset (p=0.0071) (Figure 3.12B). 
FoxP3 protein expression in CD25+CD127low Tregs from patients with RA was 
however rather varied compared to HC, with only a subgroup of patients expressing 
enhanced levels of FoxP3 compared to HC. This increase in FoxP3 expression in 
Tregs from patients with RA would argue for a more suppressive phenotype [16, 63, 
521].  
 
We next investigated whether FoxP3 expression was correlated with disease activity 
and whether a high expression of FoxP3 would correspond with a low disease 
activity score. As a measure of disease activity the DAS28 score was taken, as 
described earlier in this chapter. However, no correlation was observed between 
the expression of FoxP3 (MFI) within CD45RO+ or CD45RO- Tregs and DAS28 (Figure 
3.12C). 
 
These data overall indicate that the expression of FoxP3 is increased in some 
patients with RA compared to HC, but this is not correlated with DAS28. 
 
3.2.10 Tregs are significantly increased at the site of inflammation 
It has been reported in the literature by various groups that Tregs are increased at 
the site of inflammation in patients with RA (reviewed in [417]). However, none of the 
studies have accounted for the fact that T cells in the synovial fluid are virtually all 
of a CD45RO+ memory phenotype [362], whereas the peripheral blood consists of 
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both CD45RO+ and CD45RO- T cells (as shown in Figure 3.7). We therefore 
determined the percentages of CD25+CD127low Tregs within CD3+CD4+ T cells and 
CD4+CD45RO+ T cells in the peripheral blood (n=42) and synovial fluid (n=14) from 
patients with RA.  
 
The overall CD3+CD4+ T cell frequencies were significantly lower in SF compared to 
PB (34±3.1% vs. 46±2.0%, p=0.0021) (Figure 3.13A), but CD25+CD127low Tregs within 
CD3+CD4+ T cells were significantly increased in SF compared to PB (22±1.7% vs. 
6.7±0.3%, p<0.0001) (Figure 3.13B). We further confirmed that CD3+CD4+ T cells in 
SF were virtually all of a memory CD45RO+ phenotype (Figure 3.13C) [362]. When 
corrected for CD45RO expression, CD25+CD127low Treg frequencies were still 
significantly increased at the site of inflammation (Figure 3.13D), which was 
consistent in each paired PB and SF sample (n=13) (Figure 3.13E). 
 
We also included peripheral blood (n=18) and synovial fluid samples (n=10) from 
patients with seronegative PsA in our analysis to see whether this significant 
increase was specific to RA. Similarly to RA, frequencies of CD45RO+ Tregs were 
increased in SF of patients with PsA compared with PB (18.5±2.9% vs. 10.8±0.8%) 
whilst no significant differences were observed in CD45RO+ Treg frequencies 
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Figure 3.13 Tregs are increased in SF. 
(A-D) PBMC and SFMC were isolated from PB (n=42) and SF (n=14) from patients with RA. 
Frequencies of different T cell populations were determined based on the gating strategy described 
in Figure 3.7. Mann Whitney test or unpaired t test were used for statistical analysis: * p<0.05, *** 








 T cells in paired PB and 
SF samples (n=13) using a paired t test for significance testing: *** p<0.001. (F) Treg frequencies 
were compared within PBMC from HC (n=42), PBMC (n=42) and SFMC (n=14) from patients with RA 
and PBMC (n=18) and SFMC (n=10) from patients with PsA. Data were analysed by Kruskal-Wallis 
test with Dunn’s Multiple comparison test: *** p<0.001. 
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The observed increase in Treg frequencies at the site of inflammation seems 
paradoxical as inflammation still persists. We determined whether a high disease 
activity (DAS28) would correspond with a low frequency of regulatory T cells, hence 
less immune regulation in PB (n=41) and SF (n=10) from patients with RA. No 
correlation of peripheral blood CD45RO+ Treg frequencies with DAS28 was observed 
(Figure 3.14A), whereas SF Treg frequencies were strongly correlated with DAS28 
(r=0.7988, p=0.0072) (Figure 3.14B). However, a higher DAS score corresponded 
with a higher frequency of Tregs. 
 
3.2.11 SF Tregs show an increase in Treg-associated surface markers, but not 
FoxP3 
It has been described in the literature by our group and others that Tregs from the 
synovial fluid show a highly activated phenotype i.e. increased CD69, MHC class II, 
GITR, OX-40 and CTLA-4 expression [403, 408, 418]. We sought to investigate whether SF 
Tregs showed a decrease in Treg-associated markers due to the inflammatory 
environment, which could hint at a less suppressive phenotype. 
 
To investigate this hypothesis, we stained paired PBMC and SFMC samples (n=4-9) 
for CD4, CD25, CD127, CD39 and FoxP3 as well as for the Th17 marker CD161. To 
determine the expression of the indicated markers (MFI) by flow cytometry, we 
gated on CD25+CD127low Tregs within CD3+CD4+CD45RO+ T cells and compared cells 
from PB with SF (representative dotplots, Figure 3.15A).  
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Figure 3.14 SF Treg frequencies positively correlate with disease activity. 
(A, B) Spearman correlations between disease activity scores (DAS28) of patients with RA and 
CD45RO
+
 Treg frequencies in PB (n=41) (A) and SF (n=10) (B) were performed. Each dot represents 
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 T cells of paired PBMC and SFMC 
samples isolated from patients with RA (n=4-9) as shown in (A). Representative histograms for the 
expression of the indicated markers (MFI) in PB (black line) and SF (grey, filled) are shown in (B) and 
the cumulative data are shown in (C). Analysis was performed using Wilcoxon matched pairs signed 
rank test or paired t test: * p<0.05, ** p<0.01. 
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Tregs showed a significantly increased expression of the Treg markers CD25 and 
CD39 at the site of inflammation (Figure 3.15B, C). The expression of the IL-7Rα 
chain (CD127) was also increased on SF Tregs compared to PB Tregs, which might 
suggest an activated phenotype. FoxP3 expression data was only available in n=4 
samples with no consistent change, except for one patient where FoxP3 expression 
was greatly decreased. However, the expression of CD161 was significantly 
increased in SF Tregs compared to PB Tregs suggesting a higher propensity to 
express the pro-inflammatory cytokine IL-17 as it was recently described for JIA and 
inflammatory arthritis [245, 520]. 
 
As cells from the synovial fluid can be slightly larger than their peripheral blood 
counterparts and an increase in MFI could possibly be due to increased auto-
fluorescence, we further determined the percentages of FoxP3+, CD39+ and CD161+ 
cells within CD25+CD127low Tregs in paired PB and SF samples (n=4-9). The 
percentages of FoxP3+ cells within the CD3+CD4+CD45RO+CD25+CD127low Treg gate 
were assessed based on isotype staining, whereas the percentages of CD39+ and 
CD161+ cells were determined based on FMO staining for either CD39 or CD161 
(Figure 3.16). SF Tregs showed similar percentages of FoxP3+ cells compared to PB 
Tregs except for one patient, where the percentage was dramatically reduced in SF 
(Figure 3.16A). Furthermore, significantly higher percentages of CD39+ and CD161+ 
cells were observed in SF Tregs (Figure 3.16A, B) supporting the data in Figure 3.15. 
Of note, the percentages of CD39+ Teff and CD161+ Teff were also increased in SF 
compared to PB (data not shown). 
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Tregs (C) is shown as mean±SEM using the gating strategy shown for PBMC in the individual figures. 
Analysis was performed using Wilcoxon matched pairs signed rank test: * p<0.05, ** p<0.01. 
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3.2.12 Evidence for the interaction of Tregs with monocytes in vivo 
It has been shown recently that Tregs co-localise with dendritic cells (DCs) in the 
lymphoid aggregates of the synovium from patients with RA as determined by 
positive immunohistochemistry (IHC) staining for FoxP3 and DC-LAMP (or DEC-205), 
respectively [522]. Tregs are known for their ability to modulate monocyte phenotype 
and effector functions [12] and both monocytes and Tregs were found to be present 
at high frequencies in the synovial fluid from patients with RA (Figure 3.4 and 3.13). 
We therefore sought to investigate whether monocytes interact with regulatory T 
cells in vivo. 
 
To determine this, we performed immunohistochemistry staining of human tonsils 
with FoxP3 and either CD14 (n=1) or CD68 (n=1), a glycoprotein highly expressed by 
monocytes and macrophages. Co-staining for CD14 and FoxP3 was carried out by 
UCL Diagnostics, and co-staining of tonsil sections for CD68 and FoxP3 was 
performed in collaboration with Prof. Jo Spencer (Peter Gorer Department of 
Immunobiology, KCL) and Prof. Agi Grigoriadis (Department for Craniofacial 
Development & Stem Cell Biology, KCL). The staining protocol is described in detail 
in the materials and methods chapter. In brief, sections from paraffin-embedded 
tonsil blocks were cut with a microtome at a thickness of 5 μm. Excess paraffin was 
removed, sections re-hydrated and antigen retrieved. Thereafter, tonsil sections 
were stained with CD68 (clone: PG-M1, 1:100 dilution) overnight at +4°C and 
developed with DAB chromogen (stains brown) the next day. Sections were further 
incubated with a FoxP3 antibody (clone: 236A/E7, 1:100 dilution) for 1 hr at RT and 
developed with permanent red chromogen (stains pink). We decided to use the PG-
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M1 clone of the CD68 antibody as other clones also detect fibroblasts and 
endothelial cells [523].  
A representative example for the co-localisation for CD14+ and CD68+ cells with 
FoxP3 is shown in Figure 3.17A and Figure 3.17B, respectively. The total number of 
CD14+ or CD68+ and FoxP3+ cells was counted in 2 high powered fields (HPF = 40x 
magnification) and the percentage of CD14+/CD68+ cells co-localising with FoxP3 or 
FoxP3+ cells co-localising with CD14/CD68 calculated. The results showed that a 
substantial percentage of FoxP3+ cells co-localised with CD14+ or CD68+ cells in 
human tonsils (Figure 3.17), suggesting that Tregs and monocytes may interact in 
vivo. 
We further aimed to stain synovial tissue sections obtained from patients with 
rheumatoid arthritis or osteoarthritis (OA) for CD68 and FoxP3 to determine 
whether Tregs and monocytes co-localised at the site of inflammation in RA. The 
synovial tissue sections were kindly provided by Prof. Dominique Baeten (AMC, 
University of Amsterdam). Unfortunately, we experienced high background staining 
and low stability of the FoxP3 antibody, and for this reason the co-localisation of 
Tregs with monocytes at the site of inflammation in patients with RA could not be 
quantified. However, when we correlated the ex vivo frequencies of CD25+CD127low 
Tregs (expressed as the percentage of CD4+CD45RO+ T cells) and CD14+ monocytes 
in the synovial fluid from patients with RA (n=12), we observed a trend towards 
positive correlation (r=0.5394, p=0.0703) (Figure 3.17C). 
 
Overall, these data may suggest that Tregs interact with monocytes at the site of 
inflammation in patients with RA. 
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Figure 3.17 Interaction of CD45RO
+
 Tregs and monocytes in vivo. 
(A, B) Human tonsils stained for CD14 (brown) (A) or CD68 (brown) (B) and FoxP3 (pink) by 
immunohistochemistry. Results are expressed as the total number of CD14
+
 (A) or CD68
+
 cells (B) and 
FoxP3
+
 cells per high powered field (HPF = 40x magnification) or the percentage of co-localisation of 
those cells. (C) Spearman correlations of CD14
+
 monocyte frequencies with CD45RO
+
 Treg 
frequencies in SF were performed in patients with RA (n=12). 
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3.3 Discussion 
We have shown in this chapter that frequencies of peripheral blood CD25+CD127low 
Tregs were similar between HC and patients with RA. However, percentages of 
CD25+CD127low Tregs with a CD45RO+ memory phenotype were increased at the site 
of inflammation in RA compared to peripheral blood. Peripheral blood Tregs from 
patients with RA displayed a regulatory phenotype, with increased FoxP3 expression 
in some of the donors. The expression of the Treg markers CD25 and CD39 as well 
as the Th17 marker CD161 were increased in SF Tregs. Furthermore, CD14+ 
monocytes with an activated phenotype were found in high numbers in the synovial 
fluid of patients with RA. Frequencies of SF Tregs and SFM both positively correlated 
with DAS28. Finally, monocytes and Tregs could be found in close proximity in 
human tonsils suggesting that they interact in vivo. 
 
There is controversy in the field about peripheral Treg frequencies in patients with 
RA (reviewed in [417], Table 3.1). Reasons for these discrepant results are not well 
understood and when we reviewed the literature, we could not simply explain 
these differences by treatment regimens (e.g. TNFi therapy), gating strategies (e.g. 
inclusion of CD127) or patient cohorts (e.g. established vs. recently diagnosed) [417]. 
 
Here in this study we included CD127 in our staining panel to determine Treg 
frequencies as the combination of low CD127 expression and positive expression for 
CD25 has recently been suggested as a useful gating strategy for identifying Tregs 
[160, 161]. Furthermore, we also stained for CD45RO, which allows determining the 
frequencies of CD45RO+ Tregs, the Treg population that is found at the site of 
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inflammation in RA (Figure 3.13). We observed no differences in CD25+CD127low 
Treg frequencies in the peripheral blood of patients with RA and healthy controls 
either in the CD3+CD4+, CD4+CD45RO+ or CD4+CD45RO- T cell compartment (Figure 
3.7). Age has been described to affect Treg frequencies [514-516] and our patient 
cohort was significantly older than our healthy control donor pool (Figure 3.2C). 
However, even when we age-matched patients and healthy controls no significant 
differences were observed.  
 
It has been shown previously that TNFi treatment increases Treg frequencies, which 
was explained by the induction of a de novo CD62L-negative Treg population from 
CD4+CD25- T cells via TGF-β1 [256, 257]. These data have been recapitulated in other 
human studies [258, 524-526], as well as in a CIA model [527] and in patients with IBD [528-
531]. It was suggested that Treg frequencies did not increase in etanercept-treated 
patients and patients that were not responding to therapy [532]. However, Blache et 
al. extensively investigated CD4+CD25high Treg frequencies before and after TNF 
inhibitor therapy (6 and 12 weeks) using two different TNFi drugs (adalimumab and 
etanercept) and found no increase in Tregs post treatment regardless of whether 
patients responded to treatment [533]. Dombrecht et al. also did not find an increase 
in Treg frequencies following anti-TNF-α therapy [406]. We observed subtle 
differences in Treg frequencies, determined as CD25+CD127low T cells, in patients 
with RA with different treatment regimens (Figure 3.10). The TNFi and NSAID 
groups were quite small and more samples would be needed to draw meaningful 
conclusions. We had access to peripheral blood samples taken pre- and post-TNFi 
treatment from 3 patients with RA, but we did not observe a consistent increase in 
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Treg frequencies post TNFi treatment. In our patient cohort the great majority of 
patients were on DMARD therapy, which was also the patient group with the 
highest variability in Treg frequencies. This overall suggests that the frequencies of 
Tregs determined in our patient cohort were not influenced/ skewed by treatment.  
 
Furthermore, Tregs from patients with RA and healthy controls showed a similar 
phenotype in the peripheral blood (Figure 3.9). The only difference we observed 
was the expression of FoxP3, which was higher in some of the patients compared to 
HC. In collaboration with Dr Hayley Evans in the lab and Novo Nordisk, a microarray 
of sorted, highly pure peripheral blood CD45RO+ and CD45RA+ Tregs from patients 
with RA (n=6) and HC (n=6) was performed. Unsupervised principal component 
analysis (PCA) revealed that the gene expression profile was very similar between 
HC and RA Tregs and no differentially regulated genes could be identified (data not 
shown) supporting the phenotype stain data. The observed increase in FoxP3 
expression in Tregs from some patients with RA ex vivo however was not 
recapitulated on the mRNA level. As we had observed increased FoxP3 expression 
only in a subpopulation of patients, we investigated the possibility that an increased 
disease activity corresponded with decreased FoxP3 expression. However, no 
correlation between DAS28 and FoxP3 expression (MFI) was observed (Figure 
3.12C). Nevertheless, an increased expression of FoxP3 by RA Tregs would suggest 
an increased ability to exert suppressor functions [16, 63, 521] rather than an impaired 
ability to suppress, as it has been suggested by other groups [253, 256-258, 415]. The 
question whether Tregs from patients with RA are impaired in their ability to exert 
suppressive functions was investigated in chapter 5. 
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We observed a significant increase in the frequencies of CD25+CD127low Tregs in the 
synovial fluid from patients with RA compared to peripheral blood (Figure 3.13). 
These data are in agreement with almost all studies that have investigated Treg 
frequencies at the site of inflammation in RA [403, 405, 408-414, 489], except for a recently 
published paper, which showed similar frequencies between RA PB and RA SF [258] 
and a paper that quantified the presence of Tregs by qPCR and showed lower FoxP3 
transcripts in synovial tissue [534]. Reasons for these differences are not well 
understood. However, we corrected for CD45RO expression in our Treg frequency 
analysis as T cells in SF are predominantly CD45RO+ [362] and still observed a 
significant increase at the site of inflammation. 
 
It has previously been described that effector T cells and Tregs from the synovial 
fluid show an activated phenotype [403, 408] and that the percentage of CD4+CD69+ 
cells increased with increasing disease activity [535]. When we investigated SF Tregs 
phenotypically, we observed a significant upregulation of Treg-associated markers 
such as CD25 and CD39 (Figure 3.13), which are both markers known to be involved 
in Treg suppressive function, but also increased CD127 expression, which may 
suggest an activated phenotype. Data on FoxP3 expression were not conclusive due 
to the small sample size (n=4) but FoxP3 expression was at least not consistently 
decreased in SF. Furthermore, we observed a significant increase in CD161 
expression (Figure 3.13) as well as the percentage of CD161+ Tregs compared to PB 
(Figure 3.14), as it was previously described [245, 520]. Although these CD161+ Tregs 
were recently shown to be enriched in IL-17-producing cells, they maintained their 
suppressive capacity [245, 520], which overall suggests that Tregs from SF may not be 
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impaired in their suppressive function even when displaying a pro-inflammatory 
profile. The paradoxically increased percentage of these potentially suppressive 
cells at the site of inflammation poses the obvious question why inflammation still 
persists, which will be subject of further investigation in this thesis.  
 
Frequencies of CD14+ monocytes were higher in patients with RA compared to HC 
(Figure 3.1) and were further increased at the site of inflammation (Figure 3.4), as it 
has been previously described by our lab [447], which suggests an important role for 
these cells in rheumatoid arthritis. We further observed an activated phenotype of 
monocytes in the peripheral blood of patients with RA (Figure 3.5A), which was 
even more pronounced at the site of inflammation (Figure 3.5B-D). The increased 
expression of CD16 on monocytes from patients with RA has already been described 
in the literature [343, 536, 537]; a further analysis of CD14+CD16+ monocyte frequencies 
was performed in chapter 4. 
 
Tregs and monocytes were abundantly present at the site of inflammation in 
patients with RA (Figure 3.4 and 3.14). Interestingly, although psoriatic arthritis and 
rheumatoid arthritis show clinical, serological, radiological and genetic differences, 
which may suggest differences in immunopathology, CD25+CD127low Tregs and 
CD14+ monocytes were similarly increased at the site of inflammation. However, 
when we correlated Treg frequencies with CD14+ monocyte frequencies in patients 
with PsA, no correlation or trend was seen (data not shown). Furthermore, 
frequencies of CD14+ monocytes and Tregs in the SF from patients with RA showed 
a trend towards positive correlation (Figure 3.17C). Furthermore, in patients with 
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RA the percentage of SF Tregs strongly correlated with DAS28 (Figure 3.14B), as did 
the percentage of synovial fluid monocytes (Figure 3.6B). These findings support an 
important role for these cells in the pathogenesis of RA and might suggest a 
regulatory feedback loop between monocytes and Tregs as it was previously 
suggested for DCs and Tregs [538]. Finally, we found CD14+ and CD68+ cells in close 
proximity to FoxP3+ cells in human tonsil sections (Figure 3.17A, B), which suggests 
that monocytes do interact with Tregs in vivo.  
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Chapter 4: The effects of activated monocytes on regulatory T cell 
phenotype and function 
4.1 Introduction 
Human CD4+CD25+FoxP3+ regulatory T cells (Tregs) are important in the 
maintenance of self-tolerance and the control of immune responses through their 
ability to suppress effector functions of a wide range of immune cells including CD4+ 
and CD8+ T cells [6, 7, 539], B cells [540, 541], NK cells [10] and antigen-presenting cells 
(APCs) ([11-15], reviewed in [165, 542]). The increased presence of CD4+CD25+ Tregs at 
the site of inflammation in rheumatoid arthritis (RA) has been well documented 
over the years [403, 405, 408-414] and was confirmed in the previous chapter (see Figure 
3.13, Chapter 3). This poses the paradox as to why inflammation persists in RA 
despite the abundant presence of these potentially suppressive cells and one might 
hypothesise that Treg function is impaired in RA. 
 
The notion that CD4+CD25+FoxP3+ Tregs are terminally differentiated suppressor 
cells has been challenged recently by the finding that Tregs can display a significant 
degree of plasticity during development and differentiation in the periphery and 
when exposed to a pro-inflammatory environment (reviewed in [449, 450]). 
Furthermore, a landmark study by Miyara et al. in 2009 described at least three 
phenotypically and functionally distinct CD4+FoxP3+ Treg populations in humans. 
CD45RA-FoxP3low Tregs, which they termed population III, were non-suppressive 
and had the potential to convert into IL-17-producing cells [164]. This finding has 
been debated however in a recent paper showing that population III is fully 
suppressive despite a pro-inflammatory cytokine profile [245].  
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The existence of IL-17+ Tregs has been demonstrated in vivo in human peripheral 
blood [238, 241], as well as at sites of inflammation e.g. inflamed arthritic joints [245], 
periodontitis lesions [248], skin lesions of patients with severe psoriasis [249], human 
tonsils [241], and the lamina propria of patients with Crohn’s disease [247]. 
Additionally, Tregs from patients with psoriasis had an enhanced ability to convert 
into IL-17-producing cells ex vivo. This conversion was accompanied by a decrease in 
FoxP3 expression and an increase in Rorc2 expression [249], which overall suggests 
that Tregs from inflammatory sites may convert into pathogenic IL-17-producing 
cells thereby themselves contributing to disease. 
 
The pro-inflammatory cytokine IL-1β was shown to be a critical mediator in the 
conversion of human Tregs into IL-17-producing cells, at least in vitro [237-239, 241, 242, 
244, 245]. As described in chapter 3 of this thesis, CD14+ cells with an activated 
phenotype are present in large numbers in the synovial fluid (SF) of patients with RA 
(see Figure 3.4 & 3.5). Previous work from our lab has further shown that CD14+ 
cells from SF preferentially promote Th17 responses in total CD4+ T cells [447]. It is 
well established that CD14+ monocytes are important contributors to inflammation 
through the production of a vast range of pro-inflammatory cytokines such as IL-1β. 
Furthermore, a substantial percentage of FoxP3+ and CD14+/CD68+ cells were found 
to co-localise in human tonsils (Figure 3.17), which suggests that Tregs and 
monocytes interact in vivo.  
Based on these findings, we hypothesised that activated monocytes, which are 
abundantly present at sites of inflammation in RA, impair regulatory T cell function 
by converting them into pathogenic IL-17-producing Tregs.   
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4.2 Results 
4.2.1 LPS pre-treatment activates human CD14+ monocytes 
In order to investigate the effects of activated monocytes on the phenotype and 
function of human regulatory T cells, we established a system to activate healthy 
control monocytes in vitro by using Escherichia coli-derived lipopolysaccharide 
(LPS). The amphipathic molecule LPS, which is the major component of the outer 
membrane of Gram-negative bacteria, consists of a polysaccharide part and lipid A, 
and is commonly referred to as endotoxin. After LPS gets bound by the plasma 
protein LBP (LPS-binding protein) [543], it is delivered to the cell surface receptor 
CD14 on myeloid cells [544, 545], transferred to Toll-like receptor 4 (TLR4) and its 
accessory protein MD2 (myeloid differentiation protein 2), which leads to the 
activation of intracellular signalling pathways and the activation of transcription 
factors [546, 547]. 
 
CD14+ monocytes were isolated from the mononuclear cell (MC) fraction of 
peripheral blood (PB) from healthy controls (HC) by positive selection using 
magnetic-activated cell sorting (MACS) leading to purities always greater than 97% 
(Figure 4.1). MACS-isolated monocytes were incubated for 30 min at 37°C with 
either 100 ng/ml LPS or complete medium as a control. Incubation time and the 
concentration of LPS were chosen based on previous work in the lab (Evans HG, 
unpublished) as well as publications investigating dose responses for the 
internalisation of LPS [548] and the time course for the activation of NF-κB in 
monocytes [549]. Following pre-incubation, cells were washed twice with complete 
medium, re-counted and cultured overnight for 14-18 hrs at a density of 0.5x106 
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Figure 4.1 Purity of MACS-isolated CD14
+
 monocytes. 
Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood using Ficoll density 
gradient centrifugation. CD14
+
 monocytes were isolated by positive selection using magnetic-
activated cell sorting (MACS). Purities of isolated CD14
+
 monocytes were assessed by staining for 














 and always confirmed to be greater than 97%. 
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cells per well in a 48-well plate. The phenotype of medium-treated (mono-med) and 
LPS-treated monocytes (LPS-mono) was assessed by flow cytometric staining for 
surface markers associated with the activation and maturation of monocytes using 
the gating strategy as described in Figure 4.2A. 
 
LPS-mono (n=18) showed a significant upregulation of the co-stimulatory molecule 
CD40 [549], which binds CD154 (CD40L) expressed on activated T cells [550], and CD86 
(B7.2), which acts in concert with CD80 (B7.1) binding CD28 and CTLA-4 (CD152) 
expressed on T cells [551-553]. Furthermore, the glycoprotein ICAM-1 (CD54) and the 
major histocompatibility complex (MHC) class II surface molecule HLA-DR were also 
significantly upregulated on LPS-mono compared to mono-med. In contrast, a 
down-regulation of the low affinity Fc receptor CD16 (FcγRIII) mediating 
phagocytosis and antibody-dependent cell-mediated cytotoxicity (ADCC) [554, 555] was 
observed (Figure 4.2B). This activated phenotype by LPS-mono is similar to the 
phenotype of CD14+ cells from the synovial fluid (SFM) as described in chapter 3 
(Figure 3.5), except for the expression of CD16, which was increased in SFM 
compared to PBM. 
 
We also determined the ability of LPS-treated monocytes to secrete cytokines as 
well as chemokines to confirm the activated phenotype. To investigate this, mono-
med and LPS-mono were plated in a 48-well plate (0.5x106 cells per well) and 
supernatants collected after 40-42 hrs of culture. Supernatants (n=6) were then 
analysed with a human 25-plex cytokine array on the Luminex platform. 
 
Chapter 4: The effects of activated monocytes on Treg phenotype and function 
134 
 
Figure 4.2 LPS-treated monocytes show an activated phenotype. 
MACS-isolated CD14
+
 monocytes were treated with medium (mono-med) or 100 ng/ml LPS (LPS-
mono) for 30 min at 37°C and cultured for 14-18 hours (0.5x10
6
 cells/ml). Live monocytes were gated 
based on FSC vs. SSC analysis and duplets excluded (FSC-W vs. FSC-A). Surface expression (MFI) of 
the indicated markers was determined by gating on CD14
+
 monocytes (CD14 vs. CD16) (A) and 
results shown as mean±SEM (n=18) (B). Analysis was performed using paired t test or Wilcoxon 
matched-pairs signed rank test as determined by D’Agostino & Pearson omnibus normality test: * 
p<0.05, ** p<0.01, *** p<0.001. 
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LPS-activated monocytes produced significantly increased amounts of the pro-
inflammatory cytokines IL-1β, IL-6 and TNF-α, as reported previously [556, 557], when 
compared to their medium-treated counterparts. Furthermore, we detected 
increased levels of the anti-inflammatory cytokine IL-10, and increased levels of IL-
12 (p40/p70), IL-1Ra and IL-2R in supernatants from LPS-mono. Chemokines such as 
RANTES (CCL5), IP-10 (CXCL10), MIG (CXCL9), IL-8 (CXCL8), MIP1-α (CCL3), MIP-1β 
(CCL4) and MCP-1 (CCL2) were also significantly increased in LPS-mono relative to 
mono-med (Figure 4.3), which overall indicates and confirms an activated 
phenotype for LPS-treated monocytes. Eotaxin, GM-CSF, IFNα, IFNγ, IL-2, IL-4, IL-5, 
IL-7, IL-13, IL-15 and IL-17 were not detectable in supernatants from either LPS-
mono or mono-med. 
 
We had found increased levels of IL-12 (p40/p70) in the supernatants from LPS-
mono, but the human 25-plex assay detects both subunits of IL-12 - p70 and p40, 
the latter of which is shared by IL-23 [558]. To assess whether increased IL-12 
(p40/p70) levels were due to IL-23 secreted by LPS-activated monocytes, we 
performed an IL-23-specific ELISA, which uses a p19-specific capture antibody in 
combination with a p40-specific detection antibody. Overall, we found only very 
little IL-23 in 3 out of 5 samples (Figure 4.3) suggesting that the majority of the 
signal detected by the 25-plex is due to increased IL-12 secretion rather than IL-23.  
 
Furthermore, in a separate ELISA we also determined IL-27 and TGF-β levels in 
mono-med and LPS-mono supernatants, but no signal was detected in these 
samples (n=5, data not shown).  
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Figure 4.3 LPS-treated monocytes show increased cytokine and chemokine production. 
Mono-med (med) or LPS-mono (LPS) were cultured in a 48-well plate (0.5x10
6
 cells/ml) and cell 
culture supernatants collected after 40-42 hours. Supernatants (n=6) were quantified by a human 
25-plex cytokine array (or ELISA for IL-23, n=5) and analysis was performed using Wilcoxon matched-
pairs signed rank test: * p<0.05. Dashed lines indicate lower and/or upper detection limit. 
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4.2.2 In vitro-activated monocytes induce cytokine expression in CD25+CD127low 
Tregs 
We next assessed the effects of in vitro-activated monocytes on Treg phenotype 
and function. CD4+CD45RA-CD25+CD127low T cells (CD45RA- Tregs) were sorted to 
high purity from enriched memory CD4+ T cells of healthy controls using a BD 
FACSAria™ II machine after surface staining for CD25 and CD127 (Figure 4.4). 
Purities of cells were assessed immediately by re-running a small aliquot of the 
sorted sample on the cell sorter leading to purities greater than 98% (Figure 4.4B). 
Additionally, staining for the lineage-specific transcription factor FoxP3 and CD39 
was performed in the first few experiments to confirm successful sorting (Figure 
4.4C). The ectonucleotidase CD39 (ENTPD1) converts extracellular ATP and ADP to 
AMP, which is then further dephosphorylated into the anti-inflammatory 
metabolite adenosine by the enzyme CD73 [102]. CD39 was previously described to 
be a surface marker highly expressed on Tregs [105, 106]. Sorted CD4+CD45RA-
CD25+CD127low Tregs were confirmed to be predominantly FoxP3 positive (>85%) 
and were highly enriched for CD39 expression. It is important to note however, that 
CD39 staining was not always positive as some donors express very low levels of the 
molecule CD39. This could potentially be explained by their genotype for a certain 
SNP (rs10748643), which was shown to be associated with high (GG), intermediate 
(AG) or low (AA) expression of CD39 and low expression was further correlated with 
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 T cells were isolated from PBMC by magnetic bead isolation and cells were sorted 
based on surface expression of CD25 and CD127 using a FACS Aria™ cell sorter (A). Purities of cells 
were assessed immediately by re-running a small aliquot of the sorted samples on the machine and 
were always greater than 98% (B). Sorted Tregs (black line) and effector T cells (Teff, filled 
histograms) were also stained for the Treg markers CD39 and FoxP3 in the first experiments (C, 
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The sorted, highly pure CD45RA- Tregs were co-cultured with autologous CD14+ 
monocytes that had been pre-treated with either 100 ng/ml LPS or medium for 30 
min followed by multiple washing steps with medium to minimise LPS carryover 
into co-cultures as T cells also express TLRs such as TLR2 and TLR4 [427, 560-563] . 
To activate Tregs, soluble anti-CD3 mAb (Okt-3) was added to the co-cultures whilst 
the CD28 stimulus was provided by the monocytes. The expression of cytokines was 
assessed at day 3 by staining for the surface markers CD14 and CD2 to distinguish 
between monocytes and Tregs, respectively (see gating strategy in Figure 2.4, 
chapter 2) and by performing intracellular cytokine staining using 0.5% Saponin 
following PMA and ionomycin re-stimulation in the presence of GolgiStop to amplify 
the signal. LPS-activated monocytes induced a significant increase in the percentage 
of CD45RA- Tregs expressing IL-17, IFNγ or TNF-α relative to mono-med (n=24-26) 
(Figure 4.5A-C). Interestingly, the presence of LPS-mono also significantly increased 
the percentage of Tregs expressing the anti-inflammatory cytokine IL-10 (Figure 
4.5D). 
 
Some of the data points plotted in Figure 4.5 represent the same donor, which 
allowed an assessment of inter-experimental variability. We observed considerable 
variation in the extent of cytokine expression over time within the same donor 
especially in the LPS-mono condition; however the overall trend remained the same 
(Figure 4.6). This indicates that although some data points represent the same 
individual, it certainly does not skew the results when showing the cumulative data 
(Figure 4.5) of the different experiments (n=24-26) since variation occurs within 
donors over time, which may be due to seasonal changes. 
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) were co-cultured with autologous mono-med 
or LPS-mono (1x10
5
) in the presence of 100 ng/ml anti-CD3 mAb in a 96-well U-bottom plate (V=250 
μl). After 3 days, cells were re-stimulated with 50 ng/ml PMA and 750 ng/ml ionomycin for 6 hrs, 
with GolgiStop present for the last 3 hrs and intracellularly stained for IL-17 (A), IFNγ (B), TNF-α (C) 




 cells expressing the indicated cytokine using the 
gating strategy as described in Figure 2.4. Dot plots of one representative experiment and the 
individual data from 24-26 experiments are shown. Data were analysed using either paired t test or 
Wilcoxon matched-pairs signed rank test as determined by D’Agostino and Pearson omnibus 
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 Tregs from the same healthy control were co-cultured with 
autologous mono-med (med) or LPS-mono (LPS). Cells were isolated at 6 different time points 
throughout a 7-month period. Data were analysed using Wilcoxon matched-pairs signed rank test: * 
p<0.05. 
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In order to determine the relative magnitude of the percentage of cytokine-positive 
Tregs induced by LPS-mono, we set up parallel co-cultures of CD4+CD45RA-CD25low/-
CD127+ effector T cells (Teff, n=13) with medium-treated or LPS-activated 
monocytes. This analysis showed that although IL-17+, IFNγ+ and TNF-α+ Tregs were 
increased in the presence of in vitro-activated monocytes, the percentages were 
still relatively low compared to pro-inflammatory cytokine-expressing Teff (e.g. 
3.9±0.4% vs. 14±1.9% IL-17+ cells) (Figure 4.7A). In contrast, the percentage of IL-10+ 
cells was higher in Tregs that were co-cultured with LPS-mono compared to Teff 
(2.0±0.2% vs. 0.9±0.2% IL-10+ cells) (Figure 4.7D).  
 
Activation of T cells can induce upregulation of CD25 expression [129-131] and 
downregulation of CD127 expression [488, 564]. Recently activated T cells could 
therefore potentially contaminate the sorted CD25+CD127low Treg population due to 
a similar phenotype. To assess whether the cytokine expression profile of 
CD4+CD45RA-CD25intCD127+ Teff, which most probably comprise recently activated 
T cells, was similar to CD45RA- Tregs, we further set up co-cultures of CD4+CD45RA-
CD25intCD127+ Teff (n=10) with mono-med or LPS-mono. 
 
CD25intCD127+ Teff expressed high percentages of the pro-inflammatory cytokines 
IL-17, IFNγ and TNF-α following co-culture with mono-med relative to CD45RA- 
Tregs (Figure 4.8). The percentage of IL-17+ and TNF-α+ Teff were further induced by 
LPS-mono, suggesting that these cells are indeed more activated. Of interest, 
CD25intCD127+ Teff showed a decrease in IL-10+ cells following co-culture with LPS-
mono, which was in striking contrast to Tregs.  
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 Teff. Tregs and Teff were co-cultured with autologous CD14
+
 monocytes, which 
were either pre-treated with medium (med) or LPS (LPS). On day 3, cells were re-stimulated and 
intracellularly stained for IL-17 (A), IFNγ (B), TNF-α (C) and IL-10 (D). The cumulative data are plotted 
for Tregs (n=24-26) and Teff (n=11-13) for the indicated cytokines (mean±SEM); data were analysed 
using paired t test or Wilcoxon matched-pairs signed rank test: * p<0.05, *** p<0.001. 
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 Teff. Cells 
were co-cultured with autologous mono-med (med) or LPS-mono (LPS) in the presence of anti-CD3 
mAb. Cells were re-stimulated on day 3 with PMA/ionomycin and intracellularly stained for the 
indicated cytokines. The cumulative data are plotted as mean±SEM and data were analysed by 
paired t test or Wilcoxon matched-pairs signed rank test: * p<0.05, ** p<0.01. 
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These findings suggested to us that the observed increase in cytokine expression by 
Tregs induced by LPS-mono is not due to contaminating effector T cells. 
 
4.2.3 CD14+CD16- and CD14+CD16+ monocyte subsets can both induce pro-
inflammatory cytokine expression in CD45RA- Tregs 
Human monocytes are a heterogeneous cell population of circulating blood 
leukocytes, which comprise three different subpopulations, namely classical 
(CD14+CD16−), intermediate (CD14+CD16+), and non-classical or “patrolling” 
(CD14dimCD16+) monocytes [332, 333, 565, 566]. The so-called intermediate or “pro-
inflammatory” CD14+CD16+ monocytes are the smallest population, which are 
characterised by expression of the Fc receptors CD64 and CD32, are highly 
phagocytic and major producers of TNF-α and IL-1β in response to LPS [333, 336, 338]. 
CD16+ monocytes are increased in inflammation and disease e.g. in sepsis [339], 
atherosclerosis [344], Sjögren’s syndrome [567] as well as in the peripheral blood of 
patients with RA [342, 343, 536, 568, 569]. It was recently shown that this subpopulation of 
CD14+CD16+ monocytes is most potent in the induction of IL-17 production by CD4+ 
T cells [448]. In agreement with the study by Rossol et al., we observed a significant 
increase in PB CD14+CD16+ monocytes in patients with RA (n=22) compared to HC 
(n=26) (9.5±1.2% vs. 6.6±0.6% CD16+ cells within the CD14+ monocyte population, 
p=0.0164, Figure 4.9A).  
 
Since MACS-isolated CD14+ monocytes contain both “pro-inflammatory” 
CD14+CD16+ and classical CD14+CD16- monocytes, we FACS-sorted CD14+ 
monocytes into CD16- and CD16+ cells by staining for CD16 (Figure 4.9B). Unsorted 
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Figure 4.9 Increased cytokine expression by CD45RA
-




(A) Frequencies of CD16
+
 cells within CD14
+
 monocytes were determined in HC (n=26) and patients 
with RA (n=22) and analysed by Mann Whitney test: * p<0.05. (B) MACS-isolated CD14
+
 monocytes 








 monocytes. (C, D) Tregs were co-cultured with 
unsorted, total CD14
+








 monocytes with (LPS) or 
without (med) LPS. The percentage of cytokine
+
 cells was analysed at day 3 by ICCS. Dot plots of one 
representative experiment for IL-17 (C) and the individual data of 3 experiments (D) are shown. 
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and sorted monocytes were then co-cultured with autologous CD45RA- Tregs in the 
presence or absence of LPS. As the CD14+CD16+ monocytes are only a small 
population of cells and numbers were limited, cells were not pre-activated with LPS 
in this experimental approach and instead LPS was directly added to the co-
cultures. Although we cannot rule out the possibility of direct effects of LPS on 
Tregs in this set-up, the addition of LPS to non-sorted total CD14+ monocytes (Figure 
4.9C, D) led to similar results in terms of induction of cytokine expression by Tregs 
compared to previous experiments using monocytes pre-activated with LPS (Figure 
4.5). 
 
Both CD14+CD16+ and CD16+-depleted (CD14+CD16-) monocytes showed the 
capacity to induce pro-inflammatory IL-17 (Figure 4.9C, D) and IFNγ expression 
(Figure 4.6D) by CD45RA- Tregs following LPS stimulation, although in one donor 
(colour-coded in blue) LPS addition to co-cultures of CD14+CD16+ monocytes and 
CD45RA- Tregs decreased the percentage of IL-17+ and IFNγ+ Tregs. However, it 
needs to be noted that the baseline (medium) was already very high and as 
CD14+CD16+ monocytes are more susceptible to spontaneous cell death [570] it might 
be that they did not survive the LPS stimulation. Nevertheless, unsorted CD14+ and 
sorted CD14+CD16- monocytes of the same donor had a similar capacity to induce 
IL-17+ and IFNγ+ Tregs in the presence of LPS, which suggests that depletion of 
CD14+CD16+ monocytes does not reduce the ability of monocytes to induce 
cytokine expression in CD45RA- Tregs . The induction of TNF-α+ and IL-10+ Tregs by 
the different monocyte subsets was more varied between the three donors, which 
made it difficult to draw conclusions from n=3 experiments. 
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Together, these findings indicate that the induction of IL-17 and IFNγ expression in 
CD4+CD45RA-CD25+CD127low Tregs is not a unique feature of a particular CD14+ 
monocyte population. 
 
4.2.4 CD58 blockade does not prevent the induction of cytokines by CD2high Tregs 
One observation that we made throughout the experiments is that CD45RA- Tregs 
consistently upregulated CD2 expression (MFI) following co-culture with LPS-mono 
compared to mono-med (5,417±426 vs. 4,240±270 (mean±SEM), n=26, p<0.0001), 
whereas CD25low/-CD127+ Teff (n=13) showed much higher CD2 expression than 
Tregs after 3 days (18,936±1,397), but a significant downregulation following 
culture with LPS-mono (p=0.0021) (Figure 4.10A). Furthermore, it appeared that the 
CD2hi Tregs were the predominant cytokine-expressing cells, which was true at least 
for IL-17 (Figure 4.10B), IFNγ and IL-10 (data not shown). 
 
The cell adhesion molecule CD58 (LFA-3) is ubiquitously expressed, but 
predominantly on antigen-presenting cells (APCs), and binds to CD2 on T cells 
strengthening the interaction between these cells [571]. To determine whether the 
interaction between CD2 and CD58 was involved in the induction of cytokine-
positive Tregs, an anti-CD58 antibody was added to co-cultures of LPS-mono and 
CD45RA- Tregs (n=2). Addition of anti-CD58 did not have an effect on the 
percentage of IL-17+ or IFNγ+ Tregs compared to isotype control Ab (Figure 4.10C). 
IL-10 and TNF-α expression were decreased, but addition of the goat IgG control 
antibody had the same effect (Figure 4.10C). Furthermore, staining of medium-
treated and LPS-activated monocytes for CD58 after 18 hrs of in vitro culture  
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 Teff (n=13) were co-cultured with autologous 
mono-med or LPS-mono in the presence of anti-CD3 mAb. The expression of CD2 (MFI, mean±SEM) 
was determined on day 3. Data were analysed by Wilcoxon matched-pairs signed rank test: ** 
p<0.01, *** p<0.001. (B) A representative dot plot of CD2 vs. IL-17 expression by Tregs following co-
culture with mono-med and LPS-mono. (C) Tregs were co-cultured with mono-med, LPS-mono or 
LPS-mono with anti-CD58 Ab or the appropriate isotype. Cytokine expression was determined by 
ICCS on day 3 (n=2). (D) CD14
+
 monocytes (n=6) were treated with medium or LPS for 30 min, 
cultured for 16 hrs and CD58 expression determined. 
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showed no upregulation of CD58 by LPS-mono (n=6, Figure 4.10D) as it was 
suggested by others [572]. LPS-mono actually showed a decrease in CD58 expression 
in 4 out of 6 cases. 
 
Taken together, the interaction of CD2 and CD58 between Tregs and monocytes did 
not seem to play a role in LPS-mono-induced cytokine expression by CD45RA- Tregs. 
 
4.2.5 The increase in IL-17+ Tregs is driven by monocyte-derived IL-1β, IL-6 and 
TNF-α  
To determine whether soluble factors were involved in the induction of cytokine-
positive Tregs, monocytes were pre-activated with LPS as described above and 
cultured for 40 hrs. Supernatants from these monocytes were collected and 
transferred to co-cultures of autologous (n=3) or allogeneic (n=3) mono-med and 
CD45RA- Tregs. Intracellular cytokine expression was determined at day 3 following 
a PMA and ionomycin re-stimulation in the presence of GolgiStop. 
 
The addition of supernatants from activated monocytes led to a consistent increase 
in IL-17+ Tregs (n=6), similar to LPS-activated monocytes (Figure 4.11A). 
Furthermore, the percentage of IFNγ+ Tregs was increased by the addition of LPS-
mono sups in 5 out of 6 cases, but this was not as strong as observed with LPS-
mono (Figure 4.11B). Consistent with previous results, LPS-mono induced the 
percentage of TNF-α+ and IL-10+ Tregs, however addition of LPS-sups to co-cultures 
of mono-med with CD45RA- Tregs had no effect on IL-10 and TNF-α expression 
(Figure 4.11C, D). 
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 Tregs were co-cultured with mono-med in the absence or presence of supernatants 
from LPS-pre-treated monocytes (LPS-sups), or with LPS-mono, all in the presence of anti-CD3 mAb. 






 (C), and IL-10
+
 (D) Tregs was determined as described 
in Figure 4.5. Data (n=6) were analysed by Friedman test with Dunn’s Multiple Comparison Test: * 
p<0.05, ** p<0.01. 
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These results overall suggest that soluble factors secreted by activated monocytes 
were involved in the observed increase in IL-17+ Tregs, and partially mediated the 
increase in IFNγ+ Tregs. 
 
We next wanted to determine which soluble factors secreted by LPS-activated 
monocytes could be involved in driving the expression of pro-inflammatory 
cytokines by Tregs. As described above, the analysis of supernatants from paired 
mono-med and LPS-mono samples on a human 25-plex cytokine array showed 
increased secretion of various cytokines and chemokines (Figure 4.3). IL-1β, IL-6 and 
TNF-α were likely candidates as they are known to be pro-inflammatory mediators 
in the pathogenesis of rheumatoid arthritis [573] and can drive the induction of IL-17-
producing T cells [197]. TNF-α has further been suggested to impair Treg function by 
downregulation of the Treg-specific transcription factor FoxP3 [253]. Furthermore, IL-
1β was shown to induce IL-17+ Tregs in vitro in the presence of recombinant human 
(rh) IL-2 [237-239, 241, 242, 244, 245]. 
 
To test the possible role of IL-1β, IL-6 and TNF-α in the induction of cytokine-
positive Tregs, we performed reconstitution as well as blocking experiments for the 
three cytokines. Firstly, we added rhIL-1β, IL-6 and TNF-α (all at 10 ng/ml) to co-
cultures of CD45RA- Tregs and monocytes (n=3), which led to a consistent increase 
in the percentage of IL-17+ (Figure 4.12A) and IFNγ+ Tregs (Figure 4.12B) compared 
to medium control, but only in 2 out of 3 cases to an increase in TNF-α+ and IL-10+ 
Tregs (Figure 4.12C, D), again indicating that the expression of these two cytokines 
might be regulated differently in Tregs.  
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 Tregs were co-cultured with mono-med (med) with or without the addition of human 
recombinant IL-1β, IL-6 and TNF-α (all at 10 ng/ml, designated as +cytokines) in the presence of anti-






 (C), and IL-10
+
 (D) Tregs was 
determined as described in Figure 4.5. 
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Conversely, addition of neutralising Abs for IL-1β (final concentration: 1 μg/ml), IL-6 
(final concentration: 10 μg/ml) and TNF-α (final concentration: 1 μg/ml) to co-
cultures of CD45RA- Tregs with LPS-mono (n=5-6), prevented the increase in IL-17+ 
Tregs and to some extent of IFNγ+ Tregs (Figure 4.13 A, B), but did not affect IL-10 or 
TNF-α (n=5) expression by Tregs (Figure 4.13B). Supernatants of these co-cultures 
were analysed for IL-17 and IFNγ by ELISA demonstrating that the addition of 
neutralising Abs also reduced IL-17 secretion and to a lesser extent IFNγ secretion 
by CD45RA- Tregs (Figure 4.13C).  
 
Effective neutralisation of IL-1β, IL-6 and TNF-α was tested by ELISA for each 
individual cytokine. IL-1β was successfully neutralised (Figure 4.14A), whereas TNF-
α was not detectable in our standard ELISA at the dilution factor used (5x) (data not 
shown). Therefore supernatants from one experiment were run neat on a more 
sensitive human 25-plex cytokine array, which showed low TNF-α secretion overall 
but a complete blockade by the addition of TNF-α blocking Abs (Figure 4.14B). It is 
important to note however, that no complete neutralisation of IL-6 was achieved 
with the IL-6 blocking Ab when used at 10 μg/ml (approx. 55% reduction, n=3, 
Figure 4.14C). When increasing amounts of the IL-6 blocking antibody (20 μg/ml) 
were used, no further reduction in IL-6 levels was observed in the supernatants 
(n=1, Figure 4.14D). Furthermore, neutralisation of IL-6 using 10 μg/ml of the 
blocking antibody reduced IL-17+ Tregs already to “baseline” (mono-med condition), 
indicating that complete blockade of IL-6 is not necessary to prevent the increase in 
IL-17+ Tregs by LPS-mono (Figure 4.14E). 
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 Tregs were co-cultured for 3 days with mono-med, LPS-mono or LPS-mono and 
neutralising antibodies against IL-1β, IL-6 and TNF-α (blocking Abs) or the appropriate IgG isotype 
controls (IgG Abs). Cells were analysed for IL-17, IFNγ, TNF-α and IL-10 by ICCS (B) and IL-17 and IFNγ 
secretion by ELISA (C). One representative experiment (A) and the cumulative data (mean±SEM, n=5-
6) are shown (B). Data were analysed by Friedman test with Dunn’s Multiple Comparison Test (B) 
and Wilcoxon matched-pairs signed rank test (C): * p<0.05, ** p<0.01. 
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Figure 4.14 Testing the neutralising ability of the cytokine blocking antibodies. 
(A-E) CD45RA
-
 Tregs were co-cultured with mono-med, LPS-mono or LPS-mono and neutralising 
antibodies against IL-1β, IL-6 and TNF-α (blocking Abs) or the appropriate IgG isotype controls (IgG 
Abs). At day 3, supernatants were analysed for IL-1β (A, n=3), TNF-α (B, n=1), or IL-6 (C, n=3) 
secretion by ELISA (A, C) or with a human 25-plex cytokine array (B). A higher concentration of the IL-
6 blocking antibody was used (D, n=1) and the percentage of IL-17
+
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Overall, these data show that monocyte-derived IL-1β, IL-6 and TNF-α are crucial in 
driving IL-17 and to some extent IFNγ expression by CD45RA- Tregs, whereas TNF-α 
and IL-10 appear to be regulated by a different mechanism. 
 
4.2.6 The CD25+CD39+ Treg phenotype is maintained following co-culture with in 
vitro-activated monocytes 
We next determined whether CD45RA- Tregs still expressed regulatory T cell 
markers following incubation with activated monocytes for three days. After co-
culture with LPS-mono, the vast majority of Tregs remained positive for CD25 and 
CD39 (Fig 4.15A) and if anything showed a slightly higher expression of these 
markers (MFI) than Tregs co-cultured with mono-med (n=3, Figure 4.15B). The 
percentages of cells positive for CD69 and HLA-DR were slightly increased in LPS-
mono-Treg co-cultures. The transmembrane C-type lectin protein CD69 is a T cell 
activation marker [574-576] and HLA-DR expression has been associated with a 
particularly mature subset of Tregs [62, 145], which overall indicates an activated 
status of Tregs after co-culture with LPS-mono. Interestingly, despite the observed 
increase in IL-17+ cells following co-culture with activated monocytes, we did not 
observe an increase in the Th17 marker CD161 [220, 221] either in terms of percentage 
positive cells or expression levels (Figure 4.15).  
Co-staining for CD161 and IL-17 in co-cultures of CD45RA- Tregs (n=5) and CD25-
CD127+ Teff (n=2) with mono-med or LPS-mono further indicated that the majority 
of IL-17+ Teff were positive for CD161 (n=2, Figure 4.16B), whereas IL-17+ Tregs 
were pre-dominantly CD161- (n=5), especially after co-culture with LPS-mono 
(Figure 4.16A).  
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 Tregs were co-cultured with mono-med or LPS-mono in the 
presence of anti-CD3 mAb. At day 3, cells were stained for CD69, CD25, CD39, HLA-DR and CD161. 
Data (n=3, mean±SEM) are shown as the % of cells positive for the indicated marker (A) or the 
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Figure 4.16 Not all IL-17
+









 Teff (n=2) were co-cultured with mono-med or 





 cells within IL-17
+
 cells determined. One representative dot plot 
for Tregs (A) and Teff (B) and the cumulative data (mean±SEM) are shown. 
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To further address whether CD161+ T cells were highly enriched for IL-17+ cells as it 
was previously suggested [220, 221], we gated on CD161+ T cells in co-cultures of Tregs 
and Teff with mono-med or LPS-mono and assessed their cytokine profile. The 
percentage of IL-17+ cells (n=5) was higher than IL-10+ (n=2) or IFNγ+ cells (n=5) in 
CD161+ Tregs (Figure 4.17A), whereas in CD161+ Teff (n=2) IFNγ+ cells were actually 
the most abundant population (Figure 4.17B). Furthermore, the majority of these 
IFNγ+CD161+ Teff did not co-express IL-17 (data not shown). 
These data overall suggest that in these experiments CD161 cannot be used as a 
specific or exclusive marker to identify IL-17+ Tregs or Teff. 
 
4.2.7 IL-17+ Tregs do not lose FoxP3 expression  
We next investigated whether CD45RA- Tregs lose their FoxP3 expression following 
co-culture with activated monocytes, as an increase in IL-17 expression had 
previously been reported to be associated with a loss in FoxP3 expression [237, 239]. To 
determine FoxP3 expression in CD45RA- Tregs after a 3-day co-culture with mono-
med or LPS-mono, intranuclear staining for FoxP3 and IL-17 was performed 
following a PMA and ionomycin re-stimulation (n=6). 
 
After 3 days, the majority of CD45RA- Tregs including IL-17+ Tregs were still FoxP3-
positive and in fact, the overall percentage of FoxP3-positive Tregs was even higher 
after co-culture with LPS-activated monocytes (Figure 4.18A). In contrast, Teff 
cultured in parallel showed low percentages of FoxP3+ cells overall (Figure 4.18B). 
Furthermore, the expression of FoxP3 as determined by MFI was not significantly 
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 Teff (n=2) were co-cultured with 
mono-med or LPS-mono in the presence of anti-CD3 mAb. At day 3, cells were stained for CD161 and 
IL-17, IFNγ or IL-10. The percentage of cytokine-expressing cells within CD161
+
 cells was determined 
(mean±SEM) for Tregs (A) and Teff (B). 
 
 














 Teff (n=3) were co-cultured with mono-med or 
LPS-mono in the presence of anti-CD3 mAb. At day 3, cells were stained for FoxP3 and IL-17. One 









 Teff (B) are depicted. Wilcoxon matched-pairs signed rank 































































Chapter 4: The effects of activated monocytes on Treg phenotype and function 
163 
different between IL-17+ and IL-17- Tregs, but was significantly higher in both IL-17+ 
and IL-17- cells from LPS-mono-Treg cultures compared to their respective mono-
med-cultured counterparts (Figure 4.18A). In contrast, FoxP3 expression was low in 
Teff and no increase in FoxP3 expression was observed following co-culture with 
LPS-mono (n=3) (Figure 4.18B). 
In conclusion, Tregs do not lose their FoxP3 expression following co-culture with 
LPS-activated monocytes despite increased pro-inflammatory cytokine expression; 
in fact they rather show increased expression. 
 
We next wanted to determine whether co-cultures of CD45RA- Tregs with LPS-
activated monocytes would lead to increased proliferation and the breakage of 
anergy in Tregs. We therefore stained Tregs from these co-cultures with anti-Ki-67, 
a monoclonal antibody that detects the nuclear protein Ki-67, which is only present 
in proliferating cells [577, 578]. 
Although the percentage of Ki-67+ cells was higher in IL-17+ Tregs than in IL-17- 
Tregs from co-cultures with both mono-med and LPS-mono (Figure 4.19A), the 
overall percentages were relatively low compared to IL-17+ Teff (10-20% in Tregs vs. 
85-95% in Teff) (Figure 4.19B). 
 
Together, these data demonstrate that although CD45RA- Tregs showed increased 
pro-inflammatory cytokine expression following co-culture with activated 
monocytes, their Treg phenotype was maintained and the majority of IL-17-
expressing Tregs showed low proliferative activity, as determined by Ki-67 staining, 
suggesting that they were still anergic. 
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Figure 4.19 The majority of IL-17
+









 Teff (n=3) were co-cultured with mono-med or 
LPS-mono in the presence of anti-CD3 mAb. At day 3, cells were stained for Ki-67 and IL-17. One 
representative dot plot and the average data (mean±SEM) of the % Ki-67
+









 Teff (B) are shown. 
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4.2.8 Activated CD45RA- Tregs show an enhanced capacity to suppress T cell 
proliferation and cytokine secretion 
Expression of pro-inflammatory cytokines is not a common feature of Tregs per se 
and expression of IL-17 has been associated with impaired suppressive function [164, 
239, 244]. We therefore determined whether CD45RA- Tregs from co-cultures with 
activated monocytes showed an impaired ability to exert their suppressor function. 
To determine the ability of LPS-mono-activated Tregs to suppress the proliferation 
of autologous effector T cells, we co-cultured CD45RA- Tregs with either mono-med 
or LPS-mono in the presence of anti-CD3 mAb overnight at various cell ratios (0:1, 
0.5:1 and 1:1) to allow interaction between cells. The following day, autologous 
CFSE-labelled CD25low/-CD127+ Teff were added at a 1:1 ratio (monocytes to Teff) 
and cells cultured for another 48 hours. Proliferation of Teff was assessed by flow 
cytometry at day 3 by gating on CFSE+ cells. 
 
Effector T cells proliferated strongly in the presence of mono-med (0:1), which was 
suppressed by the presence of Tregs at both ratios (0.5:1 and 1:1) (Figure 4.20). 
Although Teff proliferated less profoundly in the presence of LPS-activated 
monocytes (Figure 4.20A, B), their proliferation was still strongly suppressed by the 
presence of CD45RA- Tregs. In fact, when we calculated the percentage of 
suppression of proliferation, we found an increased suppressive capacity when 
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 Tregs were co-cultured overnight with mono-med or LPS-mono in the presence 
of anti-CD3 mAb at the indicated cell ratios. The following day, CFSE-labelled, autologous CD45RA
-
 
Teff were added to the co-cultures and proliferation assessed on day 3 (n=5). Dot plots and 
histograms from one representative experiment are shown in (A). The cumulative data (mean±SEM) 
show the percentage proliferation of CFSE
+
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We next assessed the ability of CD45RA- Tregs to suppress the secretion of IL-17 and 
IFNγ by CD25low/-CD127+ Teff after 3 days of culture in the presence of mono-med or 
LPS-mono and anti-CD3 mAb. Following interaction with LPS-mono, CD45RA- Tregs 
were more efficient in suppressing IL-17 and IFNγ cytokine secretion compared to 
mono-med-stimulated Tregs (Figure 4.21A, B), which was particularly evident for IL-
17. Tregs from LPS-mono co-cultures suppressed IL-17 secretion already at low 
ratios (0.2:1 Treg:Teff) whilst mono-med-cultured Tregs only suppressed at a 1:1 
ratio in most cases (Figure 4.21A).  
 
Finally, the ability of activated CD45RA- Tregs to suppress cytokine secretion by LPS-
mono was investigated. Addition of CD45RA- Tregs to cultures of LPS-activated 
monocytes significantly suppressed the secretion of TNF-α (n=14), IL-1β (n=16) and 
IL-6 (n=13) by LPS-activated monocytes (Figure 4.22). However, Tregs did not 
suppress IL-10 secretion by LPS-mono and in two out of three cases did actually 
increase IL-10 secretion (Figure 4.22), which is consistent with previous 
observations in the lab [12].  
 
Overall, these data indicate that after co-culture with LPS-mono, CD45RA- Tregs 
potently suppressed proliferation as well as cytokine secretion by effector T cells 
and monocytes and in fact, showed an enhanced capacity to suppress T cell 
proliferation and IL-17 secretion, despite themselves containing more IL-17+ Tregs. 
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 Tregs were co-cultured overnight with mono-med or LPS-mono in the presence 
of anti-CD3 mAb at the indicated cell ratios. The following day, autologous CD45RA
-
 Teff were added 
to the co-cultures and supernatants collected on day 3 before PMA/ionomycin restimulation. 
Supernatants from these co-cultures were analysed for IL-17 (A) and IFNγ secretion (B) by ELISA. 
Each line represents an individual donor. 
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Figure 4.22 Activated Tregs suppress TNF-α, IL-1β and IL-6 secretion by monocytes, but not IL-10.  





 Tregs were collected at day 3 and analysed for TNF-α (n=14), IL-1β (n=16), IL-6 (n=13) 
and IL-10 (n=3) secretion. Analysis was performed using paired t test or Wilcoxon matched-pairs 
signed rank test: *** p<0.001. 
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4.2.9 Cytokine-activated monocytes as well as in vivo-activated monocytes induce 
pro-inflammatory cytokine expression by CD45RA- Tregs 
Next, we investigated whether monocytes that were stimulated in a more 
physiologically relevant way were also able to increase pro-inflammatory cytokine 
expression by CD45RA- Tregs. We therefore mimicked the environment monocytes 
may be exposed to in the inflamed joint by incubating CD14+ monocytes from HC 
for 30 min with either medium (mono-med) or a cocktail of cytokines (IL-1β, IL-6, IL-
17, IFNγ, IL-10, TNF-α and OPN), which are known to be associated with SF [573] and 
that we confirmed to be present in RA SF (Figure 4.23A). This was followed by 
various washing steps with medium after which medium- and cytokine-treated 
monocytes (0.5x106 cells per well) were cultured overnight and their phenotype 
assessed after 14-18 hrs by flow cytometric surface staining as previously described 
for LPS-mono (see Figure 4.2). 
 
A consistent increase in the expression of the monocyte activation markers CD40, 
CD54, CD86 and HLA-DR, but a concomitant decrease in CD16 was found on 
cytokine-treated monocytes compared to mono-med (Figure 4.23B, n=5), indicating 
that these cytokine-activated monocytes are similar, but not identical to in vivo-
activated SF monocytes (Figure 3.5, Chapter 3), and rather resembled LPS-activated 
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Figure 4.23 Cytokine-treated monocytes show an activated phenotype. 
(A) The presence of cytokines in RA SF (n=8-13) was determined by ELISA or FlowCytomix Th1/Th2 
assay for the indicated cytokines. For TNF-α, IL-1β, IL-6, IFNγ and IL-10 identical symbols reflect the 
same samples. Data was kindly provided by Dr Nicola Gullick. (B) Expression of the indicated surface 
markers was determined on cytokine-treated monocytes (cyto-mono) compared to medium-treated 
monocytes (mono-med) from HC (n=5). 
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Cyto-mono and med-mono were then co-cultured with CD45RA- Tregs (n=5) and 
cytokine expression assessed on day 3 following PMA/ionomycin re-stimulation in 
the presence of GolgiStop. A general increase was observed in the percentage of IL-
17+, IFNγ+ and TNF-α+ Tregs, and to a lesser extent of IL-10+ Tregs in co-cultures with 
cyto-mono after 3 days (Figure 4.24A). CD25low/-CD127+ Teff that were cultured in 
parallel under the same conditions showed a less pronounced increase in cytokine 
expression with considerable variability between donors following co-culture with 
cyto-mono (Figure 4.24B).  
 
We tested the ability of Tregs from co-cultures with cyto-mono to suppress T cell 
effector function in suppression assays as described before for LPS-mono. We found 
that CD45RA- Tregs were able to effectively suppress proliferation (Figure 4.25A) as 
well as IL-17 and IFNγ secretion (Figure 4.25B) by autologous CD25low/-CD127+ Teff 
(n=2). 
 
Finally, we had access to paired peripheral blood and synovial fluid samples (n=4) 
from patients with rheumatoid arthritis from which CD14+ monocytes were isolated 
by FACS sorting following pre-enrichment with CD14 MicroBeads leading to purities 
of >99%. The activated phenotype of SFM as described in chapter 3 (Figure 3.5) was 
confirmed by phenotypic surface marker staining of PBM and SFM (data not 
shown).  
Co-cultures of synovial fluid-derived monocytes (SFM) with either autologous (n=1) 
or allogeneic (n=3) CD45RA-CD45RO+ Tregs lead to a consistent increase in IFNγ+ 
and TNF-α+ Tregs compared with PBM, an increase in IL-17+ Tregs in 2 out of 4 
Chapter 4: The effects of activated monocytes on Treg phenotype and function 
173 
 











 Teff (B) were co-cultured with autologous 
medium-treated (med) or cytokine-activated monocytes (cyto) in the presence of anti-CD3 mAb for 3 
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 Tregs were co-cultured overnight with mono-med or cyto-mono at the 
indicated cell ratios. CFSE-labelled CD45RA
-
 Teff were added to the co-cultures the following day, 
supernatants collected on day 3 and proliferation assessed (n=2). The percentage proliferation of the 
individual experiments and the calculated percentage suppression is shown (A). Supernatants from 
these co-cultures were analysed for IFNγ and IL-17 secretion by ELISA (B). 
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donors, and a decrease in IL-10+ Tregs in 3 out of 4 donors (Figure 4.26A). In vivo-
activated monocytes consistently increased the percentage of IL-17+ and IFNγ+ 
CD25low/-CD127+ effector T cells (Figure 4.26B), but showed variable results for IL-10 
and TNF-α.  
 
We further performed a CFSE proliferation assay for the one sample where 
sufficient autologous Tregs and Teff were available. CFSE-labelled CD25low/-CD127+ 
Teff (5x104) were co-cultured with autologous PBM or SFM (5x104) and different 
ratios of CD25+CD127low Tregs (0:1, 0.5:1 and 1:1) in the presence of anti-CD3 mAb. 
At day 3, proliferation of Teff was assessed by flow cytometry (Figure 4.27A) and 
the percentage of suppression calculated (Figure 4.27B), which revealed that Tregs 
from co-cultures with SFM showed an enhanced capacity to suppress proliferation 
by autologous Teff. We also investigated the ability of Tregs to suppress IL-17 and 
IFNγ production by Teff (n=1). These preliminary results indicated that Tregs 
efficiently suppress both cytokines in co-cultures with PBM and SFM (Figure 4.27C) 
and confirmed the results from our in vitro model, where Tregs from LPS-mono co-
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(B) were sorted from isolated CD4
+
 T cells of healthy controls (or n=1 patient with RA, indicated in 
grey) and co-cultured with allogeneic (autologous) PB monocytes (PBM) or synovial fluid monocytes 
(SFM) from patients with RA in the presence of anti-CD3 mAb for 3 days. The percentage of cytokine-
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Figure 4.27 Tregs potently suppress proliferation and cytokine secretion by Teff following co-





 Tregs isolated from one patient with RA were co-cultured with sorted 




 Teff at the indicated cell ratios in the presence of anti-CD3 mAb. On day 3, the percentage 
proliferation of Teff (A) as well as the percentage of suppression (B) were determined (n=1). 
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4.2.10 FoxP3+IL-17+ Tregs can be found in vivo in patients with RA 
Finally, we wanted to investigate whether IL-17+ Tregs can be found in PB from 
patients with RA as it has been previously suggested for HC [238, 241] and whether 
these frequencies are increased at the site of inflammation. To investigate this, we 
stimulated paired PBMC and SFMC samples from patients with inflammatory 
arthritis (n=6 RA and n=2 PsA) with PMA and ionomycin for 3 hrs in the presence of 
GolgiStop. Thereafter, cells were stained for CD3 and CD14 (and CD45RO in n=6 
samples) on the surface and then intracellularly stained for CD4, IL-17 and FoxP3 
using the FoxP3 perm buffer. 
Increased frequencies of total IL-17+ T cells were found in SF compared to PB (Figure 
4.28A, B), which was also true for CD4+CD45RO+ T cells (Figure 4.28B) and is 
consistent with the published literature [388, 579, 580]. FoxP3+IL-17+ T cells could be 
found ex vivo in PB and SF as shown in the representative dot plots in Figure 4.28A, 
but frequencies of IL-17+ cells within FoxP3+ T cells were not consistently increased 
in SF even when correcting for CD45RO+ T cells (Figure 4.28C). 
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 Tregs ex vivo in PB and SF.  
(A-C) PBMC and SFMC were isolated from paired PB and SF samples from patients with inflammatory 
arthritis (n=6 RA (black) and n=2 PsA (blue)). Cells (2x10
6
 per ml) were stimulated with 
PMA/ionomycin for 3 hours in the presence of GolgiStop. One representative dot plot for FoxP3 vs. 






 T cells as described in chapter 2. The 
cumulative data for % IL-17
+










 T cells (n=6) is 














 T cells (n=6) in 
(C). Paired t test or Wilcoxon matched-pairs signed rank test were used for significance testing: * 
p<0.05. 
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4.3 Discussion 
The data presented in this chapter show that monocytes, that had been activated in 
vitro with the TLR4 ligand LPS or with cytokines commonly associated with RA 
synovial fluid, increased the percentage of IL-17+, IFNγ+, and TNF-α+ Tregs but also 
of Tregs expressing the anti-inflammatory cytokine IL-10. Despite the increase in 
pro-inflammatory cytokine expression, Tregs from these co-cultures maintained a 
Treg phenotype (CD25+CD39+FoxP3+) and showed potent suppressive capacities. 
 
Effector T cells can upregulate CD25 expression following activation [129-131], and it 
could therefore be that recently-activated CD25int effector T cells are included when 
sorting Tregs based on CD25 expression. To minimise this possibility we also 
included a staining for CD127 in our sorting strategy, as CD127 is highly expressed 
on Teff but low on Tregs [160, 161]. Furthermore, we are confident that the results we 
have seen for CD4+CD45RA-CD25+CD127low Tregs are not due to a contamination of 
effector T cells for the following reasons. In co-cultures of CD25intCD127+ Teff, that 
were set up in parallel to CD45RA- Tregs, Teff showed a decrease in IL-10 expression 
following co-culture with LPS-mono (Figure 4.8), whereas Tregs showed a significant 
increase (Figure 4.5). Furthermore, the majority of IL-17+ Teff was Ki-67+ and FoxP3-
negative whereas IL-17+ Tregs were pre-dominantly Ki-67-negative and FoxP3+ 
(Figure 4.18 and 4.19). Finally, Teff showed no difference in FoxP3 expression 
following co-culture with LPS-mono or mono-med, whilst Tregs showed an increase 
in FoxP3 expression after co-culture with LPS-mono relative to mono-med (Figure 
4.18). 
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We found that the majority of IL-17+ Tregs after co-culture with in vitro-activated 
monocytes were CD161-negative (Figure 4.16). Other studies reported that the 
potential to express IL-17 is mainly restricted to a subpopulation of Tregs expressing 
CD161 [245, 520]. In those studies cells were either stained immediately ex vivo or 
cultured after isolation based on CD161 expression, whereas we started with a 
mixed population of cells containing the whole CD45RA- Treg population, which 
could possibly explain the differences observed. 
 
The observed increase in IL-17+ Tregs and to a smaller extent in IFNγ+ Tregs was 
driven by monocyte-derived IL-6, TNF-α and IL-1β. It is important to note, that 
although IL-1β and TNF-α could be successfully neutralised by the use of blocking 
Abs in co-cultures of LPS-mono with CD45RA- Tregs (Figure 4.14), no complete 
blockade of IL-6 was achieved even when increasing amounts of the IL-6 blocking 
antibody were used (Figure 4.14C). Nevertheless, IL-17 expression by Tregs was 
brought almost back to “baseline” (mono-med condition) when IL-1β and TNF-α 
were fully neutralised and about 55% of IL-6 was neutralised in co-cultures of Tregs 
with LPS-mono indicating that a reduction of the pro-inflammatory environment 
was sufficient. Due to limited numbers of Tregs per assay we were not able to 
delineate whether it is the combination of the three cytokines that induces IL-17 
expression or whether it is due to an individual cytokine. Preliminary data (n=1) 
where only IL-1β was blocked suggested however, that blockade of IL-1β alone was 
not sufficient to prevent the increase in IL-17 expression (data not shown). 
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The role of IL-23 in the differentiation of Th17 cells is well documented [195, 202, 581] 
and it has been suggested that IL-23 can boost the conversion of Tregs into IL-17-
producing cells [237, 249]. In our assays we detected only low amounts of IL-23 
secretion by LPS-mono (Figure 4.3); however we cannot rule out a possible 
involvement of IL-23 in driving IL-17 expression. 
 
Blockade of IL-1β, IL-6 and TNF-α only partially prevented the increase in IFNγ 
expression by CD45RA- Tregs and did not have an effect on TNF-α or IL-10 
expression (Figure 4.13B). Furthermore, the addition of supernatants from LPS-
mono to co-cultures of mono-med and Tregs did not increase IL-10 and TNF-α and 
only partially increased IFNγ expression (Figure 4.11) overall indicating that multiple 
mechanisms might be involved in driving different cytokine expression in Tregs. This 
will be of interest to study in the future as TNF-α in fact was the most abundantly 
expressed cytokine by Tregs with percentages of up to 28 % in certain donors (Figure 
4.5). It seems likely that cell contact between Tregs and LPS-mono is important in 
the induction of IL-10+ and TNF-α+ Tregs given that the transfer of supernatants from 
LPS-mono did not have a profound effect. Since Tregs upregulated CD2 expression 
following co-culture with LPS-mono we tested the possible involvement of the cell 
adhesion molecule CD58 (LFA-3), but addition of anti-CD58 Ab did not affect 
cytokine expression (Figure 4.10). Future studies could be aimed to address the 
involvement of cell contact in the induction of IL-10+ and TNF-α+ Tregs by using 
transwell assays or blocking antibodies to T cell co-stimulatory molecules expressed 
on activated monocytes. 
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The pro-inflammatory cytokines IL-6, TNF-α and IL-1β are known to be involved in 
the pathogenesis of rheumatoid arthritis [573] and have been implicated in 
converting Tregs into IL-17-producing cells and/or impairing their regulatory 
function. Stimulation of human Tregs with α-CD3/CD28 mAb-coated beads in the 
presence of hrIL-1β and IL-2 in vitro was able to convert Tregs into IL-17-producing 
cells [237-239, 241, 242, 244, 245]. TNF-α was further shown to break human Treg function 
when added in vitro [250] and Valencia et al. suggested that this was due to the ability 
of TNF-α to downregulate FoxP3 expression in Tregs [253]. In line with these in vitro 
observations, treatment of patients with RA using TNF inhibitor therapy led to a 
restoration of immune regulation, which was ascribed to positive effects on Tregs 
[256-258]. A recent study in JIA however indicated that TNFi therapy targets PKB/c-Akt 
hyperactivation in effector T cells [421]. In mice, Treg-mediated suppression was 
abrogated by dendritic cell (DC)-derived IL-6 [264] and it was suggested that this was 
due to increased resistance of CD4+CD25- T cells. In the absence of TGF-β, IL-6 was 
further shown to increase IL-17 production by murine Tregs [582], and to induce a loss 
in FoxP3 expression, which was exacerbated in the presence of IL-1β [228]. The 
inhibition of IL-6 in patients with rheumatoid arthritis using tocilizumab, a 
humanised anti-IL-6R antibody, corrected for the imbalance of Th17 cells to Tregs 
[583] and the suppressive capacity of SF-derived Tregs could be enhanced by in vitro 
IL-6 blockade [584]. Furthermore, the ability to control monocyte-derived IL-6 
production was recently suggested to be critical for the ability of Tregs to suppress 
Th17 responses in patients with RA [532].  
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However, a lot of these in vitro studies do not allow for a distinction of whether Treg 
function is impaired or whether Teff become refractory to Treg-mediated 
suppression under pro-inflammatory conditions. 
 
It is well described in literature that Tregs isolated from the site of inflammation in 
patients with inflammatory arthritis are fully suppressive ex vivo [403, 405, 408-411, 418, 585] 
and might even be more suppressive than their peripheral blood-derived 
counterparts [403, 418]. Another argument for Tregs being functional is the fully 
demethylated FoxP3 promoter region in SF-derived Tregs, indicating that these cells 
may be “true” Tregs, despite low level IL-17 and IFNγ expression upon stimulation 
[584]. One of the key questions that needs to be answered is whether human pro-
inflammatory cytokine-expressing Tregs maintain their suppressive capacity. We 
were able to show here that Tregs induced to become IL-17+ following co-culture 
with activated monocytes maintained their suppressive capacity and furthermore, 
that IL-17+ Tregs did not show a loss in FoxP3 expression. It has been reported 
however, that the induction of IL-17 expression in naïve Tregs under inflammatory 
conditions was accompanied by impaired suppression [239, 244]. Another study using 
single-cell clone analysis further suggested that Tregs transiently lost their 
suppressive function when actively secreting IL-17, but FoxP3 expression was not 
affected [242]. In contrast, IL-17+ Treg clones [238, 241, 242] as well as IL-17+ Tregs from 
the inflamed intestinal mucosa of patients with Crohn’s disease, were shown to be 
suppressive [247]. The newly described CD161+ Treg population that is highly enriched 
in IL-17+ cells was also shown to be suppressive [245, 520] and further showed a fully 
demethylated TSDR (Treg-specific demethylation region) [520]. Furthermore, IFNγ-
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expressing Tregs were reported to be increased in patients with type 1 diabetes, but 
these cells expressed high levels of FoxP3, and possessed suppressive activity [276]. 
Additionally, IFNγ production by Tregs was recently suggested to be essential for the 
prevention of Graft-versus-Host disease [277]. Our data suggest that Tregs exposed to 
an inflammatory environment may have enhanced suppressive effects particularly 
on T cell proliferation and IL-17 production, despite the fact that Tregs themselves 
become more IL-17+, which has also been suggested by studies in mice where IL-17+ 
Tregs were shown to be more suppressive than IL-17- Tregs [270]. Th17 cells are 
thought to be more resistant to Treg-mediated suppression [215, 216, 586, 587], and 
successful suppression of IL-17 requires the presence of the exon 2-encoded 
sequence in Foxp3 (Foxp3ΔEx2) [227]. Our findings that an increase in IL-17+ Tregs 
corresponds with enhanced suppression of Th17 cells are in line with elegant 
studies in mice demonstrating that Tregs adapt to their cytokine milieu through the 
upregulation of specific transcription factors, thus ensuring appropriate T helper-
specific control of inflammation [278-280]. These data therefore highly suggest that 
pro-inflammatory cytokine-expressing Tregs maintain their suppressive capacity. 
 
Papers showing increased pro-inflammatory cytokine expression by Tregs mostly 
obtained their data after PMA/ionomycin restimulation, which is a commonly used 
system to detect cytokine-expressing cells, but it might be that Tregs don’t secrete 
those cytokines and that the levels reported may therefore not reflect the actual 
levels. It has also become clear that caution needs to be taken when translating in 
vitro findings into the in vivo situation as was recently exemplified by a preclinical 
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model for xenogeneic Graft-versus-Host Disease where the in vitro suppressive 
activity of iTregs could not predict the in vivo function of Tregs [588]. 
 
Short-term treatment of CD14+ monocytes from healthy controls for 30 min with 
the TLR4 ligand LPS in vitro effectively led to activation of these cells as it was 
previously suggested [549, 556, 557, 572, 589, 590], which was confirmed by the upregulation 
of surface marker expression (Figure 4.2) as well as increased cytokine and 
chemokine secretion (Figure 4.3). LPS-activated monocytes and monocytes that had 
been treated with cytokines commonly associated with RA SF (Figure 4.23B) showed 
a similar phenotype to in vivo-activated monocytes from the synovial fluid (Figure 
3.9, Chapter 3). However, CD16 expression was decreased on in vitro-activated 
monocytes compared to medium-treated monocytes, which is in striking contrast to 
SFM. It has been shown previously that in vitro culture of monocytes had a positive 
effect on CD16 expression [591]. Since in our experiments, phenotypic staining of in 
vitro-activated monocytes was carried out after cells had been cultured for 16-18 
hrs whereas SFM had been stained ex vivo, it is difficult to compare these two 
conditions. 
 
Synovial fluid samples are scarce these days due to more effective treatment of 
patients over the years and this limited availability of SF samples reduced the 
number of experiments we could perform with monocytes and Tregs isolated from 
the site of inflammation in RA. Since LPS is a potent stimulator of monocyte 
activation, we used this as a strong and reproducible model to study the effects of 
activated monocytes on Treg phenotype and function. Although stimulation of 
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monocytes with LPS does not necessarily reflect the physiological stimulus via which 
monocytes are activated in the inflamed rheumatic joint, there is some evidence in 
the literature that TLR4 signalling might be involved in triggering the disease [592]. In 
a mouse model of spontaneous arthritis using IL-1Ra-deficient mice, the 
spontaneous onset of arthritis was dependent on TLR activation as germ-free mice 
did not develop arthritis [593]. Furthermore, IL-1Ra-TLR4 double-knockout mice were 
shown to be protected against spontaneous arthritis [593, 594] and TLR4-knockout 
mice showed a less severe course of the disease in a collagen-induced arthritis 
model [595]. TLR4 is expressed in synovium from patients with RA [596, 597] and the 
presence of endogenous TLR ligands such as fibronectin fragments [598, 599] and heat 
shock proteins [600], which mainly act via TLR4, has been well documented in human 
rheumatoid synovium. Thus it is possible that monocytes are activated via TLR4 in 
the RA joint strengthening the relevance of the data obtained with our in vitro 
model. 
 
Furthermore, we saw similar results in co-cultures of RA PBM and RA SFM with HC 
Tregs compared to co-cultures with in vitro-activated monocytes in terms of 
induction of IFNγ+ and TNF-α+ Tregs, which was consistent throughout all 
experiments (Figure 4.19A) and provided us with further confidence in our in vitro-
model. The striking difference was however, that IL-10 did only get upregulated in 1 
out of 4 cases by Tregs following co-culture with SFM and the percentage of IL-17+ 
Tregs was only increased in 2 out of 4 cases (Figure 4.19A). In the one experiment 
where autologous PB Tregs from a patient with RA were used (colour-coded in grey), 
we observed an increased percentage of IL-17+ Tregs, but a decrease in the 
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percentage of IL-10+ Tregs in co-cultures with SFM suggesting that Tregs at the site 
of inflammation might show a more “pro-inflammatory” cytokine expression profile. 
Tregs from co-cultures with SFM were still able to suppress proliferation and 
secretion of cytokines by Teff similarly or slightly better than Tregs from co-cultures 
with PBM (Figure 4.27) indicating that the “pro-inflammatory” profile does not 
hamper their function. 
 
Together, these data suggest that the induction of pro-inflammatory cytokine 
expression in Tregs is not per se indicative of a conversion towards a more 
pathogenic cell or a loss in Treg function (summarised in Figure 4.29). Furthermore, 
we have provided evidence that Tregs exposed to an inflammatory environment 
might not be impaired in their regulatory function and may rather be enhanced, 
which overall suggests that the pro-inflammatory environment in the rheumatic 
joint might not impair Treg function.  
 




Figure 4.29 Summary of chapter 4.  
In vitro-activated monocytes were able to induce pro-inflammatory, but also anti-inflammatory 
cytokine expression by CD45RA
-
 Tregs. The increase in IL-17
+
 Tregs was mediated by monocyte-
derived IL-1β, IL-6 and TNF-α. Monocyte-activated Tregs maintained their Treg phenotype and were 
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5.1 Introduction 
Rheumatoid arthritis is a chronic inflammatory and disabling immune disorder, 
which is characterised by swelling and damaging of cartilage and bone around the 
joints. Despite the abundant presence of regulatory T cells in the inflamed joints of 
patients [403, 405, 408-414, 489], inflammation persists, which poses the question whether 
Tregs are impaired in RA. 
 
Evidence for a possible role of regulatory T cells in rheumatoid arthritis comes from 
various animal models for the disease. In both collagen-induced arthritis (CIA) and 
antigen-induced arthritis, depletion of Tregs using an anti-CD25 depleting antibody 
before immunization resulted in exacerbated disease [398, 601] and conversely, 
adoptive transfer of CD4+CD25+ Tregs in the early phase of the disease led to a 
reduction in disease severity [399, 601]. Depletion of CD25+ Tregs with an anti-CD25 
mAb can possibly eliminate other cell types that express CD25 e.g. Teff cells, NK 
cells and B cells [400]; two other groups therefore made use of the scurfy mouse 
instead. Scurfy mice bear a mutation in the foxp3 gene, are totally devoid of Tregs, 
and as a result develop severe multi-organ inflammation [63, 68]. Absence of Tregs 
(scurfy mice) in the K/BxN spontaneous arthritis model [602] resulted in an earlier 
onset of disease as well as a more aggressive progression [401, 402]. These data overall 
argue for an important role of Tregs in preventing and controlling inflammatory 
arthritis. 
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However, only few mice depleted of Tregs using an anti-CD25 mAb actually showed 
signs of polyarthritis under non-disease inducing conditions, whilst the great 
majority spontaneously developed thyroiditis, oophoritis and gastritis [57]. In line 
with that, only very few cases of IPEX (Immune Dysregulation Polyendocrinopathy 
Enteropathy X-linked) patients carrying a mutation in the foxp3 gene have been 
reported to show signs of arthritis [71, 603]. The majority of IPEX patients present with 
thrombocytopenia, insulin-dependent diabetes mellitus, diarrhoea or thyroiditis 
(reviewed in [71]), which may suggest that the absence of functional Tregs does not 
play an essential role in the development of RA. 
 
Human Tregs and their role in rheumatoid arthritis have been studied extensively 
during the last years. However, there is considerable controversy in the field about 
Treg frequencies and function in peripheral blood of patients with RA (reviewed in 
[417]). It has been reported in some studies that peripheral Tregs are functionally 
impaired in patients with RA [253, 256-258, 415, 604] (listed in Table 5.1). Some groups 
explained this impairment by negative effects of TNF-α on Treg function [253, 258], 
which is supported by the finding that TNFi treatment was able to overcome this 
defect [253, 257, 258, 532] potentially by the induction of a de novo Treg population [256]. 
Defective Treg function has further been linked to reduced expression of CTLA-4 by 
Tregs from patients with RA [604] or increased recruitment of protein kinase C-θ to 
the immunological synapse [415]. One study further suggested that the inability of 
Tregs to mediate suppression of Teff was due to the resistance of Teff [495]. 
However, several other papers studying peripheral Treg function in RA, including 
work from our lab, showed that Tregs from the peripheral blood of patients with RA 
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are intact in suppressing proliferation as well as cytokine production [403-405, 411, 413, 
486]. The reasons for these conflicting results are not well reported or understood 
and might be explained by different isolation procedures (MACS vs. FACS) or due to 
different patient characteristics (e.g. disease activities, disease duration). However, 
when we reviewed the literature it did not seem to be as simple as that [417]. 
Furthermore, most papers only looked at a certain aspect of Treg-mediated 




Table 5.1 Literature review – Papers showing impaired Treg function in RA. 
Table lists papers that showed impaired peripheral blood Treg function in RA and provides details on 
patient characteristics, isolation method and readout systems.  
* intact Treg function; [
3
H]: Tritium; CFSE: carboxyfluorescein succinimidyl ester; DAS28: disease 
activity score 28; FACS: fluorescence-activated cell sorting; MACS: magnetic-activated cell sorting; 
MTX: methotrexate; TNFi: TNF inhibitor. 
 
 
We sought to shed light on whether Tregs are dysfunctional in RA by performing an 
extensive analysis of their phenotype and cytokine expression profile ex vivo and 
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after in vitro stimulation. We further investigated the ability of Tregs from patients 
with RA to suppress proliferation and cytokine production of autologous effector T 
cells and monocytes. We also performed a detailed analysis of the Teff population 
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5.2 Results 
All patient samples used in this chapter were peripheral blood samples obtained 
from patients with rheumatoid arthritis receiving disease-modifying anti-rheumatic 
drugs (DMARDs) or in one case from a patient on non-steroidal anti-inflammatory 
drug (NSAID). Patients in our cohort presented with moderate to active disease as 
determined by DAS28 [454] (mean±SEM: 4.7±0.3) and the majority (80%) were 
rheumatoid factor positive (see Table 5.2 and 5.3 for details). Healthy controls were 
age- and gender-matched as best as possible and taken alongside every experiment 
to account for inter-experimental variation. 
 
 
Table 5.2 Summary of healthy controls and patients characteristics. 
Summary of demographic and clinical parameters for peripheral blood samples from patients with 
RA (n=15) and healthy controls (n=12) where available. 
CRP: C-reactive protein; DAS28: disease activity score 28; DMARD: disease-modifying anti-rheumatic 
drug; ESR: erythrocyte sedimentation rate; N/A: not available; NSAID: non-steroidal anti-
inflammatory drug; TNFi: TNF inhibitor therapy. 
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Table 5.3 Patient characteristics for each individual donor. 
Clinical and demographic details relating to the individual patient samples (n=15) indicating the 
sample type, gender, age as well as the clinical parameters where available. 
CRP: C-reactive protein; DAS28: disease activity score 28; DMARD: disease-modifying anti-rheumatic 
drugs; ESR: erythrocyte sedimentation rate; f: female; m: male; N/A: not available; NSAID: non-
steroidal anti-inflammatory drugs; RF: rheumatoid factor. 
 
In this chapter, the sorting protocol for Tregs and Teff was slightly adapted 
compared to chapter 4, since we also wanted to investigate the CD45RA+ Treg 
population. Therefore, we enriched for bulk CD4+ T cells first and stained the cells 
for CD4, CD45RA, CD45RO, CD25 and CD127 on the surface. The gating strategy for 
sorting CD25+CD127low Tregs within CD4+CD45RA+CD45RO- and CD4+CD45RA-
CD45RO+ T cells, hereafter named CD45RA+ and CD45RO+ Tregs, respectively, is 
shown in Figure 5.1. CD25-CD127+ and CD25intCD127+ effector T cells within the 
CD4+CD45RA-CD45RO+ T cell compartment were also sorted and purities assessed 
afterwards by re-running the sample on the cell sorter. Purities of cells were usually 
around 95% (as determined by the cell sorter). It should be noted however that 
when purity samples were analysed by FlowJo, a drop in CD25 expression was 
observed, which was particularly evident for the CD25intCD127+ Teff population. 
Possible reasons for this loss in CD25 expression could be that the fluorochrome  
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Figure 5.1 Sorting strategy for different T cell populations and purities of sorted cells. 
(A) MACS-isolated CD4
+
 T cells were stained with antibodies against CD4, CD45RA, CD45RO, CD25 
and CD127. Cells were then sorted based on a live cell gate (FSC vs. SSC), duplet exclusion (FSC-W vs. 

























 population. (B) To determine the purities of the sorted cells, a small aliquot of the samples 
was immediately re-run on the machine and analysis performed by FlowJo. 
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conjugated to anti-CD25 mAb (PE) bleached when the sample was sitting on ice 
while the other samples were being sorted or because CD25intCD127+ Teff 
downregulated CD25 expression following cell sorting. We will further refer to these 
cells as CD25intCD127+ Teff in this chapter although this population might potentially 
also contain CD25lowCD127+ cells. 
 
5.2.1 Percentages of IL-17+ and TNF-α+ cells within FoxP3+ T cells in HC and 
patients with RA  
It has been suggested in the literature that Tregs may convert into IL-17+ Tregs 
under pro-inflammatory conditions [237-239, 241, 242, 244, 245, 247, 249]. We first investigated 
whether Tregs from patients with RA showed a more pro-inflammatory profile by 
determining the percentages of IL-17 and TNF-α expressing Tregs ex vivo.  
 
For this, we stimulated PBMC (2x106/ml) from patients with RA (n=9) and HC (n=7) 
for 3 hrs with PMA and ionomycin in the presence of GolgiStop. Cells were taken off 
the plate and stained for CD3, CD14 and CD45RO on the surface. Thereafter, cells 
were intracellularly stained for CD4, IL-17, TNF-α and FoxP3; CD4 was stained 
intracellularly as CD4 gets down-regulated following stimulation [464]. Samples were 
acquired on a BD FACS CantoII within 24 hrs and data analysed with the FlowJo 
software using the gating strategy as described in chapter 2 (Figure 2.3). 
 
There was no significant difference in the percentages of IL-17+ or TNF-α+ cells 
within the CD3+CD4+FoxP3- T cell population of HC and patients with RA (Figure 
5.2A). In fact, the percentages of IL-17+ cells seemed to be slightly lower in the 
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Figure 5.2 The percentage of IL-17 and TNF-α expressing cells within different CD4
+
 T cell 
populations is similar between HC and patients with RA ex vivo. 
(A, B) PBMC were isolated from peripheral blood of HC (n=7) and patients with RA (n=9). Cells 
(2x10
6
) were stimulated with 50 ng/ml PMA and 750 ng/ml ionomycin for 3 hrs in the presence of 
GolgiStop and stained for CD3, CD14 and CD45RO on the surface, followed by intracellular staining 
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CD4+CD45RO+ T cell compartment of patients with RA (HC: 2.3±0.3% vs. RA: 
1.8±0.3%, p=0.1142). Furthermore, no significant differences were observed in the 
percentages of IL-17+ cells within FoxP3+CD3+CD4+ T cells of HC and patients with RA 
(Figure 5.2B). The percentages of TNF-α+ cells within FoxP3+ T cells were slightly 
higher in some of the patients compared to HC, which was observed in both 
CD45RO+ and CD45RO- T cells, but these differences did not reach statistical 
significance (Figure 5.2B). These data overall indicate that RA FoxP3+ Tregs do not 
contain a higher percentage of pro-inflammatory cytokine-expressing cells than HC 
Tregs ex vivo. 
 
FoxP3 has been described as a lineage-specific transcription factor for human 
regulatory T cells [65], but effector T cells can upregulate FoxP3 expression following 
activation [65, 132-134]. Gating on CD3+CD4+FoxP3+ T cells for Treg analysis after 
PMA/ionomycin stimulation could therefore potentially contain recently activated T 
cells.  
 
We compared the percentages of ex vivo Tregs as determined by a high expression 
of CD25 with concomitant low CD127 expression with the percentages of FoxP3+ T 
cells following PMA/ionomycin stimulation in vitro. We did not observe significant 
differences in CD3+CD4+CD25+CD127low Treg frequencies between HC and patients 
with RA in either the CD45RO+ or CD45RO- T cell compartment (Figure 5.3A). 
Similarly, no differences in the percentages of FoxP3+ T cells after PMA/ionomycin 
stimulation were observed in HC and patients with RA (Figure 5.3B), which 
suggested that PMA/ionomycin stimulation did not preferentially induce a FoxP3+ 
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 cells following 
PMA/ionomycin stimulation is similar between HC and patients with RA. 

















 T cells in PBMC from HC (n=7) and patients with RA (n=9) were determined as 
described in Figure 3.1. (B) The percentages (mean) of FoxP3
+















 T cells were 
determined in the same samples. (C) The percentage of FoxP3
+
 cells was determined in sorted 
CD45RO
+
 Tregs and CD45RO
-
 Tregs from patients with RA (n=3-7) and HC (n=4-5). Statistical analysis 
was performed using Mann Whitney test. 
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population in either PBMC from patients with RA or HC. We noticed however, that 
the overall percentages of CD3+CD4+FoxP3+ T cells were smaller than the 
percentages of CD3+CD4+CD25+CD127low Tregs determined ex vivo (HC: 4.4±0.6% vs. 
5.9±0.5% and RA: 4.6±0.6% vs. 6.0±0.4%). The biggest difference between ex vivo 
Treg frequencies and FoxP3+ T cells was observed within the CD4+CD45RO+ T cell 
compartment (HC: 6.8±0.6% vs. 9.2±0.8% and RA: 6.7±1.1% vs. 8.2±0.6%). This 
might be explained by the fact that not all CD45RO+ Tregs are FoxP3-positive, 
whereas virtually all CD45RA+ Tregs are FoxP3+, which is true for both patients with 
RA and HC (Figure 5.3C). Gating on FoxP3+ T cells in PMA/ionomycin-stimulated 
PBMC from patients with RA and healthy controls might therefore underestimate 
the percentages of Tregs; although this would have affected both HC and RA results 
similarly. 
 
5.2.2 Cytokine expression of RA and HC CD45RO+ Tregs is similar after in vitro 
culture  
We have shown in chapter 3 that monocytes from the peripheral blood of patients 
with RA displayed an upregulation of activation markers compared to HC PBM 
(Figure 3.5). In vitro-activated monocytes were able to induce the percentages of IL-
17+, IFNγ+, TNF-α+ and IL-10+ Tregs following co-culture (Chapter 4) [412]. We 
therefore wished to investigate whether Tregs from patients with RA showed 
increased expression of cytokines following in vitro culture with autologous 
monocytes. We focused on CD45RO+ Tregs for this analysis as this population is 
known to be more plastic compared to the CD45RA+ Treg population [164, 605] and 
Tregs at the site of inflammation in RA are virtually all CD45RO+ (Chapter 3, Figure 
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3.13). Furthermore, we did not observe cytokine expression by CD45RA+ Tregs from 
HC following in vitro culture with monocytes, except for TNF-α (data not shown). 
 
CD45RO+ Tregs from patients with RA (n=13) and HC (n=10) were sorted as 
described in Figure 5.1 and cultured in vitro with autologous monocytes at a 1:1 
ratio in the presence of 100 ng/ml anti-CD3 mAb to activate the Tregs. On day 3, 
cells were re-stimulated with PMA and ionomycin in the presence of GolgiStop to 
amplify the signal and cells stained for IL-17, IFNγ, TNF-α and IL-10 by ICCS. Fixed 
samples were acquired with a BD FACS CantoII and data analysed using the FlowJo 
software and the gating strategy as described in Figure 2.4. 
No significant differences were observed i.e. patients with RA showed similar 
percentages of Tregs expressing the pro-inflammatory cytokines IL-17, IFNγ, and 
TNF-α following co-culture with monocytes compared to HC (Figure 5.4). 
Percentages of IL-10+ Tregs were also similar between patients and HC. 
 
To investigate whether RA Tregs showed a different cytokine profile when exposed 
to a pro-inflammatory environment compared to HC Tregs, we added 100 ng/ml LPS 
to co-cultures of monocytes with CD45RO+ Tregs. We have shown in chapter 4 that 
stimulation of HC monocytes with LPS resulted in increased secretion of pro-
inflammatory cytokines, such as IL-1β, IL-6 and TNF-α, which were the major drivers 
of IL-17 expression by Tregs. 
CD45RO+ Tregs from HC showed a significant increase in IL-17+ (Figure 5.5A) and 
IFNγ+ Tregs (Figure 5.5B) and a trend towards increased IL-10+ Tregs (Figure 5.5.D) 
following in vitro culture with autologous monocytes in the presence of LPS, 







Figure 5.4 There is no difference in the percentage of cytokine-positive cells following in vitro 















) from HC (n=10) and patients with RA 
(n=13) were co-cultured with autologous monocytes (1x10
5
) in the presence of 100 ng/ml anti-CD3 
mAb in a 96-well U-bottom plate (V=250 μl). After 3 days, cells were re-stimulated with 50 ng/ml 
PMA and 750 ng/ml ionomycin for 6 hrs, with GolgiStop present for the last 3 hrs. Cells were stained 
for CD2 and CD14 on the surface and intracellularly stained for the indicated cytokines. Results are 




 cells using the gating strategy as described 
in Figure 2.3. Data were analysed using an unpaired t test or Mann Whitney test as determined by 
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Figure 5.5 Cytokine expression of CD45RO
+





) from HC (n=10) and patients with RA (n=13) were co-cultured with 
autologous PBM at a 1:1 ratio in the absence or presence of 100 ng/ml LPS. After 3 days, cells were 
re-stimulated and intracellularly stained for IL-17 (A), IFNγ (B), TNF-α (C) and IL-10 (D). Results were 
analysed by paired t test or Wilcoxon matched-pairs signed rank test as determined by D’Agostino 
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recapitulating the data from chapter 4 (Figure 4.5). The percentage of TNF-α+ Tregs 
in these co-cultures showed an inconsistent picture in response to LPS with n=5 
showing an increase and n=5 showing a decrease or no difference. These 
differences could possibly be explained by the slightly different experimental set-up 
in chapter 4 (i.e. pre-stimulation of monocytes with LPS and sorting of Tregs from 
pre-enriched CD4+CD45RA- T cells). CD45RO+ Tregs from patients with RA showed a 
less consistent increase in the percentages of cytokine-positive cells in response to 
LPS (Figure 5.5). However, the overall percentages were lower than in HC, except 
for TNF-α (summarised in Table 5.4). These results suggest that Tregs from patients 
with RA do not show an increased propensity to express pro-inflammatory 
cytokines. 
 



















































Table 5.4 Cytokine expression of HC and RA Tregs following in vitro culture. 
Table summarises the data from Figure 5.4 and 5.5. Results are shown as mean±SEM (%) and median 
(range) (%) for Tregs from HC (n=10) and patients with RA (n=13) after co-culture with autologous 
monocytes (+/- LPS). 
 
 
5.2.3 Tregs from patients with RA suppress proliferation of autologous Teff 
We next wanted to investigate whether CD45RO+ Tregs from patients with RA were 
able to suppress proliferation of autologous effector T cells. CD45RO+ Tregs and 
CD25-CD127+ Teff were sorted using CD4+ T cells isolated from the peripheral blood 
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of HC (n=8) and patients with RA (n=9) (see sorting strategy Figure 5.1). Sorted 
CD4+CD45RA-CD45RO+CD25-CD127+ Teff were labelled with CFSE and co-cultured 
with autologous monocytes at a 1:1 ratio in the presence of anti-CD3 mAb. 
CD45RO+ Tregs were added to these co-cultures at the indicated cell ratios (0:1, 
0.5:1 and 1:1) and proliferation assessed at day 3 by gating on CFSE+ Teff.  
 
Figure 5.6 shows representative histograms for the loss in CFSE staining following 
cell divisions, which was used to assess the percentage proliferation of RA and HC 
CFSE+ Teff in the absence (Figure 5.6A) or presence of LPS (Figure 5.6B). Taking all 
experiments together, addition of CD45RO+ Tregs from either patients with RA or 
HC led to a cell ratio-dependent reduction in proliferation of autologous CD25-
CD127+ Teff (Figure 5.7A). When we calculated the percentage suppression 
mediated by Tregs, no significant differences were observed between HC and 
patients with RA although the mean percentages were slightly lower for RA Tregs at 
both ratios (Figure 5.7B). The cumulative data for Treg-mediated suppression in the 
presence of LPS showed similar results, and overall suppression was lower for both 
HC and RA Tregs compared to the medium condition (Figure 5.7C, D).  
 
It has been shown recently that the ability of Tregs to suppress CD25lowCD127+ Teff 
proliferation was reduced compared to CD25-CD127+ Teff due to a more activated 
phenotype and higher proliferation rate of CD25lowCD127+ Teff [606]. We investigated 
whether the ability of Tregs to suppress proliferation of Teff was different for the 
CD25intCD127+ Teff population, which most probably comprises recently activated T 
cells. 
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Figure 5.6 Representative examples for CFSE suppression assay data from HC and patients with RA. 










 Teff from patients with RA and HC were co-
cultured with PBM in the absence (A) or presence (B) of LPS at a 1:1 cell ratio and the addition of α-
CD3 mAb. CD45RO
+
 Tregs were added to these co-cultures at the indicated cell ratios. Proliferation 
was assessed on day 3 by flow cytometry. Representative histograms for the loss of CFSE labelling 
following rounds of division for one HC and one patient with RA are shown. 
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(A-D) Suppression assays were set up as described in Figure 5.6 using cells isolated from HC (n=8) 
and patients with RA (n=9). The cumulative data for % proliferation is shown for the medium (A) and 
LPS condition (C). The percentage suppression was calculated based on the formula described in 
chapter 2 (B, D). Data are plotted as the mean±SEM and statistical analysis performed using Kruskal-
Wallis test with Dunn’s multiple comparison test: * p<0.05, ** p<0.01 and *** p<0.001. 
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Co-cultures were set up as described above using CFSE-labelled CD25intCD127+ Teff 
from patients with RA (n=4) and HC (n=6). Tregs from patients with RA were able to 
effectively suppress proliferation of autologous Teff at both cell ratios (Figure 5.8A) 
and in fact, rather showed increased suppression compared to HC Tregs (Figure 
5.8B). Addition of LPS to these co-cultures did not abrogate their suppressive 
function, but slightly reduced it, which was more evident in RA Tregs compared to 
HC Tregs (Figure 5.8C, D). Because of the lower n numbers in the RA group (n=4), 
statistical analysis was not employed for these experiments. 
 
It has been suggested in patients with MS that the functional Treg defect resided 
within naïve Tregs [148, 607]. So far, we had only focused on Tregs from the CD45RA-
CD45RO+ T cell compartment and all papers that have investigated peripheral blood 
Treg function in RA studied total CD4+ Tregs. We therefore examined whether 
CD45RA+ Tregs from patients with RA were able to suppress CD25-CD127+ Teff 
proliferation. Due to the limited number of CD45RA+ Tregs obtained by cell sorting, 
we did not include the 0.5:1 condition in these experiments. 
CD45RA+ Tregs from both patients with RA and HC suppressed less efficiently than 
CD45RO+ Tregs. However, the overall ability of CD45RA+ Tregs from patients with RA 
and HC to suppress Teff proliferation was similar in the absence or presence of LPS 
(Figure 5.9). 
Together, these data show that there is no significant difference in the ability of 
CD45RO+ and CD45RA+ Tregs from patients with RA to suppress proliferation of 
autologous effector T cells compared to Tregs from HC. Furthermore, the addition 
of LPS to mimic a pro-inflammatory environment did not abrogate their function. 
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 Teff proliferation. 










 Teff isolated from HC (n=6) and patients with RA (n=4). The cumulative data 
for % proliferation is shown for the medium (A) and LPS condition (C). The percentage suppression 
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 Teff from patients with RA (n=7) and HC (n=6) were co-cultured 
with PBM in the absence (A, B) or presence (C, D) of LPS at a 1:1 cell ratio. CD45RA
+
 Tregs were 
added to these co-cultures at the indicated cell ratios. Proliferation was assessed on day 3 by flow 
cytometry and the cumulative data for % proliferation is shown for the medium (A) and LPS 
condition (C). The percentage suppression was calculated based on the formula described in chapter 
2 (B, D). Data are plotted as the mean±SEM and data analysed by Kruskall-Wallis test with Dunn’s 
multiple comparison test: * p<0.05, ** p<0.01. 
 
Chapter 5: Investigating the function of peripheral blood Tregs in RA 
212 
5.2.4 CD45RO+ Tregs from patients with RA suppress IFNγ secretion by autologous 
Teff  
A study by Ehrenstein et al. described that Tregs from patients with RA are unable 
to suppress IFNγ secretion by effector T cells despite being capable of suppressing 
their proliferation [257]. An impaired capacity of Tregs from patients with RA to 
suppress IFNγ secretion by Teff has also been reported by other studies [253, 256, 415, 
604]. We therefore wished to examine whether CD45RO+ Tregs suppressed IFNγ 
secretion in co-cultures of CD25-CD127+ Teff with autologous monocytes. 
 
To determine this, co-cultures of CD25-CD127+ Teff from patients with RA (n=8) or 
HC (n=8) with autologous monocytes and different ratios of CD45RO+ Tregs were set 
up and supernatants (day 3) analysed for IFNγ levels with a human 25-plex cytokine 
array. CD45RO+ Tregs from patients with RA showed a similar ability to suppress 
IFNγ secretion by autologous CD25-CD127+ Teff compared to HC Tregs (Figure 
5.10A, B). However, there appeared to be Tregs from some patients that were less 
efficient in suppressing IFNγ secretion, especially at the lower cell ratio (0.5:1). This 
effect was more pronounced in the presence of LPS (Figure 5.10C, D). It is 
interesting to note however, that it was not necessarily the patients with high IFNγ 
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 Teff.  
(A-D) Supernatants from co-cultures as described in Figure 5.7 were collected on day 3 (HC n=8, RA 
n=8) and analysed on a human 25-plex cytokine array. The cumulative data for IFNγ secretion is 
shown for the medium (A) and LPS condition (C). The percentage suppression is shown in (B, D). Data 
are plotted as the mean±SEM and statistical analysis was performed using Kruskal-Wallis test with 
Dunn’s multiple comparison test: * p<0.05, ** p<0.01 and *** p<0.001. 
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We further tested the ability of Tregs to suppress TNF-α secretion in co-cultures of 
CD25-CD127+ Teff with autologous monocytes as the pro-inflammatory cytokine 
TNF-α is known to be a major contributor to the disease (reviewed in [259, 352]). The 
picture for suppression of TNF-α was similar to IFNγ showing slightly lower 
suppression by some patients’ Tregs, especially in the 0.5:1 condition, which was 
again more evident in the presence of LPS (Figure 5.11). It should be noted however 
that in the latter condition levels of TNF-α secretion were overall lower in patients 
with RA i.e. there was less to suppress. 
 
To facilitate the interpretation of the data, the results are summarised in Table 5.5 
for the medium condition and in Table 5.6 for the LPS condition. In these tables, the 
percentage suppression mediated by Tregs is classified as good suppression (dark 
blue, >50%), intermediate suppression (light blue, 21-50%), poor suppression 
(green, 1-20%) and no suppression (yellow, 0%). Interestingly, patients that were 
less able to suppress proliferation of Teff (RA#277, RA#278, RA#294, RA#295), were 
not necessarily the ones that were less able to suppress IFNγ and/or TNF-α 
(RA#261, RA#285, RA#295, RA#296) in the medium condition (Table 5.5). A reduced 
ability of Tregs from patients with RA to suppress was not due to a higher DAS28. In 
fact, patients with a higher DAS28 (RA#284, RA#289) were actually amongst the 
better suppressors than patients with lower DAS28 (Table 5.5 and 5.6). We further 
examined clinical parameters i.e. CRP, ESR as well as disease duration, but could not 
find particular differences in patients with slightly reduced abilities to suppress 
(data not shown). 
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Figure 5.11 Tregs from some patients show a reduced ability to suppress TNF-α secretion in co-




 Teff.  
(A-D) Supernatants from co-cultures as described in Figure 5.7 were collected on day 3 (HC n=8, RA 
n=8) and analysed on a human 25-plex cytokine array. The cumulative data for TNF-α secretion is 
shown for the medium (A) and LPS condition (C). The percentage suppression is shown in (B, D). Data 
are plotted as the mean±SEM and statistical analysis was performed using Kruskal-Wallis test with 
Dunn’s multiple comparison test: * p<0.05, ** p<0.01 and *** p<0.001. 
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Table 5.5 Summary table for Treg-mediated suppression of Teff proliferation and cytokine secretion. 
Table shows the calculated percentage suppression mediated by CD45RO
+













 Teff as well as the ability of CD45RA
+





 Teff at the indicated cell ratios. 
N/A: not available 
 
DAS28
2.73 RA#261 22% 39% N/A N/A 29% 40% 25% 29% N/A
3.2 RA#277 16% 28% N/A N/A N/A N/A N/A N/A 18%
4.68 RA#278 16% 5% N/A N/A 64% 72% 81% 91% 0%
5.6 RA#284 42% 58% 48% 85% 88% 81% 86% 75% 8%
3.6 RA#285 47% 49% 43% 52% 54% 90% 18% 59% 61%
6.17 RA#289 40% 66% 41% 63% 91% 96% 81% 90% N/A
3.9 RA#294 6% 28% N/A N/A 59% 86% 80% 98% 9.5%
5.4 RA#295 14% 35% 41% 64% 0% 27% 57% 61% 23%
5.54 RA#296 28% 44% N/A N/A 0% 30% 35% 70% 27%
0.5:1 1:1 0.5:1 1:1 0.5:1 1:1 0.5:1 1:1 1:1
HC 3 31% 56% N/A N/A 56% 70% 93% 96% 8%
HC 5 26% 56% 34% 47% 91% 95% 93% 94% 44%
HC 6 41% 57% 47% 71% 93% 100% 97% 100% 51%
HC 7 23% 56% 18% 49% 61% 83% 71% 83% 29%
HC 8 20% 41% 0% 12% 20% 50% 42% 70% N/A
HC 9 6% 18% N/A N/A 45% 74% 38% 86% N/A
HC 10 88% 94% 58% 84% 96% 96% 95% 98% 52%



















Table 5.6 Summary table for Treg-mediated suppression of Teff proliferation and cytokine secretion in the presence of LPS. 
Table shows the calculated percentage suppression mediated by CD45RO
+













 Teff as well as the ability of CD45RA
+





 Teff at the indicated cell ratios. 
N/A: not available 
 
DAS28
2.73 RA#261 9% 28% N/A N/A 21% 59% 5% 38% N/A
3.2 RA#277 N/A 74% N/A N/A N/A N/A N/A N/A 0%
4.68 RA#278 18% 44% N/A N/A 22% 59% 8% 36% 32%
5.6 RA#284 27% 43% 22% 30% 80% 81% 50% 73% 0%
3.6 RA#285 16% 27% N/A 36% 57% 64% 36% 60% 47%
6.17 RA#289 31% 45% 26% 32% 81% 90% 62% 76% N/A
3.9 RA#294 0% 9% N/A N/A 0% 9% 5% 44% 11%
5.4 RA#295 7% 10% 0% 0% 14% 41% 35% 65% 3%
5.54 RA#296 10% 28% N/A N/A 12% 55% 15% 60% 27%
0.5:1 1:1 0.5:1 1:1 0.5:1 1:1 0.5:1 1:1 1:1
HC 3 22% 37% N/A N/A 76% 86% 69% 86% 17%
HC 5 44% 67% 21% 39% 84% 90% 89% 93% 48%
HC 6 48% 75% 38% 59% 84% 94% 83% 90% 45%
HC 7 16% 47% 7% 28% 59% 91% 48% 79% 21%
HC 8 4% 21% 11% 18% 44% 73% 47% 69% N/A
HC 9 24% 32% N/A N/A 70% 76% 31% 65% N/A
HC 10 71% 83% 21% 47% N/A N/A N/A N/A 37%
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Overall the data suggest that Tregs from patients with RA are not dysfunctional in 
their ability to suppress effector T cell proliferation or cytokine secretion in vitro 
compared to Tregs from HC. 
 
5.2.5 CD25-CD127+ Teff from patients with RA express lower percentages of IL-10+ 
cells in vitro  
There is evidence in the literature that Teff might be more resistant to Treg-
mediated suppression at inflammatory sites in inflammatory arthritis [419, 420, 584]. 
Based on the results obtained above we were not able to distinguish whether the 
slightly reduced suppression in some patients was due to the Tregs themselves or 
due to Teff being more resistant to suppression. We therefore sought to investigate 
the proliferative capacities and cytokine expression profiles of CD25-CD127+ and 
CD25intCD127+ Teff in patients with RA and HC following in vitro culture with 
monocytes. 
We tested whether Teff from patients with RA proliferated more at “baseline”, 
which would make it harder for Tregs to suppress. However, when we compared 
the co-cultures of CFSE-labelled HC vs. RA Teff with autologous monocytes, we did 
not observe a significant difference in the percentage proliferation for either CD25-















 Teff from patients with RA and HC show similar proliferative 
capacity in co-cultures with autologous monocytes. 








 Teff (B) from patients with RA (n=4-9) 
and HC (n=6-8) were co-cultured with PBM at a 1:1 cell ratio in the presence of 100 ng/ml α-CD3 
mAb. Proliferation was assessed on day 3 by flow cytometry by the loss of CFSE labelling following 
rounds of division. 
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Following in vitro culture with autologous monocytes, we observed a trend towards 
an increased percentage of IL-17+ CD25-CD127+ Teff in patients with RA (n=14) 
compared to HC (n=11) (7.4±0.9% vs. 6.2±1.6%, p=0.0752, Figure 5.13A), which fits 
with previous data from the lab describing increased ex vivo frequencies of IL-
17+CD4+ T cells in PB of patients with RA [388]. The percentages of IFNγ+ and TNF-α+ 
Teff were not significantly different between HC and patients with RA, but we did 
observe significantly lower percentages of IL-10+ cells within CD25-CD127+ Teff in 
patients with RA compared to HC Teff (Figure 5.13A). We also saw a trend towards 
lower IL-10+ cells within the CD25intCD127+ Teff population (p=0.0786), whilst the 
percentages of IL-17+, IFNγ+ ot TNF-α+ cells were similar between HC and patients 
with RA (Figure 5.13B). 
 
We further wished to investigate whether a pro-inflammatory stimulus provided by 
the addition of LPS induced differences in the cytokine expression profiles of 
effector T cells. CD25-CD127+ Teff and CD25intCD127+ Teff from patients with RA 
showed similar percentages of cytokine-positive cells compared to effector T cells 
from HC following LPS stimulation, but there was again a trend towards lower IL-10 
expression in patients with RA (CD25low: p=0.1165 and CD25int: p=0.0907) (Figure 
5.14). 
 
Finally, we analysed cell culture supernatants from co-cultures of HC and RA CD25-
CD127+ Teff with autologous monocytes in the absence or presence of LPS for the 
indicated cytokines to determine whether there were differences in secretion levels 
between patients and healthy controls. IL-17 was below the detection limit for most 









 Teff from patients with RA show a reduction in IL-10
+
 cells 
following in vitro culture with autologous monocytes. 





















 Teff from HC (n=7) and patients with RA (n=9) (B) were co-
cultured with autologous monocytes in the presence of anti-CD3. After 3 days, cells were re-
stimulated and stained for CD2 and CD14 on the surface and intracellularly for the indicated 




 cells using 
the gating strategy as described in Figure 2.3. Data were analysed using an unpaired t test or Mann 
Whitney test as determined by D’Agostino and Pearson omnibus normality test: * p<0.05. 
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 Teff following in vitro culture with 
monocytes and LPS is similar between HC and patients with RA. 









from HC (n=7) and patients with RA (n=9) (B) were co-cultured with autologous monocytes in the 
presence of anti-CD3 and 100 ng/ml LPS. Results are shown as the median percentage of cytokine-
positive Teff using the gating strategy as described in Figure 2.3. Data were analysed using an 
unpaired t test or Mann Whitney test as determined by D’Agostino and Pearson omnibus normality 
test. 
 
Chapter 5: Investigating the function of peripheral blood Tregs in RA 
223 
of the samples, but still detectable in n=2 patients with RA in the medium condition 
(Figure 5.15A). There was no significant difference for any of the cytokines, but 
again a suggestion towards less IL-10 secretion in the patient samples in the LPS 
condition (p=0.1206) (Figure 5.15D). One needs to appreciate that IL-10 and TNF-α 
can be secreted by both T cells and monocytes and that the supernatants were 
collected before PMA/ionomycin re-stimulation, which is why cytokine levels were 
overall relatively low. 
 
Overall, these data show that effector T cells from patients with RA might show a 
more pro-inflammatory phenotype, expressing higher percentages of IL-17+ and 
lower percentages of IL-10+ cells than Teff from HC. The reduced expression of IL-10 
by Teff could possibly contribute to less suppression mediated by Tregs, but data so 
far do not support this hypothesis (data not shown). 
 
5.2.6 The ability of RA Tregs to suppress monocyte-derived cytokines and 
chemokines varies between individual patients 
We have described earlier that monocytes from patients with RA show a more 
activated phenotype than HC PBM (see Figure 3.5). We therefore wanted to 
investigate whether RA Tregs were able to suppress monocyte-derived cytokines 
and chemokines induced by LPS stimulation. 
 
PBM from patients with RA (n=9) and HC (n=8) were cultured with 100 ng/ml LPS in 
the absence or presence of autologous CD45RO+ Tregs for three days. Supernatants 
were collected on day 3 and analysed with a human 25-plex cytokine array. 
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 Teff from HC (n=8) and patients with RA (n=8) were co-cultured with 
autologous PBM in the absence or presence of LPS. Supernatants were taken on day 3 before 
PMA/ionomycin re-stimulation and analysed for IL-17 (A), IFNγ (B), TNF-α (C) and IL-10 (D) using a 
human 25-plex cytokine array. Horizontal lines indicate the median. Dotted lines show the lower 
detection limit. 
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Eotaxin, GM-CSF, IFNγ, IL-2, IL-4, IL-5, IL-13, IL-17 and MIG were below the 
detection limit (data not shown). IL-6 and IL-8 were above the detection limit and 
were repeated with individual ELISA using higher dilutions of the samples. The 
results for all other detectable cytokines and chemokines are shown in Figure 5.16-
5.18. Each individual patient (n=9) is colour-coded to be able to distinguish which 
data point belongs to which patient. All patient samples were analysed for each of 
the 25 analytes except for IL-8 (n=7), but sometimes data points are on top of each 
other, which is why not all 9 different colours are visible in each graph. 
 
The secretion of MIP-1α (CCL3), MIP-1β (CCL4), IL-1β, IL-1Ra, IL-7 and IL-6 were 
suppressed by CD45RO+ Tregs from all healthy controls, but the majority of patients 
showed a reduced ability or complete inability to suppress these chemokines and 
cytokines (Figure 5.16A-F). However, the magnitude of suppression of IL-7 and IL-6 
mediated by HC Tregs was not particularly strong either (Figure 5.16E, F). IL-8, MCP-
1, TNF-α, IL-15, IL-12, IP-10 and RANTES on the other hand were similarly 
suppressed by Tregs from HC and patients with RA (Figure 5.17A-G). However, 
overall secretion levels of IP-10 and RANTES were very low in most donors (Figure 
5.17F, G). IL-10, IFN-α and IL-2R were hardly suppressed by either HC or RA Tregs 
(Figure 5.18). Instead, IL-10 was mostly increased in the presence of Tregs in both 
patients with RA and HC (Figure 5.18A) as it has been previously shown for HC [12, 
608]. 
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Figure 5.16 The ability of Tregs to suppress monocyte-derived MIP-α, MIP-1β, IL-1β, IL-1Ra, IL-7 
and IL-6 is reduced in patients with RA. 
Figure continued on next page. 
 
 
Chapter 5: Investigating the function of peripheral blood Tregs in RA 
227 
 
Figure 5.16 The ability of Tregs to suppress monocyte-derived MIP-α, MIP-1β, IL-1β, IL-1Ra, IL-7 
and IL-6 is reduced in patients with RA. 
(A-F) Monocytes from patients with RA (n=9) and HC (n=8) were cultured in the presence of LPS with 










 Tregs. After 3 days, supernatants were 
collected and analysed on a human 25-plex cytokine array (individual ELISA for IL-6). Data are plotted 
as the mean±SEM and statistical analysis performed using paired t test or Wilcoxon matched-pairs 
signed rank test as determined by D’Agostino and Pearson omnibus normality test: * p<0.05, ** 
p<0.01. Each colour represents an individual patient. 
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Figure 5.17 The ability of Tregs to suppress monocyte-derived IL-8, MCP-1, TNF-α, IL-15, IL-12, IP-10 
and RANTES is similar between HC and patients with RA. 








Figure 5.17 The ability of Tregs to suppress monocyte-derived IL-8, MCP-1, TNF-α, IL-15, IL-12, IP-10 
and RANTES is similar between HC and patients with RA. 
(A-G) Experiments were performed as described in Figure 5.16. Supernatants were analysed for IL-8 
(HC, n=6 and RA, n=7) by individual IL-8 ELISA and IL-7, MCP-1, TNF-α, IL-15, IL-12, IP-10 and RANTES 
(HC, n=8 and RA, n=9) with a human 25-plex. Data are plotted as the mean±SEM and statistical 
analysis performed using paired t test or Wilcoxon matched-pairs signed rank test as determined by 














Figure 5.18 The secretion of IL-10, IFN-α and IL-2R is hardly suppressed by Tregs. 
(A-C) Experiments were performed as described in Figure 5.16. Supernatants were analysed with a 
human 25-plex (HC, n=8 and RA, n=9). Data are plotted as the mean±SEM and statistical analysis 
performed using paired t test or Wilcoxon matched-pairs signed rank test as determined by 
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CD45RO+ Tregs from patients with RA overall showed a slightly reduced ability to 
suppress some of the monocyte-derived cytokines and chemokines (MIP-1α, MIP-
1β, IL-1β, IL-1Ra, IL-7 and IL-6), but this reduced capacity varied for each analyte and 
for each patient (Figure 5.16-5.18). Interestingly, there seemed to be some degree 
of variability in the ability of CD45RO+ Tregs from healthy controls to suppress 
cytokines and chemokines secreted by LPS-stimulated monocytes, which was 
particularly evident for MCP-1 (Figure 5.17B), IFN-α (Figure 5.18B) and IL-2R (Figure 
5.18C). The summary of the data is also shown in Table 5.7, which represents the 
percentage suppression of the indicated cytokines and chemokines by Tregs from 
the individual donors, classified as good suppression (dark blue, >50%), 
intermediate suppression (light blue, 21-50%), poor suppression (green, 1-20%) and 
no suppression (yellow, 0%). 
 
These data suggest that Tregs from patients with RA are not globally defective. 
Although some patients seemed to suppress certain cytokines and chemokines less 
efficiently (e.g. MIP-1α and MIP-1β), they were still able to suppress other cytokines 
to a similar extent as HC Tregs. 
 




Table 5.7 Summary table for Treg-mediated suppression of monocyte-derived cytokines and chemokines. 
Table shows the calculated percentage suppression mediated by CD45RO
+
 Tregs from patients with RA (n=7-9) and HC (n=6-8) for the ability to suppress the secretion of 
LPS-treated monocytes for the indicated cytokines and chemokines. 




3.6 RA#249 3% 48% 20% 4% 55% 45% 9% 47% 20% N/A 6% -10% 79% 44% 19% 85%
6.17 RA#250 -11% 21% 8% -12% 21% -5% N/A -16% -19% -3% -19% -6% 63%
2.73 RA#277 3% -56% 8% -91% 67% 30% -7% 17% 14% 59% 60% -4% 10% 29% 24% 81%
3.9 RA#278 -5% 26% 6% -76% 69% 67% -8% 12% 6% 0% 90% -28% 32% 17% 67% 76%
5.6 RA#289 -19% -3% -8% 21% 19% 3% 6% -8% 2% 4% -18% -6% 11% 33% 80%
3.2 RA#291 6% -23% -3% 46% -23% -22% 11% -3% 26% -32% 2% -68% -13% 8% 86%
4.68 RA#292 24% 6% 34% -16% 91% 68% 1% 29% 15% 66% 86% 44% 69% 45% 57% 85%
5.54 RA#296 8% 10% 18% 9% 13% -15% -5% -5% -37% 12% 57% -26% -38% 7% 61%





IFN-α IL-1β IL-1Ra IL-10 IL-12 IL-15 IL-2R IL-6 IL-7 IL-8 IP10 MCP1 MIP1α MIP1β RANTES TNF-α
HC 1 -46% 51% 14% 1% 40% 14% N/A -6% -125% 40% 26% 21% 87%
HC 2 -38% 51% 23% 20% 27% 23% N/A -13% -87% 45% 34% 90%
HC 3 -1% 33% 52% -2% 84% 42% 3% 16% 16% 28% 58% -35% 46% 57% 62% 86%
HC 4 41% -9% 32% -14% 86% 78% -10% 11% 7% 42% 92% 79% 31% 17% 11% 78%
HC 5 27% 33% 56% 7% 92% 62% 9% 31% 23% -5% 68% 61% 77% 58% 68% 95%
HC 6 21% 40% 40% 81% 53% 33% 32% 24% 18% 52% 39% 85% 67% 82% 96%
HC 7 17% 50% 35% -29% 66% 34% -7% 25% 16% 18% 0% 53% 73% 47% 45% 83%
HC 8 18% 21% 32% -106% 67% 21% -8% 30% -2% 19% 9% 37% 26% 2% -4% 87%
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5.3 Discussion 
In this chapter, we investigated the ability of Tregs from the peripheral blood of 
patients with RA to suppress effector T cell proliferation and IFNγ secretion, as well 
as their ability to suppress monocyte-derived cytokines and chemokines. Overall, 
our data suggest that Tregs from patients with RA are not globally dysfunctional. 
Tregs from some of the patients showed a reduction in their ability to suppress 
certain aspects of immune function, but not others, which was different for each 
individual patient. More importantly, none of the patients showed a complete 
impairment in Treg suppressive function for all the readout parameters analysed. It 
is worthwhile noting that healthy control Tregs also showed a certain amount of 
variability in their suppressive capacity. Finally, effector T cells from patients with 
RA showed a similar proliferative capacity to Teff from HC, but a more pro-
inflammatory cytokine expression profile, which suggests that Teff might be more 
activated in the blood of patients with RA. 
 
Considerable controversy exists in the Treg field about the function of Tregs from 
PB of patients with RA and the papers that reported impaired peripheral blood Treg 
function partially contradict each other (see Table 5.1). Valencia et al. reported that 
TNF-α down-modulated FoxP3 expression [253], a finding that was not seen by other 
groups [254, 258]. Although Nie et al. did not see a decrease in FoxP3 expression in the 
presence of TNF-α, they agreed that TNF-α abrogates Treg function [258]. The 
reported negative effects of TNF-α on regulatory T cell function are further 
supported by studies showing that immune regulation was restored following anti-
TNF-α treatment in patients with RA [253, 256-258]. The beneficial effects of blocking 
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TNF-α were recapitulated in a mouse model of TNF-driven arthritis, where blockade 
of TNF restored Treg suppressive activity and expanded CD62L- Tregs [609]. However, 
TNF-α was also reported to have beneficial effects on Treg function e.g in a mouse 
model for diabetes, where Teff boosted Treg function, which was partially 
dependent on TNF-α [263]. Strikingly, only two groups claim that Tregs from patients 
with RA were unable to suppress proliferation of Teff [253, 258], whereas all other 
groups that investigated the ability of peripheral blood Tregs to suppress 
proliferation showed intact function [257, 403-405, 413, 486]. 
 
The obvious factors that could influence regulatory T cell function are disease 
activity, treatment and genetic background, which will be discussed in the following 
sections. 
When we correlated disease activity from patients with RA as determined by DAS28 
with the ability of Tregs to suppress proliferation and cytokine secretion, we did not 
find a correlation (data not shown). It was reported in animal models of 
inflammatory arthritis that Tregs are not involved in controlling the acute phase of 
autoimmune joint inflammation, but instead control the resolution of the initial 
response. Adoptive transfer once the disease was established could not cure the 
disease [601, 610]. This prompted us to investigate whether disease duration 
correlated with suppressive capacity of RA Tregs, but no correlation was found 
(data not shown). 
 
A second factor that could contribute to impaired Treg function is treatment. The 
effects of TNFi therapy on Treg function have been discussed above. Since patients 
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on anti-TNF-α therapy were excluded in our cohort, this could have not affected our 
results. It has further been reported in one study that different DMARDs have 
different effects on Treg function in vitro [611]. Sulfasalazine (SSZ) and leflunomide 
(LEF) were shown to impair the ability of Tregs from HC to inhibit proliferation of 
Teff, whereas MTX did not have an effect. Almost all our patients were treated with 
MTX, but some were additionally treated with SSZ. The n numbers overall were too 
small (n=2) in our cohort to draw conclusions on whether SSZ had an effect on Treg 
function but this could potentially be an explanation for the differences reported on 
Treg function in other studies. 
 
Thirdly, genetics may play a role in the ability of Tregs to exert effector functions. 
CTLA-4 expression on Tregs from patients with RA was previously shown to be 
significantly reduced compared with HC Tregs due to increased CTLA-4 
internalization [604]. Several single nucleotide polymorphisms (SNPs) within the 
CTLA-4 gene and elevated serum levels of soluble CTLA-4 (sCTLA-4) have been 
associated with RA [612]. Other risk loci associated with rheumatoid arthritis are HLA-
DRB1 and PTPN22 [304, 305]. The tyrosine phosphatase PTPN22 was recently shown to 
be a key regulator of Treg function in mice [613]. It would be interesting to analyse 
the genotype for certain SNPs in the patients of our cohort to determine whether 
genotype affected the capacity of Tregs to suppress effector cells. 
 
Chemokines are soluble mediators that promote chemotactic activity in various 
leukocyte cell types and play an important role in the accumulation of inflammatory 
cells at the site of inflammation in RA (reviewed in [614, 615]). CCL3, also known as 
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MIP-1α, is known to be increased in serum and synovial fluid from patients with RA 
[616] and is considered as a risk locus for RA [617]. In our patient cohort, we observed 
that most of the patients had a reduced or impaired ability to suppress MIP-
1α/CCL3 and MIP-1β/CCL4. It would therefore be interesting to investigate whether 
those patients that showed reduced suppression of CCL3 and CCL4 show increased 
levels of MIP-1α and MIP-1β in their sera.  
 
Human Tregs were previously shown to display a reduced ability to suppress Th17 
cells [215, 216, 586]. It has further been described in the literature that IFNγ is able to 
suppress IL-17 induction [195, 196, 618-620]. The slightly reduced ability of Tregs from 
some patients to suppress IFNγ might therefore not necessarily be detrimental. 
Unfortunately, we were not able to conclude on the ability of Tregs from patients 
with RA to suppress IL-17 secretion by autologous Teff as secretion levels without 
PMA/ionomycin restimulation overall were very low. 
 
A key question that arises is whether a decreased ability of Tregs to suppress Teff 
proliferation or cytokine production is due to an increased resistance of the effector 
T cell population rather than an intrinsic defect in Tregs. There is evidence in the 
literature from studies in T1D that Teff might be more resistant to Treg-mediated 
suppression [621], which may be due to increased IFNγ and decreased IL-10 secretion 
by Teff [622]. We observed lower percentages of IL-10+ Teff following in vitro culture 
with autologous monocytes and a trend towards increased IL-17 expression in 
patients with RA (Figure 5.12A), which suggests that Teff from patients with RA 
might be more pro-inflammatory and less anti-inflammatory.  
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Furthermore, it has been shown in one study that Tregs from the peripheral blood 
of patients with RA were unable to suppress proliferation as well as TNF-α and IFNγ 
secretion by Teff cells, which was due to an increased resistance of Teff to Treg-
mediated suppression rather than an intrinsic defect of Tregs [495]. Increased 
resistance of Teff cells to Treg-mediated suppression in the presence of APCs was 
also reported in a spontaneous experimental arthritis model [623]. In JIA, various 
groups have shown that Teff at the site of inflammation might be more resistant to 
Treg-mediated suppression [419, 420, 584] and Wehrens et al. suggested that the 
increased resistance is due to PKB/c-Akt hyperactivation of Teff from the synovial 
fluid [419]. 
One of the potential candidates that could be involved in inducing resistance of Teff 
to Tregs is IL-15 [624]. IL-15 is found in increased levels in sera of patients with RA [385, 
625] and is able to recruit memory T cells to the synovial membrane [626]. IL-15 can 
trigger the production of IL-17 by PBMC [384] and induces the production of TNF-α by 
macrophages and T cells thereby contributing to disease [627]. Furthermore, 
macrophage-derived IL-15 was shown to stimulate the proliferation of autoreactive 
T cells [628]. However, the ability of Tregs from patients with RA to suppress IL-15 
secretion by activated monocytes was only slightly reduced in some of the patients 
when compared to HC (Figure 5.17D). 
Another possible candidate is IL-6. It was shown in a landmark study in mice that 
DC-derived IL-6 induced resistance of CD4+CD25- Teff to Tregs [264] and blockade of 
IL-6 in co-cultures of SFMC and Tregs from patients with inflammatory arthritis 
enhanced the suppressive capacity of Tregs [584]. We saw a reduced ability of Tregs 
from some patients to suppress monocyte-derived IL-6 (Figure 5.16F, Table 5.7), 
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and a complete impairment in n=2 patients, which could potentially lead to 
increased resistance of Teff. 
 
We have shown in chapter 3 that frequencies of peripheral CD25+CD127low Tregs 
were similar between HC and patients with RA and that these cells also showed a 
similar phenotype. Tregs from patients with RA rather showed an increased 
expression of FoxP3, which would argue for a more suppressive phenotype [16, 63, 
521]. Of note, we sorted CD45RA+ and CD45RO+ Treg samples from patients with RA 
(n=6) and age- and gender-matched HC (n=6) and analysed the samples on a 
microarray, which was done in collaboration with Novo Nordisk and Dr Hayley 
Evans from the Taams lab. Principal component analysis revealed that Tregs showed 
a highly similar gene expression profile in HC and patients with RA (unpublished 
data). Here in this chapter, we further provide evidence that the cytokine 
expression profiles of RA and HC Tregs are similar ex vivo and following in vitro 
culture. Finally, functionally we show that Tregs from patients with RA showed a 
similar capacity to suppress proliferation and cytokine secretion by Teff. Some of 
the patients showed a reduced Treg ability to suppress certain cytokines and 
chemokines secreted by activated monocytes, but there was also some degree of 
variation in HC. Summarising all the data, Tregs from the peripheral blood of 
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Chapter 6: Discussion 
6.1 Summary of the results of this thesis 
In this thesis, I have shown that CD4+CD45RO+CD25+CD127low Tregs (CD45RO+ Tregs) 
and CD14+ monocytes are present in high frequencies at the site of inflammation in 
RA. Synovial fluid Tregs from patients with RA showed a regulatory phenotype with 
increased expression of the Treg markers CD25 and CD39, but also an increased 
expression of the Th17 marker CD161. Monocytes were found in high frequencies in 
patients with RA and showed an activated phenotype, particularly at the site of 
inflammation. Synovial fluid Treg frequencies and SF monocyte frequencies 
correlated positively with each other and with disease activity. Monocytes and Tregs 
were found in close proximity in human tissue, which overall suggested that 
monocytes and Tregs can interact in vivo (Chapter 3). 
We set up an in vitro system in HC to study the effects of activated monocytes on 
Treg phenotype and function. CD45RO+ Tregs showed increased percentages of pro-
inflammatory (IL-17, IFNγ, TNF-α), but also anti-inflammatory (IL-10) expressing cells 
following interaction with activated monocytes. The increase in IL-17+ Tregs was 
mediated by monocyte-derived IL-1β, IL-6 and TNF-α. Despite the increase in pro-
inflammatory cytokine-expressing Tregs in those co-cultures, Tregs maintained their 
phenotype, did not show a loss in FoxP3 expression and were highly suppressive in 
suppression assays (Chapter 4). 
Finally, we investigated the function of peripheral blood Tregs in RA. Tregs isolated 
from PB of patients with RA and HC showed a similar phenotype and similar 
cytokine expression profiles. The ability to suppress IFNγ secretion and proliferation 
of autologous effector T cells was also similar. However, Tregs from some patients 
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showed a reduced ability to suppress certain cytokines or chemokines secreted by 
activated monocytes. Overall however, the data suggest that Tregs are not globally 
defective in rheumatoid arthritis (Chapter 5). 
 
6.2 Are Tregs from patients with RA impaired? 
The question that emerges from this thesis is whether Tregs from patients with 
rheumatoid arthritis are impaired. The inability of Tregs to restore immune 
regulation in rheumatoid arthritis could be due to various reasons: (I) a decrease in 
Treg numbers; (II) an intrinsic defect of Tregs; (III) negative effects of the pro-
inflammatory environment on Treg function; (IV) or the resistance of effector T cells 
to Treg-mediated suppression. 
 
We have shed light on some of these aspects in this thesis, which will be described 
in the following sections by placing the results into the context of the published 
literature and discussing what this thesis adds. In the end, I will discuss future 
therapeutic target strategies for the treatment of RA. 
 
(I) Tregs are not decreased in patients with RA 
Using a combination of high CD25 expression and a low expression of CD127 as 
surface markers to identify Tregs, we showed that CD45RO+ and CD45RO- Treg 
frequencies are similar in the blood of patients with RA. Furthermore, Tregs were 
found to be increased at the site of inflammation even after correcting for CD45RO 
expression and their frequencies correlated positively with DAS28. Thus, Tregs are 
not decreased in patients with RA and are abundantly present at the site of 
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inflammation. This finding might suggest that the inability of Tregs to control 
inflammation is due to qualitative rather than quantitative effects. 
 
(II) Tregs from the peripheral blood of patients with RA are not globally defective 
We determined the phenotype of peripheral blood Tregs from patients with RA and 
their cytokine expression profile ex vivo and after in vitro culture. This extensive 
analysis revealed that Tregs from patients with RA did not show a more pro-
inflammatory phenotype than Tregs from HC ex vivo i.e. we did not observe an 
increase in the Th17 marker CD161 or in the expression of pro-inflammatory 
cytokines. In fact, we even observed an increase in FoxP3 expression in some of the 
patients. Unpublished data from the Taams lab further support this finding as 
microarray results revealed similar gene expression profiles for CD45RA+ and 
CD45RO+ Tregs from patients with RA and HC. We further tested the ability of Tregs 
to suppress proliferation and cytokine production by autologous effector T cells as 
well as the ability to suppress monocyte-derived cytokines and chemokines. The 
ability of highly pure Tregs isolated from patients with RA to suppress the 
proliferation and cytokine secretion by Teff was similar to Tregs from age-matched 
HC. Although Tregs from some patients were hampered in their capacity to suppress 
certain cytokines and chemokines (IL-1β, IL-1Ra, IL-6, IL-7, MIP-1α and MIP-1β) 
secreted by activated monocytes, this was not a global defect as those Tregs were 
still intact in other suppressor functions (e.g. suppression of proliferation). This 
reduced capacity could not be explained by disease activity and in fact, Tregs from 
age-matched HC also showed some degree of variation. 
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It is not well understood why studies investigating peripheral blood Treg function in 
RA show controversial results. Ehrenstein et al. showed that CD4+CD25+ Tregs are 
able to suppress proliferation of Teff, but are unable to suppress cytokine 
production by Teff (TNF-α, IFNγ) and monocytes (TNF-α) [257]. They showed that 
these defects were Treg-intrinsic as Tregs from the same patient pre-therapy could 
not suppress Teff from the same patients post-therapy. This impaired ability was 
restored following TNFi (infliximab) treatment leading to increased CD4+CD25high 
Treg frequencies, although addition of varying doses of TNF-α to co-cultures did not 
affect Treg function [257]. In a follow-up paper, they revealed that infliximab 
treatment of active patients gave rise to a new CD62L- Treg population, which 
exerted their suppressive effects via TGF-β and IL-10 and were more potent than 
their CD62L+ counterparts [256]. More recently they further suggested that Tregs 
from patients with active RA are unable to suppress Th17 responses, but that anti-
TNF-α (adalimumab) treatment of patients leads to inhibition of Th17 cells via the 
suppression of monocyte-derived IL-6, which was only mediated by adalimumab but 
not etanercept [532]. Ehrenstein’s group further showed that Tregs from patients with 
RA showed lower CTLA-4 expression, which might affect Treg function in RA [604]. It 
should be mentioned that the patient cohorts in those studies were quite specific 
i.e. patients with active disease (DAS28 >5.1) that were about to go on TNFi therapy 
and the results from these studies might therefore not be applicable to all patients 
with RA.  
Valencia et al. described in 2006 that TNF-α signalling via TNFRII downregulated 
FoxP3 expression, which impaired regulatory T cell function [253]. CD4+CD25high Tregs 
from patients with active RA (DAS28 >5) were unable to suppress both proliferation 
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and IFNγ secretion of CD4+CD25- Teff, which was restored following TNF therapy 
(infliximab) [253]. However, in these assays no co-stimulation was provided, and only 
anti-CD3 mAb added to co-cultures of Tregs with Teff, which might affect the results. 
Michael Dustin’s group showed that TNF-α leads to the recruitment of protein 
kinase C (PKC)-θ to the immunological synapse (IS) in Tregs, which impairs Treg 
function [415]. They suggested that this might happen in patients with RA, as 
CD4+CD25+ Tregs isolated from patients with RA showed a reduced ability to 
suppress IFNγ secretion by autologous CD4+CD25- Teff, which could be reversed by 
adding a PKC-θ inhibitor (C20) to co-cultures [415]. However, direct proof for the 
effects of TNF-α on the recruitment of PKC-θ to the immunological synapse in 
patients with RA was not provided. Two years later, they further showed that the 
scaffold protein Dlgh1 (Disc large homolog 1) is strongly recruited to the IS in Tregs, 
but not in Teff [629]. They showed that Dlgh1 provided a link between the TCR and 
stimulation of Treg function by activation of p38 and NFAT, which synergized with 
Foxp3 and acted independently of PKC-θ [629]. They further went on to show that 
patients with RA showed an impaired recruitment of Dlgh1 and that TNF-α can 
negatively affect its recruitment [629]. However, direct evidence for this mechanism 
to affect Treg function in RA was not provided. 
Xiao et al. further showed an impaired ability of Tregs from patients with RA to 
suppress proliferation and cytokine secretion by Teff [495]. However, they suggested 
that this was not due to an intrinsic defect of Tregs, but due to the resistance of Teff 
to Treg-mediated suppression possibly by increased TRAIL expression on effector T 
cells [495]. 
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An increased resistance of Teff to Treg-mediated suppression was also suggested by 
Han et al. due to the observed increased expression of GITR by Teff and GITRL on 
monocytes, although the ability of Tregs to suppress Teff proliferation was not 
significantly different [630]. 
On the other hand, it was shown by various other groups including our own that the 
ability of peripheral blood Tregs from patients with RA to suppress Teff proliferation 
and/or cytokine production was similar to HC [403, 411, 413, 486]. Benito-Miguel et al. 
even suggested that peripheral blood Treg function was increased in patients with 
RA [405]. 
 
All studies that have investigated peripheral blood Treg function in RA have used 
different experimental set-ups for suppression assays (live APC vs. beads or no co-
stimulation), different patient cohorts (e.g. disease activity, therapeutic treatment) 
or isolation strategies for Tregs (MACS vs. sorting). These studies further only looked 
at one or two aspects of Treg-mediated suppression i.e. proliferation or cytokine 
secretion and did not always provide evidence that the mechanism they suggest to 
be disrupted in patients with RA does lead to impaired suppression. Although it was 
reported that TNFi therapy can restore immune regulation in RA [253, 256-258, 532], 
negative effects of the pleiotropic cytokine TNF-α on Treg function are not well 
reported and results from different papers contradict each other. It has further been 
suggested that TNF-α can be beneficial for Treg function [261-263]. Overall it is difficult 
to find reasons for the conflicting data seen in the different studies. 
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TNF-α is further known to be able to stimulate apoptosis in lymphocytes and 
monocytes [631]. An important question that needs to be answered is whether Tregs 
are more susceptible to apoptosis in RA, which could explain reduced abilities to 
suppress effector cells in in vitro assays. Toubi et al. showed that the spontaneous 
apoptosis rate was higher in CD4+CD25+ Tregs from patients with RA compared to 
HC [632]. An increased apoptosis rate of Tregs was also seen in the blood from 
patients with SLE [633] and subjects with recent-onset T1D [634, 635]. Furthermore, in 
patients with IBD, Tregs were shown to be more apoptosis prone in the blood and 
inflamed mucosa, which was overcome by anti-TNF-α treatment [529]. However, 
when we analysed co-cultures of Tregs from patients with RA and HC with 
autologous monocytes by FSC/SSC to determine whether there was an indication 
towards increased death in co-cultures with RA Tregs, we did not observe obvious 
differences between patients and HC (data not shown). 
 
Previous studies investigating the function of Tregs in the peripheral blood of 
patients with RA used bulk CD4+ Tregs for suppression assays and it was suggested 
recently that the naïve Treg population is defective in multiple sclerosis (MS), [148, 
607]. We investigated the ability of CD45RA+ Tregs to suppress Teff proliferation and 
saw no difference between HC and patients with RA. However, further experiments 
are needed testing the ability of CD45RA+ Tregs to suppress cytokine secretion by 
Teff and monocytes to draw conclusions on whether naïve Tregs may be defective in 
patients with RA since we showed that CD45RO+ Tregs from some patients were 
reduced in their ability to suppress certain cytokines and chemokines by activated 
monocytes, but still suppressed the proliferation of Teff. 
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Our data overall show that Tregs from patients with RA are not globally defective 
when compared to Tregs from age-matched HC although some impairments were 
observed. This could suggest that the pro-inflammatory environment impairs Treg 
function. 
 
(III) The pro-inflammatory environment does not impair Treg function in vitro 
We found that monocytes with an activated phenotype were present in high 
numbers in the inflamed joint. These cells are a potential source of pro-
inflammatory cytokines in the inflamed joint [352]. As synovial fluid samples are 
scarce, we set-up an in vitro system with CD14+ monocytes from HC that were 
stimulated with LPS or cytokines known to be present in the inflamed rheumatic 
joint. These monocytes showed an activated phenotype and secreted high amounts 
of pro-inflammatory cytokines. In vitro-activated monocytes increased the 
percentage of IL-17+, IFNγ+ and TNF-α+ Tregs, but also Tregs that expressed the anti-
inflammatory cytokine IL-10. However, when we determined the relative magnitude 
of the percentage of cytokine-expressing Tregs by setting up co-cultures of CD25low/-
CD127+ Teff or CD25intCD127+Teff with medium-treated or LPS-activated monocytes 
in parallel, we showed that the percentage of cytokine-positive Tregs was relatively 
low. The increase in IL-17+ Tregs was driven by monocyte-derived IL-1β, IL-6 and 
TNF-α, cytokines that are known to be involved in the pathogenesis of RA [352]. 
Despite the pro-inflammatory cytokine profile Tregs maintained a Treg phenotype 
(CD25+CD39+FoxP3+) and were able to suppress the proliferation and cytokine 
secretion by autologous effector T cells. Th17 cells are thought to be more resistant 
to Treg-mediated suppression [215, 216, 586, 587], but we show here that Tregs from co-
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cultures with activated monocytes showed an enhanced capacity to suppress IL-17 
secretion. This finding might be explained by the ability of Tregs to adapt to the 
environment to exert optimal suppressor functions as was shown in mice studies 
[278-280]. These in vitro data were supported by the finding that we can indeed find 
FoxP3+IL-17+ T cells in the synovial fluid from patients with RA although these 
percentages were not increased compared to the blood. Furthermore, Tregs from 
the synovial fluid showed a regulatory phenotype with increased expression of CD25 
and CD39.  
 
These data are also supported by studies investigating the suppressive function of 
Tregs from the synovial fluid. Almost all studies agree that these cells are fully 
capable of suppressing T-cell proliferation and/or cytokine production when studied 
ex vivo and that the ability of Tregs from the synovial fluid is even enhanced when 
compared to their peripheral blood counterparts or Tregs from healthy controls [403, 
405, 408-411]. A recent paper published in Nature Medicine showed however that SF 
Tregs are dysfunctional, which they explained by increased levels of TNF-α in the 
synovial fluid [258]. In this study, TNF-α had no effect on FoxP3 expression as it had 
been suggested by other groups [253], but induced the activity of protein 
phosphatase PP1, which dephosphorylates FoxP3 at a specific serine residue 
(Ser418) [258]. They further showed that Treg frequencies were similar in PB and SF 
[258], which is in striking contrast to all other studies that have investigated Treg 
frequencies in SF including our own, which show markedly elevated frequencies in 
the synovial fluid [403, 405, 408-414, 489]. The patient cohort in this paper consisted of “a 
fraction of patients who sought more advanced medical care from remote or rural 
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regions of China, where their treatment options were limited or not optimized” [258], 
which may have impacted on immune cell function. 
 
Recently, IL-17+ Tregs have been described to exist in vivo in the peripheral blood 
[238, 241] and at sites of inflammation [247-249]. It is still not clear whether the 
expression of pro-inflammatory cytokines by Tregs impairs their function and 
whether these cells can contribute to disease. However, elegant animal studies 
have suggested that Tregs can adapt to their environment by upregulation of 
transcription factors characteristic for a certain T helper subset [278-280]. So it might 
be beneficial for Tregs to express IL-17 to be able to optimally suppress Th17 cells. 
In line with that, we showed here that in a pro-inflammatory environment where 
Tregs express IL-17 they are more efficient in suppressing Th17 cells than Tregs 
cultured under non-inflammatory conditions.  
 
It is possible nowadays to isolate cells that express pro-inflammatory cytokines by 
stimulating cells with PMA and ionomycin and subsequent use of a cytokine 
secretion assay. However, due to the small percentages of cytokine-expressing 
Tregs it is still challenging to isolate these cells for functional analysis. Two recent 
studies used CD161 expression as an alternative strategy and revealed that CD161+ 
Tregs are highly enriched for IL-17+ cells and that increased frequencies of CD161+ 
Tregs can be found at the site of inflammation in patients with JIA and inflammatory 
arthritis [245, 520]. CD161+ Tregs from HC were shown to exert potent suppressive 
capacity [245, 520] and Pesenacker et al. further showed that these cells displayed a 
fully demethylated Treg-specific demethylation region (TSDR) [520]. The TSDR is a 
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CpG-rich enhancer region within the FoxP3 locus, which is supposed to determine 
long-term stability of FoxP3 expression when hypomethylated [175-177] and is thus far 
the best marker to discriminate between Tregs and recently activated effector T 
cells [179]. However, another study showed that although IFNγ+ Tregs isolated by 
cytokine secretion assay expressed FoxP3 and possessed suppressive activity, they 
were predominately methylated at the TSDR [276].  
 
Profiling of synovial fluid CD4+ T cells isolated from patients with RA using ELIA 
(Epigenetic Immune Lineage Analysis) revealed that cells are committed towards a 
Treg and Th1 phenotype as determined by demethylation status of the FOXP3 and 
IFNG locus, respectively [636]. CD4+ T cells from the peripheral blood however 
showed hypermethylation at the FoxP3 locus compared to HC [636] and these data 
would suggest that Tregs in PB are unstable, but more stable at the site of 
inflammation. Consistent with these findings Herrath et al. showed that isolated SF 
Tregs from patients with chronic inflammatory arthritis showed increased 
demethylation at the promoter region compared to PB Tregs, and that overall 
demethylation in PB was quite low [584]. The region used for FoxP3 demethylation 
analysis in these two studies was the region preceding the 5’UTR of the FoxP3 
promoter region [637], but it has been claimed that the only locus to identify stable 
Tregs is the TSDR. Tregs from the blood and synovial fluid of patients with 
spondylarthritis (SpA) were predominantly demethylated at the TSDR [638], which 
suggests that Tregs are stable at the site of inflammation. Two studies recently 
published in Immunity back to back have shed more light on how FoxP3 expression 
might be additionally regulated post-translationally during inflammation. The 
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ubiquitin ligase Stub1, expression of which was induced by pro-inflammatory 
stimuli, was shown to promote the degradation of FoxP3 thereby inhibiting Treg 
function [639]. Van Loosdregt et al. showed that the deubiquitinating enzyme USP7 
stabilised the expression of FoxP3 thereby inhibiting proteasomal degradation and 
that silencing of USP7 resulted in abolished Treg-mediated suppression [640]. The 
pro-inflammatory cytokine IL-6 had negative effects on USP7 expression and led to 
reduced FoxP3 expression [640]. USP7 polymorphisms have been associated with 
various autoimmune diseases including rheumatoid arthritis [641], which suggest that 
USP7 might play a role in FoxP3 stability in rheumatoid arthritis, which would be 
interesting to investigate further in the future. 
 
Taken together, although it is clear that inflammatory signals can affect FoxP3 
stability and potentially Treg function, there is also clear evidence that Tregs 
exposed to an inflammatory environment in vivo or in vitro maintain their function. 
This could suggest that the impairment in immune regulation is due to effector T 
cells being resistant to Treg-mediated suppression at the site of inflammation in RA. 
 
(IV) Are effector T cells resistant to Treg-mediated suppression? 
Our analysis of the cytokine expression profile of peripheral blood Teff from patients 
with RA revealed that they expressed less IL-10 and more IL-17 than HC Teff, which 
could indicate that Teff from patients with RA show a more pro-inflammatory 
profile. It would be interesting to investigate whether those Teff that expressed 
higher percentages of IL-17 and/or lower percentages of IL-10 get less suppressed 
by Tregs. However, data so far (n=8) rather suggest that Teff that express low levels 
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of IL-10 and high levels of IL-17 are suppressed less well by Tregs, but data were not 
conclusive (data not shown). 
 
In juvenile idiopathic arthritis (JIA), which is the most common form of arthritis in 
children, CD4+CD25bright Tregs were shown to express high levels of FoxP3 mRNA in 
the synovial fluid and were further able to suppress proliferation of autologous 
CD4+CD25- Teff [139, 418]. Similarly to RA, it was shown that SF Tregs have increased 
suppressive capacity compared to Tregs from the peripheral blood [418]. Two other 
studies suggested that effector T cells from the site of inflammation might be 
refractory to Treg-mediated suppression [419, 420]. Wehrens et al. identified that the 
resistance of Teff was mediated by hyperactivation of PKB/c-Akt, which was induced 
by TNF-α and IL-6 [419] and could be targeted by TNFi blockade [421]. In patients with 
inflammatory arthritis, blocking of IL-6 and TNF-α had beneficial effects on Treg 
suppressive function in vitro [584] suggesting that the pro-inflammatory environment 
might affect Treg function or Teff phenotype. It has been shown in the literature that 
Teff in the synovial fluid from patients with RA show a more activated phenotype 
[403, 408, 418], which may suggest that they are more resistant to Treg-mediated 
suppression. Furthermore, a resistance of effector T cells to Treg-mediated 
suppression has also been reported in the blood from patients with SLE [642, 643], 
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6.3 Therapeutic targets in RA: boosting Treg function or targeting Teff? 
Nowadays, much effort has been made to invest in cell-based therapy in 
autoimmunity and transplantation using Tregs that have been expanded ex vivo or 
have been induced in vitro for reinfusion into the patient later on. It is crucial to 
understand whether Tregs are dysfunctional in rheumatoid arthritis before 
attempting to develop Treg-based therapies. However, drugs like TNFi have been 
approved for the treatment of RA, which may work in part by promoting the 
function or increasing the numbers of Tregs [253, 256-258, 532]. Furthermore, 
experimental arthritis models have provided evidence that Tregs are involved in RA 
and are able to ameliorate disease when adoptively transferred [398, 399, 402, 646]. Kong 
et al. recently showed that both ex vivo expanded nTregs and in vitro-induced iTregs 
were able to suppress CIA when injected at the time of immunisation but only iTregs 
were able to suppress effector T cells once the disease was established [647]. By 
tracking the cells in vivo they further showed that nTregs either died following 
transfer or lost FoxP3 expression and converted into IL-17-producing cells, whereas 
iTregs survived better and stably expressed FoxP3 [647]. Thus, Treg cell-based therapy 
might have the potential to induce disease remission in patients with RA, but we are 
faced with two difficulties in humans. Firstly, it is difficult to distinguish between 
thymus-derived Tregs and peripherally-induced Tregs and secondly it is not possible 
to adoptively transfer Tregs before disease onset.  
 
Ex vivo expansion of Tregs is usually achieved by anti-CD3/CD28 stimulation in the 
presence of IL-2, which does not result in loss of Treg function [6, 648, 649]. A downside 
of this method however is the potential for expansion of contaminating effector T 
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cells, which can be detrimental to the host. Ex vivo-expanded CD45RA- Tregs showed 
demethylation at the RORC locus and converted into IL-17+ cells, whereas CD45RA+ 
Tregs were relatively stable [605]. However, overall CD45RA+ Treg frequencies are low, 
which limits their use for ex vivo expansion. One of the difficulties that we face is 
the question of which surface markers to use for the isolation of stable human 
Tregs. Teff can upregulate CD25 expression following activation [129-131], which is why 
there is still a need for an exclusive Treg marker. The lineage-specific transcription 
factor FoxP3 is intranuclear, which makes it difficult to isolate cells based on FoxP3 
expression in humans. Furthermore, at the moment there are almost only MACS-
based purification protocols available that follow good manufacturing practice 
(GMP) guidelines, which compromise purity of cells. Addition of rapamycin to anti-
CD3/CD28 and IL-2 has been shown effective in depletion of Teff while expanding 
Tregs [650]. Ex vivo-expanded Tregs have been used in pre-clinical trials of umbilical 
cord blood transplantation for prevention of Graft-versus-Host Disease (GvHD) and 
proven to be safe [651]. Furthermore, in mouse models for diabetes adoptive transfer 
of ex vivo-expanded islet antigen-specific Tregs were shown to prevent disease [652, 
653]. Battaglia et al. reported that rapamycin-expanded Tregs from patients with T1D 
were as suppressive as Tregs from HC and they suggested that defects could be 
overcome by expansion ex vivo [654]. CD4+CD25+ Tregs from patients with immune-
mediated diseases such as RA that were expanded ex vivo using α-CD3/CD28 beads 
and rhIL-2 showed lower FoxP3 expression following expansion than HC, but 
potently suppressed proliferation of effector T cells [655]. Similarly to the study by 
Battaglia et al., ex vivo-expanded Tregs were better suppressors than freshly 
isolated Tregs [655]. A lower FoxP3 expression might however indicate that these 
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cells are not very stable and it also needs to be investigated whether ex vivo-
expanded Tregs from patients with RA are also able to suppress cytokine secretion 
of effector cells.  
Mouse studies have shown that high Treg doses are required to efficiently and 
reproducibly suppress GvHD (1:1 Tregs to T cells) [656]. Therefore large numbers of 
Tregs are required for adoptive transfer, which is potentially limited by the small 
number of Tregs obtainable and the cost of GMP-compliant expansion protocols. 
 
Tregs can further be induced in vitro from CD4+CD25- T cells in the presence of TGF-
β [121, 657]. Furthermore, rapamycin was found to induce suppressive Tregs from 
CD4+CD25- T cells in the presence of B cells [658]. However, in vitro-induced Tregs 
have been shown to be unstable and lose FoxP3 expression when stimulated in vitro 
[176] or adoptively transferred [659], but this finding was not supported by all studies 
[647]. Stable FoxP3 expression is dependent on complete demethylation at the TSDR 
[175, 176], but TGF-β-induced Tregs have been shown to be incompletely 
demethylated [176]. Aza (5-Aza-2’deoxycytidine), a DNA-methyltransferase (DNMT) 
inhibitor, was shown to promote stable FoxP3 expression in Tregs that were induced 
from effector T cells [175]. Furthermore, the administration of IL-2 following adoptive 
transfer has been shown to stabilise FoxP3 expression in vivo [660] as well as the 
combination of IL-2 and rapamycin [661]. Low dose IL-2 administration alone was 
already shown to be beneficial as it preferentially increased Treg frequencies in 
patients with active chronic GvHD and resulted in clinical improvement in half of the 
patients [662]. 
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Furthermore, Tregs can be induced in vivo by the use of immunomodulatory agents 
such as retinoic acid, neuropeptides, CD3-specific antibodies or histone deacetylase 
inhibitors (reviewed in [663]). Histone deacetylase inhibitors (HDACi) can directly 
affect human FoxP3 acetylation and chromatin binding [664, 665] and it has been 
shown that HDACi increased Treg suppressive activity, which was associated with 
increased CTLA-4 expression [666]. Administration of HDACi such as trichostatin A 
(TSA) in collagen-induced arthritis (CIA) could reduce disease severity [667-669]. Saouaf 
et al. further reported that HDACi treatment resulted in an increased suppressive 
function of Tregs in CIA [668]. Similar positive effects on Tregs were seen in a diabetes 
model, where administration of the DNA demethylation agent Aza induced Foxp3 
expression and significant demethylation in Tregs, which ameliorated the disease in 
animals [670]. In humans, the HDAC inhibitor Givinostat, was shown therapeutically 
beneficial in patients with JIA in a recent clinical trial [671] and was subsequently 
approved as an orphan drug in Europe for treating JIA. However, the exact 
mechanism of action is still unknown and it is currently not clear whether the 
beneficial effects are mediated via Tregs. 
 
As described above it has been suggested that effector T cells from the synovial fluid 
of patients with JIA are refractory to Treg-mediated suppression [419, 420]. Effector T 
cells in the synovial fluid from patients with RA were shown to have a more 
activated phenotype than their peripheral blood counterparts [403, 408, 409], which 
might suggest that they are more resistant to Treg-mediated suppression. Another 
strategy might therefore be to target the effector T cell population to enhance the 
responsiveness to Treg-mediated suppression. A likely candidate might be protein 
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kinase B/c-Akt as Teff from the synovial fluid from patients with JIA showed 
increased activation of PKB [419]. However, it has not been confirmed that PKB is 
hyperactivated in RA and it might be specific to JIA. It has further been suggested 
that ectopic FoxP3 expression in synovial Teff cells would render them more 
susceptible to Treg-mediated suppression [672]. Furthermore, in an experimental 
model for arthritis the severity of the disease could be significantly reduced by 
treating mice with recombinant Foxp3 protein fused to a cell penetrating 
polyarginine [673], but this approach might target both Tregs and Teff. 
 
Taken together, I have shown in this thesis that there is clear evidence for the 
presence of Tregs at the site of inflammation in RA, that the inflammatory 
environment does not impair Treg function per se, and that Tregs from the 
peripheral blood of patients with RA are not globally defective. We therefore need 
to better understand why inflammation persists in patients with RA despite the 
abundant presence of Tregs at the site of inflammation before attempting Treg cell-
based therapies. A point to consider is that Tregs in the RA joint are in fact 
functionally suppressive and that the inflammation in the rheumatic joint would 
probably be much worse if Tregs were not there at all. Future work should be aimed 
at determining whether the chronic inflammation in rheumatoid arthritis is due to 
the resistance to immune regulation by effector T cells and possibly other 
inflammatory cells such as monocytes and fibroblasts. If that was the case, 
reinfusion of more Tregs into patients might not be beneficial and it should rather 
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